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ABSTRACT 
 
Papain, A Novel Urine Adulterant 
by 
David Lewis Burrows 
 
The estimated number of employees in the United Stated screened annually for illicit drugs is 
approximately 20 million, with marijuana being the most frequently abused drug. Urine 
adulterants provide an opportunity for illicit drug users to obtain a false negative result on 
commonly used primary drug screening methods such as the Fluorescence Polarized 
Immunoassay (FPIA) technique. Typical chemical adulterants such as nitrites are easily detected 
or render the urine specimen invalid as defined in the proposed federal guidelines for specimen 
validity testing based on creatinine, specific gravity, and pH. Papain is a cysteine protease with 
intrinsic ester hydrolysis capability. The primary metabolite of the psychoactive chemical in 
marijuana, 11-norcarboxy-delta-9-tetrahydrocannibinol (THC-COOH), was assayed by FPIA in 
concentrations ranging from 25 to 500 ng/mL, at pH values ranging from 4.5 to 8, over the 
course of 3 days with papain concentrations ranging from 0 to 10 mg/mL. FPIA analysis of other 
frequently abused drugs: amphetamines, barbiturates, benzodiazepines, cocaine, opiates, and 
phencyclidine, along with gas chromatography/mass spectrometry (GC/MS) of THC-COOH and 
high pressure liquid chromatography/ultraviolet detection (HPLC/UV) of nordiazepam was 
performed in order to determine if the mechanism of urine adulteration by papain was analyte 
specific. Control and adulterated urine specimens (n=30) were assayed for creatinine, specific 
gravity, and pH to determine if papain rendered the specimens invalid based on the proposed 
federal guidelines.   There was a direct pH, temperature, and time dependent correlate between 
the increase in papain concentration and the decrease in THC-COOH concentration from the 
untreated control groups (p<0.01). The average 72 hour THC-COOH concentration decrease at 
pH 6.2 with a papain concentration of 10 mg/mL was 50%. Papain did not significantly 
decrease the concentration of the other drugs analyzed with the exception of nordiazepam.  
GC/MS of THC-COOH and HPLC/UV of nordiazepam revealed a 66% and 24% decrease in 
concentration of the respective analyte with 10 mg/mL papain after 24 hours at room 
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temperature (~23 °C).  No adulterated specimens were rendered invalid based on the SAMHSA 
guidelines.  Immediate FPIA analysis is suggested to minimize the interfering effects of papain 
with regards to primary drug screening.
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CHAPTER 1 
INTRODUCTION 
 
A Brief History of Drug Testing 
 Circa 1950, drug abuse treatment facilities were one of the first institutions to implement 
drug testing (Coombs and West 1991).  In 1967, the International Olympic Committee outlined 
the definition of doping and the concept of banned drugs, however testing was met with 
resistance because it would be potentially damaging to the public and commercial image of 
athletes (Wolmar 1992).  Concurrently, the military began screening for heroin use among those 
returning from Vietnam in the late 1960s and early 1970s, and drug screening was subsequently 
extended to include all soldiers reporting for active duty.  In 1981, an investigation into an 
aircraft crash aboard an aircraft carrier revealed that cannabinoids were present in over 50% of 
the total fatalities.  This finding accelerated the Navy’s decision to implement across-the-board 
drug screening (Zwerling 1993). 
Federal Statute CFR49R mandated that all federally regulated industries, shipping, 
railway, and airline employees be drug tested due to their responsibilities that pertain to the 
safety of large numbers of individuals (SAMHSA 2004).  National sports leagues (i.e., NFL and 
NHL) began drug testing during the mid-1980s (NCDFS 2003).  The Drug Free Workplace Act 
(DFWA) of 1988 stated that businesses and institutions receiving federal funds ensure that their 
employees were drug free (Holtorf 1998).  The DFWA led to a multitude of private company 
policy changes to include pre-employment and/or random drug testing.  The estimated number 
of employees screened annually is approximately 20 million, at a cost of several hundred million 
dollars to industry. 
 
Drug Testing Procedures 
 Drug testing consists of two levels: the primary drug screen to efficiently detect multiple 
drugs or classes of drugs and the confirmation of any positive results obtained from the primary 
drug screen by a more specific and sensitive method.   Primary drugs screens are commonly 
performed by an immunoassay technique due to efficiency and automaticity.  Immunoassays 
involve the binding of a specific antibody with a labeled drug or with an enzyme-drug complex.  
 21 
The overall principle involved with immunoassays is the competitive binding of the analytes of 
interest that may be present in the specimen and displacement of the labeled complex from the 
antibody.  The degree by which the labeled complex is displaced is proportional to the 
concentration of analytes in the specimen.  Depending on the specific type of immunoassay, a 
secondary phenomenon occurs after the labeled complex is displaced that allows the investigator 
to calculate the analyte concentration.  Secondary phenomena include, but are not limited to, 
absorption of ultraviolet light from an enzymatic substrate conversion, reflection of polarized 
light from polymerized tracers, and emission of radioactivity from radio-labeled tracers.  
The ability to differentiate between a positive and negative result lies in the practice of 
using a "cutoff" concentration.  A cutoff concentration is a concentration of drug below which 
all specimens are to be considered negative and at or above which all specimens are to be 
considered positive.  Oversight agencies dictate the specific cutoff concentration for each drug 
or drug class of interest.  The practice of using cutoffs normalizes interlaboratory results and 
standardizes the interpretation of results that can differentiate active and passive drug usage. 
Table 1 lists the cutoff concentrations for screening and confirmation procedures for the most 
commonly abused/highest potential for abuse illicit drugs. 
 
 
Table 1  Cutoff concentrations for screening and confirmation procedures 
Analyte Screening (ng/mL) Confirmation (ng/mL) 
Amphetamines 
     Amphetamine 
     Methamphetamine 
1000 
 
 
500 
500+200 amphetamine 
Barbiturates 200 200 
Benzodiazepines 200 200 
Cannabinoids 50 15 
Cocaine 300 150 
Opiates 
     Codeine 
     Morphine 
300  
300 
300 
Phencyclidine 25 25 
Source: Adapted from Liu R, Goldberger B. 1996. Handbook of Workplace  
Drug Testing. Washington DC. AACC Press. 390p. 
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Assays, Specimens and Analytes of Interest 
 
Enzyme Multiplied Immunoassay Technique (EMIT)   
The EMIT assay is based on competitive binding between drug in the specimen and drug 
labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PD) for antibody binding sites.  
In the cannabinoid assay, the antibody is biomanufactured to preferentially bind with the THC-
COOH metabolite.  G6PD activity is stereo-chemically hindered upon binding to the antibody.  
Unobstructed G6PD converts nicotinamide adenine dinucleotide (NAD) to the protonated form, 
NADH resulting in an absorbance change that is measured spectrophotometrically at 340 nm 
(Levine 2003).  Assay reagents and specimen are added to a heated (37 °C) reaction vessel and 
absorbance is measured for a period of 30 to 60 seconds after an incubation period (if 
applicable, depending on the analyte being measured).  The rate of the absorbance change 
(delta-mabs/t) is proportional to the amount of free drug in the specimen.  Figure 1 illustrates the 
EMIT assay mechanism.  A negative, cutoff, and high control are assayed daily to set the rate of 
absorbance change that correlates to the cutoff concentration for a particular analyte.  The EMIT 
immunoassay is a qualitative assay and is limited to providing categorical data, i.e., a specimen 
is either positive or negative.  Dose-dependent effects of adulterating substances are difficult to 
observe and analyze statistically.  Therefore, we reserved the use of the EMIT assay for the 
purpose obtaining preliminary data. 
 
 
Figure 1  Depiction of the EMIT reaction 
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Fluoresence Polarized Immunoassay (FPIA)   
The FPIA immunoassay is based on competitive binding between drug in the specimen 
and a drug-fluorophore complex for the antibody (Figure 2).  Energy absorbed from polarized 
light focused on the specimen rotates the molecules in the solution.  Larger molecules (i.e., the 
antibody:tracer complex) will rotate slower than the smaller molecules (i.e., tracer molecules 
alone).  Slower rotating molecules reflect the polarity of the incident beam.  Therefore, a high 
quantity of reflected polarized light is indicative of a specimen with a relatively low 
concentration of free drug.  Conversely, a low quantity of reflected polarized light is indicative 
of a specimen with a relatively high concentration of free drug.  The FPIA and radiological 
immunoassay (RIA) do not tend to yield false negative results due to the inverse proportionality 
of the measured immunoassay indicator and free drug in the specimen.  Specimens and reagents 
are added to a reaction vessel with an automated probe.  The reaction vessel is allowed to 
incubate for 10-12 minutes depending on the assay before the quantity of polarized light is 
quantitated.  The FPIA is a quantitative immunoassay that requires each lot of reagents to be 
calibrated with a six point standard curve that is confirmed daily with bi-level controls. 
 
 
Figure 2  Depiction of the FPIA reaction 
Source: Adapted from Levine B. 2003. Principles of forensic toxicology. Washington DC: 
AACC Press. 385 p. 
 
Confirmation of Positive Drug Screen Results 
         Confirmation of positive primary drug screen results is performed by a more specific and a 
more sensitive method of detection of drugs of interest.  If a particular immunoassay is 
established as a primary drug screening method, gas chromatography or high performance liquid 
chromatography with mass spectrometry (GC/MS, HPLC/MS) or high performance liquid 
chromatography/ultraviolet detection ( HPLC/UV) are usually employed for confirmation of 
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positive drug screen results.  Compared to the methods performed for drug screening procedures, 
GC, GC/MS, LC/MS, and HPLC/UV methodologies are more resistant to urine specimens that 
have been adulterated in an attempt to obtain a false negative result from a drug test. 
 
 Gas Chromatography/Mass Spectroscopy.  GC/MS is a powerful tool in quantitative 
chemical analysis.  Gas chromatography involves the volatilization of a specimen such that all of 
the analytes exist in the gas phase.  The volatilized specimen transverses a column under 
pressure of an inert carrier gas such as nitrogen or helium.  In a capillary column, the analytes 
are separated due to chemical interactions with the stationary phase on the capillary walls as 
they transverse the column, these interactions cause the analytes to elute from the column with 
individual retention times.  The chemical interactions within the stationary phase are a factor of: 
the McReynolds constants that define the stationary phase, column temperature, carrier gas flow 
rate, and the chemistry of the analyte itself.  Electron ionization mass spectroscopy involves a 
focused electron beam that fractionates a molecule into discrete molecular weights or mass 
fragments for detection by a mass selective ion detector.  The elution time, presence, and ratios 
of specific molecular weights are unique to every molecule and become a “fingerprint” to 
identify and quantitate analytes within a specimen. 
 
 High Performance Liquid Chromatography/Ultraviolet Detection.  HPLC/UV is another 
vital tool in quantitative chemical analysis.  A liquid specimen dissolved in an aqueous mobile 
phase is forced through a radial compression or stainless steel column by a precision tooled 
piston pump.  The analytes are separated due to chemical interactions with column packing 
material, these interactions cause the analytes to elute from the column with individual retention 
times.  The chemical interactions within the column are a function of: the phase of the packing 
material, the flow rate of the specimen through the column, the polarity of the mobile phase, and 
the chemistry of the analyte itself.  Analytes such as benzodiazepines will absorb ultraviolet light 
of a specific wavelength due to the configuration of the electron orbitals within the molecule.  
Thus, the degree of ultraviolet absorption is proportional to the concentration of the analyte. 
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Specimens 
 The presence of parent drugs and/or their metabolites can be detected in many biological 
specimens.  Urine is typically the specimen of choice for drug testing for several reasons.  The 
collection of urine is non-invasive and has less potential to accidentally transmit pathogens such 
as those associated with a blood collection.  Urine typically has a higher concentration of the 
analytes of interest due to the physiology of the kidney which collects and concentrates 
hydrophilic drug metabolites.  The matrix effect of a urine specimen is typically less than that of 
a blood specimen due to the decreased number of lipophilic constituents.  Alternative matrices 
including salvia and hair are available for drug testing.  The pharmacodynamics and 
interpretation of the results obtained from alternative matrix testing are not established (Dolan 
and others 2004).  Urine is therefore the specimen most frequently assayed for drugs and/or drug 
metabolites. 
 
Primary Analyte of Interest 
Cannabinoids are a class of compounds that encompass the psychoactive parent drug 
found in marijuana, delta-9-tetrahydrocannabinol (THC), four primary metabolites: 11-hydroxy-
THC, 8,11-dihydroxy-THC, 11-oxo-THC, and 11-norcarboxy-delta-9-ΤΗC (THC-COOH ), and 
over 60 natural and synthetic related structures (Burstein 1979).  Marijuana is the most 
frequently administered illicit drug in the United States (SAMHSA 2002).  The EMIT and FPIA 
immunoassays are optimized to measure THC-COOH because it is the principle urine 
metabolite that has a decreased lipid solubility relative to the parent compound.  The 
hydrophilicity of THC-COOH allows it to partition into urine in far greater quantities than the 
lipophilic parent compound.  The chemical structure of THC-COOH is illustrated in Figure 3. 
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Figure 3  The chemical structure of THC-COOH 
 
 Other analytes of interest include: amphetamine, secobarbital, nordiazepam, 
benzoylecgonine, morphine, and phencyclidine.  These parent compounds or metabolites are the 
substances that are assayed in drug screens for amphetamines, barbiturates, benzodiazepines, 
opiates, and phencyclidine; respectively.  Each analyte presents structurally different chemical 
moieties and functional groups as illustrated in Figure 4.  Each chemical moiety may dictate the 
susceptibility of the analyte to the effects of a urine adulterant.  Previous literature has 
demonstrated that only specific analytes may be susceptible to the effects of certain urine 
adulterants (Cody and Valtier 2001). 
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Figure 4  The chemical structures of morphine, amphetamine,  
 phencyclidine, nordiazepam, secobarbital, and  
 benzoylecgonine 
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Methods Currently Used to Adulterate a Urine Specimen 
Illicit drug users who wish to mask the detection of drugs in a urine specimen have 
several in vivo and in vitro methods currently available to them.  Each method differs with 
respect to the target of the adulterating agent (i.e., the analyte in the specimen, the matrix, or 
reagents within the assay) and the complexity of the mechanism of interference associated with 
the adulterating agent.  The target of the adulterating agent is of concern to forensic toxicologists 
because it dictates the protocol that will be followed to resolve this issue caused by the particular 
urine adulterant.  Urine adulterants that target the reagents within the immunoassay generally 
require the reformulation of the immunoassay reagents by the manufacturer.  If a urine 
adulterant targets individual analytes, the drug testing laboratories will focus on methodologies 
to detect the adulterant.  In attempt to suppress information that could be used by individuals 
who intend to adulterate their urine specimen, there are relatively few scientific publications 
describing urine adulterants.  The scientific literature cited herein comprises a vast majority of 
the total published scientific literature related to urine adulterant.  Much of the information 
pertaining to novel urine adulterants and adulteration methodologies is obtained by “counter-
culture” and “pro-drug” media.   
 
Pharmaceutical and Chemical Adulteration of Urine 
In vivo methods of urine adulteration include sodium bicarbonate ingestion that can 
increase urine pH and modify the excretion profile of parent drugs or metabolites. Diuretics will 
produce a more dilute urine by a variety of mechanisms dependent on their class (Winek and 
others 1993; Cone and others 1998).  Salicylate containing drugs in the urine will decrease the 
absorbance at 340 nm. 
In vitro methods of urine adulteration include diluting the specimen with tap water to 
bring the analytes of interest below their cutoff concentrations.  Substitution is also an effective 
means of obtaining a false negative drug screen result in which an individual can adhere a 
plastic container that is filled with a "clean" specimen close to the body and add the clean 
specimen to the urine cup at the time of collection. Detergents added to urine specimens can 
encapsulate analytes of interest in micelles rendering them unattainable to the antibody in 
immunoassays.  Urine adulteration is also achieved by the addition of acidic and basic 
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chemicals that cleave analytes of interest that contain susceptible moieties.  Bleach, nitrates, and 
nitrites will oxidize and modify the chemical structure of the analytes or immunoassay reagents 
when added to a urine specimen. Many commercially available oxidant based urine adulterants 
are easily detected in urine via osmolality or capillary ion electrophoresis (Ferslew, and others 
2003).  
 
Adulteration by Biologically Active Substances 
In addition to the chemical means of adulteration, the adulteration of urine has been 
accomplished by the addition of biologically active substances such as enzymes.  The kinetics of 
oxidizing materials such as nitrate and nitrites alone may be insufficient in those urine 
specimens that contain a high concentration of the analyte to effectively produce a false negative 
drug screen result.  Some commercial adulterants consist of an oxidant containing solution that 
is fortified with a peroxidase.  Peroxidases are a family of enzymes that catalyze the oxidation of 
a substrate.  The oxidizing adulterant reacts more quickly and efficiently with the analytes in the 
urine specimen which decreases the possibility of detecting an oxidizing adulterant while 
simultaneously yielding a lower concentration of the analyte of interest.  Those peroxidases that 
have been thoroughly investigated have molecular weights ranging from 45-150 kDa, and have 
Michaelis-Menton constants (Km) ranging from 0.004-181.3 mM, depending on the substrate 
(Kariya and others 1987).  
Proteases are enzymes that target proteins and cleave them at specific locations based on 
a particular amino acid, amino acid sequences, or any number of physical properties or 
functional groups.  Papain is a cysteine protease that cleaves peptide bonds of basic amino acids 
and can hydrolyze esters and amides (Townes-Anderson and others  1985).  Papain is obtained 
from the latex of the papaya plant, Carica Papaya, and is the active ingredient in Adolph’s® 
Meat Tenderizer and other consumer products.  Scientific investigation into the fermentative 
properties of papain began circa the 1870s (Wittmack 1878).  The application of papain in 
wound debridement has been described by Mekkes and others (1997).  Kinetic data for papain is 
listed in Table 2 and papain’s quaternary structure that reveals 6 alpha helices and 8 beta sheets 
is illustrated in Figure 5.  In addition to the variety of substrates that are enzymatic substrates to 
papain, it has demonstrated nonspecific binding to a variety of substances (An and others 2004).   
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The proliferative quantities of papaya latex worldwide yields gross quantities of papain 
to be sold in a variety of preparations with purities ranging from crude latex to refined-
recrystallized enzyme.  Each preparation has an associated quantity of papain enzyme with 
innate enzymatic activity.  Quantitation of the effects of a particular preparation of papain must 
be interpreted within the context of that preparation.  For example, the crude latex preparation of 
papain contains other proteins, both proteolytic and inert, including globulin, albumin, and 
peptones (Hwang and Ivey 1951).   
Currently, there are no published scientific literature sources that implicate papain as a 
potential or currently used urine adulterant.  Counter-culture internet web sites have cited papain 
as a potential urine adulterant (Erowid 1998).  Papain has the potential to be employed as a 
urine adulterant due to it being readily available, concealable, and relatively inexpensive.   
 
 
 
 
Figure 5  The quarternary structure of papain 
 
 
In general, commercially available urine adulterants are formulated with sufficient 
quantities of the active ingredient to mask the detection of drugs and/or metabolites in a chronic 
“heavy” user.  The product will then be effective for all types of illicit drug users.  The excessive 
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quantities of active ingredient(s) in currently available urine adulterants are easily detected by a 
variety of screening methods including colorimetric test strips such as MASK® and 
confirmation procedures such as capillary ion electrophoresis (Ferslew and others 2003).  The 
implementation of a chemical or biologically active substance as a novel method to effectively 
adulterate a urine specimen requires that the chemical or biologically active substance avoid 
detection.  The urine adulterant should therefore be stabile and easily transported at room 
temperature, able to be discretely added to the urine specimen, and not produce a gross 
abnormal appearance to the urine specimen.  
 
Table 2  Kinetic parameters of papain 
Parameter Value 
Molecular weight 20 - 24 kDa1,2 
Km 0.008 - 320 mM,1 
Turnover number 3.84 - 2 x 105 per sec3,4 
Optimum pH 6 - 9.55 
Optimum temperature 40 - 85 °C6 
pI 9.67 
Sources: 1 Glazer A, Smith E. 1971. Papain and other plant sulfhydryl proteolytic enzymes. The 
Enzymes, 3rd. Ed., 3:501-546; 2 Brocklehurst K, Baines B, Kierstan M. 1981. Papain and other 
constituents of Carica papaya L, Top. Enzyme Ferment. Biotechnol., 5:262-335; 3 Khouri H, and 
others. 1991. Engineering of papain, Biochemistry, 30:8929-8936; 4Storer A, Carey P. 1985. 
Comparison of the kinetics and mechanism of the papain-catalyzed hydrolysis of esters and 
thiono esters. Biochemistry. 24:6808-6818; 5 Skelton G. 1968. Papaya proteinases. I. 
Temperature-and pH-stability curves. Enzymologia 35:270-274; 6Chiou R, Beuchat L. 1986. 
Characteristics and application of immobilized papain in a continuous-flow reactor. Biotechnol. 
Appl. Biochem.8:529-536; 7Balls A, Lineweaver J. 1939. Isolation and properties of crystalline 
papain. J. Biol. Chem. 130: 669. 
 
 
Adulteration Detection 
The Department of Health and Human Services has developed guidelines in which they 
propose the implementation of adulterant testing by drug testing laboratories to determine if a 
given specimen is diluted, substituted, or adulterated  (NLCP Program Document #35 1998).  
The guidelines define the ranges of specific gravity (SG), pH, nitrite concentration, and 
creatinine values that label the urine specimens as normal, substituted, diluted, or adulterated.  
Table 3 lists the normal values of SG, pH, and creatinine for random urine specimens (n=40). 
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A specimen is considered diluted if the creatinine is < 20 mg/dL and the specific gravity 
is < 1.003.  Substituted urine specimens have creatinine concentrations < 5 mg/dL and specific 
gravities < 1.001 or > 1.020.  The urine is adulterated if the pH is < 3 or > 11  or a nitrite 
concentration >500 µg/mL (NLCP Program Document #35 1998).  Dual qualifying parameters 
(i.e., creatinine and specific gravity) were necessary to differentiate a urine specimen from a 
patient with polydipsia or renal disease from a diluted or substituted urine specimen.  In an 
evaluation of over 100 polydipsia case studies, there were no instances in which the patient’s 
urine was classified as substituted, diluted, or adulterated based on the Department of Health 
and Human Services guidelines (Cook and others 2000).   
 
Table 3  Creatinine, specific gravity, and pH  
  values of normal urine 
Parameter Value 
Creatinine 37 – 300 mg/dL 
(female) 44 – 250 
mg/dL (male) 
Specific gravity 1.002-1.030 
pH 4.5-8 
Adapted from: Tietz N. 2001. Fundamentals of  
clinical chemistry, 5rd ed. Philadelphia: WB  
Saunders. 1010 p. 
 
 Point of care (POC) adulterant testing kits such as Multiple Adulterant Strip Kemistry 
(MASK) allow the rapid detection/semi-quantitation of multiple urine parameters and 
adulterants including specific gravity, creatinine, pH, nitrite concentration, and the presence of 
oxidants and glutaraldehyde.  The MASK test strip contains multiple 1 cm x 1 cm absorbent 
pads infused with an adulterant chromaphor substrate that produces a color reaction in the 
presence of a particular adulterant or urine analyte.  The absorbent pads are then compared with 
a reference chart that illustrates examples of absorbent pads which indicate positive or negative 
results, or an approximate concentration of an analyte.   
 
Specific Aims of this Study 
Hypothesis: The concentration of THC-COOH in urine specimens, as measured by 
primary immunoassay drug screen analyses and confirmation analyses, will be reduced by the 
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adulteration of the urine specimen with papain such that the urine specimen will not be rendered 
invalid based on the current federal specimen validity guidelines. 
The hypothesis will be addressed by the following specific aims: 
1.  To determine if papain yields a false negative result by qualitative EMIT analysis on a 
specimen that contains THC-COOH. 
2.  To determine the quantities of papain required to obtain a false negative result on synthetic 
urine specimens that contain various amounts of THC-COOH, with respect to pH, papain 
concentration, and time. 
3.  To determine if the addition of papain to urine specimens will yield a false negative result by 
FPIA analysis on specimens that contain other commonly abused drugs. 
4.  To determine if the observed effects of papain are obtained with purified protein and with 
purified protein that has its enzymatic site is irreversibly inhibited. 
5.  To use a more selective and sensitive assay to determine if the mechanism of the effects of 
papain are due to manipulation of the analyte.  
6.  To determine if the maximum concentration of papain involved in adulterating the specimen 
renders the specimen invalid based on the proposed guidelines for substituted, adulterated, 
or diluted urine specimens, or due to qualitative analysis based on rapid chromaphore 
adulterant testing. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
Volumetric and Gravimetric Equipment 
 The analytical balance (Mettler H33AR, Mettler-Toledo, Columbus OH) used to obtain 
reagent masses in our research was calibrated with the National Institute of Standards and 
Technology (NIST) mass standards.  The following pipettes were calibrated by volumetric 
analysis with 18 MOhm deionized water from Nanopure water systems (Barnstead Company, 
Boston, MA.): Wheaton Calibra® 20-200 microliter adjustable pipette (Fisher Scientific, 
Pittsburgh, PA.); Wheaton Calibra® 2-20 microliter adjustable pipette (Fisher); Finnpipette® 
100-1000 microliter adjustable pipette (Fisher); Eppendorf Repeater® repeating single channel 
pipette (Brinkmann Instruments, Westbury, NY).  Eppendorf Research® 10, 50, and 100 µL 
pipettes (Fisher).   All graduated cylinders and ground glass volumetric flasks with penny 
stoppers used in our research were Pyrex™ brand obtained from Fisher Scientific.  All 
volumetric pipettes used in our research were Kimax™ brand obtained from Fisher Scientific. 
 
Laboratory Instruments 
 Specimen and buffer pH was measured on a model 4500 digital pH meter (Beckmann, 
Norcross, GA.) with a calomel glass combination electrode that was calibrated with a pH 7.0 
standard (Fisher) and a pH 4.0 or pH 10 standard (Fisher) as necessitated by the pH range 
measured.  Specimens were vortexed on a Barnstead/Thermolyne M16715 mixer (Barnstead 
International, Dubuque, IA.).  Liquid/liquid specimen extraction was assisted by a test tube 
rocker (American Dade, Miami, Fl.).  EMIT analyses were performed on a ETS™ analyzer 
(Syva-Dade Behring, San Jose, CA.) calibrated daily with negative, cutoff, and high calibrators 
as described below.  FPIA analyses were performed on an Abbott Axsym™ (Abbott Diagnostics, 
Abbott Park, IL.) FPIA analyzer.  Each lot of reagent kits was calibrated once with a 6 point 
standard curve in duplicate and two standard controls were assayed every 8 hour shift as 
described below.  Operation, maintenance, and proper handling of the reagents, controls, and 
calibrators were followed as instructed by the respective ETS™ and Axsym™ operation 
manuals.  UV/Vis Spectrophotometry was performed on a Cary 300 Bio UV/VIS split beam 
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spectrophotometer (Varian, Palto Alto, CA.) integrated to a Dell Optiplex® PC (Dell Inc., 
Round Rock, TX.).  Microplate spectrophotometry was performed on a Elx808 microplate 
reader (Bio-Tek Instruments, Winooski, VT.) integrated to a Dell Optiplex PC (Dell Inc.).  Gas 
chroma-tography/mass spectroscopy was performed on a model 5890 gas chromatograph 
(Hewlett Packard, Palo Alto, CA.) with a model 18596C autosampler (Hewlett Packard), a 
model 18593B autoinjector (Hewlett Packard), and a 30 m x 0.25 mm DB-5 capillary column 
(Supelco, St. Louis, MO.) coupled to a model 5972 electronic ionization mass selective ion 
detector (Hewlett Packard) integrated into a Vectra PC (Hewlett Packard).  High performance 
liquid chromatography/ultraviolet detection was performed on a model M-45 solvent delivery 
system (Waters, Millford, MA.) with a model 717 plus autosampler (Waters) and a 8 mm x 100 
mm NOVA-PAK C18-4 micron radial compression column (Waters) coupled to a Lambda-Max 
480 ultraviolet detector (Waters) integrated into a model 746 data module (Waters).  Specific 
gravity was measured with a model 300026 temperature compensated digital refractometer (Sper 
Scientific, Scottsdale, AZ.).  Osmolality was measured with a model 302 Advanced Digimatic® 
osmometer (Advanced Instruments, Needham Heights, MA.) or on an Osmette S automatic 
osmometer (Precision Systems Inc., Natick, MA.). 
 
Enzymes and Pharmaceutical Standards 
 Papain (Sigma Chemical, St. Louis, MO. Catalog # P3375, Lot # 51K1540),  
1.5-3.5 U/mg, was purchased in the form of crude latex granules. The crude latex granules were 
pulverized with a pestle and mortar to a fine powder and refrigerated at 4 °C.  Unless otherwise 
noted, all assays were performed with the crude latex powder form of papain.  A 26.4 mg/mL 
stock suspension of twice recrystallized papain (RP) with a standardized enzyme activity of 21 
U/mg (Sigma, Catalog # P3125, Lot # 30H8030) was donated (Johnson 2002) and refrigerated 
at 4 °C (Dubois and others 1988).  A 200 mM dithiothreitol (DTT) stock standard solution was 
prepared by placing 309 mg of dithiothreitol (Sigma, Catalog # D-9163, Lot # unknown) in a 10 
mL volumetric flask with 5 drops of dimethyl sulfoxide (DMSO, Sigma) and diluting to volume 
with 18 MOhm deionized water. N-alpha-Benzoyl-DL-Arg-p-Nitroanalide, BANI, (Sigma 
Chemical, Catalog # B4875, Lot # 63F-0436) was donated (Johnson 2002) and refrigerated at 4 
°C.  
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 Working standards of THC-COOH (Cerilliant, Round Rock, TX, Catalog #01422, Lot 
#’s 44,45) were purchased in the form of a 100 mcg/mL stock methanol standards in a sealed 
1.5 mL glass vial.  Deuterated 11-norcarboxy-delta-9-tetrahydrocannibinol (d3 -THC-COOH) 
(Cerilliant, Catalog # T-015, Lot # 35002-42C) was purchased in the form of a 10 mcg/mL stock 
methanol standard in a sealed 1.5 mL glass vial.  A 1 mg/mL nordiazepam stock methanol 
standard was prepared by placing 10 mg of nordiazepam free base (Sigma, Catalog # D7282, 
Lot # 17F-4024) in a 10 mL volumetric flask and diluting to volume with methanol (Optima®, 
Fisher).  A 1 mg/mL benzoylecgonine stock methanol standard was prepared by placing 10 mg 
of benzoylecgonine free base (Sigma, Catalog # B4147, Lot #68F-4001) in a 10 mL volumetric 
flask and diluting to volume with methanol (Optima®, Fisher).  A 1 mg/mL prazepam stock 
methanol standard was prepared by placing 10 mg of prazepam free base (Sigma, Catalog 
#P3654, Lot #56F-0684) in a 10 mL volumetric flask and diluting to volume with methanol 
(Optima®, Fisher). Phencyclidine (Cerilliant, Catalog# P-007, Lot # 65004-06D) was purchased 
in a 10 mcg/mL stock methanol standard in a sealed 1.5 mL glass vial. A 1 mg/mL morphine 
stock methanol standard was prepared by placing 10.4 mg of morphine sulfate (Mallinckrodt, 
Hazelwood, MO, Catalog # unknown, Lot # E633-102) ) in a 10 mL volumetric flask and 
diluting to volume with methanol (Optima®, Fisher). A 1 mg/mL amphetamine stock methanol 
solution was prepared by placing 13.6 mg of amphetamine sulfate (Smith-Kline, Research 
Triangle Park, NC., Catalog # Unknown, Lot # Unknown) in a 10 mL volumetric flask and 
diluting to volume with methanol (Optima®, Fisher). A 1 mg/mL secobarbital stock methanol 
solution was prepared by placing 10 mg of secobarbital free acid (Sigma, Catalog # S1503, Lot 
# 030H0288) in a 10 mL volumetric flask and diluting to volume with methanol (Optima®, 
Fisher).  
 
Papain Standardization 
The proteolytic activity of papain was quantitated by spectrophotometric observance of 
the hydrolysis of N-alpha-Benzoyl-DL-Arg-p-Nitroanalide (BANI) adapted from a previously 
published method (Erlanger, Kokowsky, and Cohen  1961).  The activity of cysteine proteases 
are augmented by a reducing agent such as sodium sulfide or DTT.  A 20 mM DTT standard 
solution was prepared by pipetting 1 mL of the 200 mM stock DTT solution into a 10 mL 
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volumetric flask and diluting to volume with 18 MOhm deionized water and vortexing for 1 
minute.  A 20 mM stock solution of BANI was prepared by placing 87.0 mg of BANI into a 10 
mL volumetric flask with 1 mL of DMSO and diluting to volume with 18 MOhm deionized 
water. The solution was stoppered and vortexed for 1 minute.  A 2 mM BANI/DTT working 
solution was prepared by pipetting 1 mL of the 20 mM BANI stock solution and 1 mL of the 20 
mM standard solution into a 10 mL flask and diluting to volume with 18 MOhm deionized water 
to yield a working solution of 2 mM BANI/DTT.  The 2 mM BANI/DTT working solution was 
stoppered and mixed thoroughly by repeated inversion of the volumetric flask.  A working 
solution of 0.13 mg/mL (2.73 U/mL) twice recrystallized papain (RP) was prepared by pipetting 
49.0 µL of the 26.4 mg/mL RP stock standard into a 10 mL volumetric flask and diluting to 
volume with 18 MOhm water. A 0.065 mg/mL (1.37 U/mL) RP working standard was prepared 
by pipetting 50 µL of 0.13 mg/mL RP standard in a 1.5 mL flat top microcentrifuge tube 
(Fisher) followed by 50 µL of 18 MOhm deionized water.  A 0.0325 mg/mL (0.68 U/mL) RP 
working standard was prepared by pipetting 50 µL of 0.065 mg/mL RP standard in a 1.5 mL flat 
top microcentrifuge tube (Fisher) followed by 50 µL of 18 MOhm deionized water.  A blank 2 
mM DTT working solution was prepared by pipetting 10 µL of the 200 mM DTT into a 1 mL 
volumetric flask and diluting to volume with 18 MOhm deionized water.  A 10 mg/mL crude 
latex papain (CLP) solution was prepared by placing 10.0 mg of CLP in a 10 mL volumetric 
flask and diluting to volume with 18 MOhm deionized water.  A 5 mg/mL CLP solution was 
prepared by pipetting 200 µL of the 10 mg/mL papain solution into a 1.5 mL flat top 
microcentrifuge tube (Fisher) followed by 200 µL of 18 MOhm deionized water.  Repeated 
serial dilutions with equal volumes of 18 MOhm deionized water were performed to obtain 2.5 
and 1.25 mg/mL CLP solutions. 
The Cary UV/Vis spectrophotometer was allowed to stabilize for 1 hour.  The 
accompanied software program “Kinetics” was opened and wavelength was adjusted to 410 nm.  
The reference cuvette consisted of 1.0 mL of the 2 mM BANI/DTT solution and 67 µL of  18 
MOhm deionized water pipetted into a 1-cm matched quartz cuvette (Fisher).  The sample cell 
contained 1.0 mL of the 2 mM BANI/DTT solution.  Immediately prior to recording absorbance 
data, 67 µL of the 0.13 mg/mL RP standard was pipetted into the sample cuvette and mixed by 
repeated pumping of the pipette plunger.  The sample cuvette was placed in the 
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spectrophotometer and the absorbance was measured for 20 minutes.  The initial rate of 
absorbance change (delta-mabs/min) was obtained in the first 45 seconds of the reaction.  The 
analysis was repeated with 67 µL of 0.065 mg/mL, 0.0325 mg/mL RP working standards, and 
blank 2 mM DTT working solution.  The BANI proteolytic activity assay was repeated with CLP 
solutions in concentrations of 10, 5, 2.5, and 1.25 mg/mL.  
 
Synthetic Urine 
 Enzyme activity is dependent on several parameters such as pH, temperature, co-factors 
and ionic strength.  The effect of papain on THC-COOH and other drugs of abuse was 
monitored in a matrix of synthetic urine.  The synthetic urine provided a matrix with discrete 
constituents that defined the environment in which the enzyme was active.  The synthetic urine 
also provided a matrix that was completely devoid of over-the-counter pharmaceuticals or other 
potentially adulterating substances that may be present in a pooled urine matrix.  Two-4 liter 
batches of synthetic urine were prepared and homogenized as described by Kark and others 
(1964).  Each batch of synthetic urine was prepared by placing the quantities, in grams, of the 
following constituents (Table 4) into a 5.5 L polypropylene beaker (Nalgene®, Fisher): urea 
(Fisher), 64; sodium chloride (Fisher), 9.3; potassium chloride (Fisher), 13.7; creatinine (Fisher), 
4.4; sodium sulfate (Fisher), 17.25; ammonium chloride (Fisher), 4.25; citric acid (Fisher), 2.2; 
magnesium sulfate (Fisher), 1.85; sodium phosphate dibasic monohydrate (Fisher), 12.55; 
calcium chloride dihydrate (Fisher), 3.75; sodium oxalate (Fisher), 0.119; lactic acid (Fisher), 
320 µL of 85% solution; glucose (Fisher), 1.95; sodium silicate pentahydrate (Fisher), 0.212; 
pepsin (Fisher), 0.1; sodium fluoride (Fisher), 1.0.  Two-2000 mL aliquots of deionized water 
were added to the 5.5 liter beaker by a 2000 mL graduated cylinder (Fisher).  Both 4 liter 
batches of synthetic urine were mixed for 1 hour by a 3 inch magnetic stir bar on a 
Fisherbrand® variable speed mixer (Fisher).  The synthetic urine was titrated to pH 6.2 with 
concentrated HCl (Optima®, Fisher). The two batches of synthetic urine were then homogenized 
with each other and stored at 4 °C until needed.  The osmolality of the synthetic urine was 
measured on an Osmette S automatic osmometer (Precision Systems Inc.).  The osmometer was 
turned on and allowed to stabilize for 1 hour.  The instrument was calibrated with a 500 
mOsm/L calibration standard (Advanced Instruments).  A 200 µL aliquot of the calibrator and 
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synthetic urine was pipetted into disposable plastic osmometer sample cups.  The sample cup 
was placed into the sample cup reservoir and the probe was lowered into the sample cup.  
Osmolality was measured directly by depressing the “seed” switch. 
 
Table 4. Constituents of synthetic urine 
Constituent Quantity (g/4 kg) 
Urea 64 
Sodium Chloride 9.3 
Potassium Chloride 13.7 
Creatinine 4.4 
Sodium Sulfate 17.25 
Ammonium Chloride 4.25 
Citric Acid 2.2 
Magnesium Sulfate 1.85 
Sodium Phosphate Dibasic Monohydrate 12.55 
Calcium Chloride Dihydrate 3.75 
Sodium Oxalate 0.119 
Lactic Acid 320 µL of 85% solution 
Glucose 1.95 
Sodium Silicate Pentahydrate 0.212 
Pepsin 0.1 
NaF 1 
Source: Adapted from Kark RM, Lawrence JR, Pollack VE, Pirani CL,  
Muehrcke RC, Silva H. 1964. A primer of urinalysis (2nd ed.). New  
York: Hoeber Medical Division, Harper & Row. 74 p. 
 
Enzyme Multiplied Immunoassay Technique  
 A preliminary investigation into papain’s effects on synthetic urine specimens containing 
THC-COOH was performed by enzyme multiplied immunoassay technique. A 125 ng/mL THC-
COOH solution was prepared by pipetting 125 µL of 100 mg/mL THC-COOH stock methanol 
standard into a 100 mL volumetric flask with 1 mL of 200 mM DTT and diluting to volume 
with pH 6.2 synthetic urine. Six replicate adulterated specimens containing 10 mg/mL papain 
were prepared by placing 10 mg of papain in a 1.5 mL flat top microcentrifuge tube (Fisher) and 
delivering 1 mL of the 125 ng/mL THC-COOH solution with an Eppendorf Repeater®.  Six 
positive control specimens were prepared by delivering 1 mL of the 125 ng/mL THC-COOH 
solution in a 1.5 mL flat top microcentrifuge tube (Fisher) with an Eppendorf Repeater®.  The 
specimens incubated at room temperature (~23 0C) for 5 hours.   
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The ETS™ analyzer was allowed to stabilize for 1 hour. The initialization and calibration 
procedure as defined in the operator’s manual was followed to calibrate the instrument.  
Negative (0 ng/mL THC-COOH), cutoff (100 ng/mL THC-COOH), and high (200 ng/mL THC-
COOH) calibrators were removed from the refrigerator and allowed to attain room temperature 
for 1 hour.  Calibrators were pipetted into ETS™ sample cups with a 200 µL disposable glass 
pasteur pipette.  The ETS™ sample cups were placed on an ETS™ sample cup carousel that was 
placed in and ETS™ reagent rack position on the instrument.  The instrument calibration, 
involving duplicate assays of the cutoff calibrator and a single assays of the negative and high 
calibrators, was performed.  The delta-mabs/t separations between the negative and the cutoff 
calibrator values, and between the cutoff and the high calibrator values exceed the minimum 
values for the particular reagent lot used.   A 200 µL aliquot of the prepared unadulterated and 
adulterated synthetic urine specimen was pipetted into an ETS™ sample cup with a 200 µL 
disposable glass pasteur pipette.  The ETS™ sample cups were placed on an ETS™ sample cup 
carousel that was placed in and ETS™ reagent rack position on the instrument.  “Cannabinoid 
100” assay was selected for each specimen and the assay sequence was started. 
 
Fluorescence Polarized Immunoassay 
 The following FPIA analyses provided information on the dose dependent effects of 
papain on synthetic urine with respect to the analyte of interest, the pH of the urine matrix, the 
temperature of the urine matrix, and the time of analyte exposure to papain.  The experiments 
were constructed to emulate specimen analysis performed in laboratories within 8 hours, 24 
hours , and 3 days of after the time of specimen collection .  A typical FPIA cannabinoid assay 
calibration curve is illustrated in Figure 6.  The quantity of polarized light (mP) of THC-COOH 
calibrator was plotted against its respective THC-COOH calibrator concentration (ng/mL), and 
the mathematical fit, mP= A+(B/(C+[THC-COOH]^D)),  as defined by the Axsym™ operator’s 
manual was performed to yield a standard curve with a calculated correlation coefficient (r2).  
All daily calibrators were within the allowable range as noted by the Axsym™ operator’s manual 
guidelines.   
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Figure 6  Typical FPIA cannabinoid assay calibration curve 
 
THC-COOH Assays 
A 25 ng/mL THC-COOH solution was prepared by pipetting 50 µL of the 100 mcg/mL 
THC-COOH stock methanol standard into a 200 mL volumetric flask with 2 mL of 200 mM 
DTT.  The flask was diluted to volume with pH 6.2 synthetic urine.  Six replicate specimens of 
pH 6.2  synthetic urine containing 0, 0.5, 1, 2, 5, and 10 mg/mL papain (36 total specimens) 
were prepared by placing 0, 2.5, 5, 10, 25, and 50 mg of papain in 13 x 100 mm glass screw top 
test tubes (Fisher) and delivering 5 mL of pH 6.2 synthetic urine with an Eppendorf Repeater® 
to every tube.   
The Axsym™ analyzer was allowed to stabilize for 1 hour. The initialization calibration 
procedure as defined in the operator’s manual was followed to calibrate the instrument.  Each 
cannabinoid reagent lot was calibrated with a 6 point control.  A 200 µL aliquot of  0, 25, 40, 
60, 80, 135 ng/mL THC-COOH calibrators (Abbott) were pipetted into Axsym™ sample cups 
with a 100-1000 mL Eppendorf™ pipette.  The sample cups were placed in a sample cup rack 
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and placed on the sample cup rack carousel.  The calibrators were assayed to calibrate the 
reagent lot.  A 200 µL aliquot of the 36 prepared specimens and 2 cannabinoid controls (Abbott) 
were pipetted into the Axsym™ sample cups with a 100-1000 mL Eppendorf™ pipette. The 
sample cups were placed in a sample cup rack and placed on the sample cup rack carousel.  
Specimen identifiers were entered on the Axsym™ touch screen and assayed for cannabinoids.  
The specimens were capped with a teflon screw cap and allowed to remain at room temperature 
(~23 °C) before being re-assayed for cannabinoids 4 and 6 hours after the specimens were 
initially prepared.  The specimens were then refrigerated at 4 °C before being re-assayed for 
cannabinoids at 24 and 72 hours after the initial preparation of the specimens.  
 Standard solutions of pH 6.2 synthetic urine containing 75, 100, 250, and 500 ng/mL 
THC-COOH were prepared by pipetting 150, 200, 500, and 1000 µL of 100 mcg/mL THC-
COOH stock methanol standard into separate 200 mL volumetric flasks with 2 mL of 200 mM 
DTT and diluting to volume with pH 6.2 synthetic urine.  The set of FPIA assays as described 
above for 25 ng/mL THC-COOH were performed with the synthetic urine containing 75 - 500 
ng/mL THC-COOH.  The upper limit of the calibration curve for the cannabinoid assay was 135 
ng/mL.  Prepared specimens that had reported concentrations >135 ng/mL were diluted 
accordingly with blank synthetic urine and re-assayed such that the reported concentration was 
<135 ng/mL. 
 Standard solutions of pH 8.0 and 4.5 synthetic urine were prepared by placing 1.2 liters 
of pH 6.2 synthetic urine in a 2 L Kimax beaker (Fisher) with a magnetic stir bar.  The beaker 
was then placed on an automatic stir plate and allowed to stir with the pH electrode protruding 
into the liquid.  Adjustment to the pH 4.5 or 8.0 was accomplished with the titration of 
concentrated 12 M hydrochloric acid (Reagent Grade®, Fisher) or 10 M sodium hydroxide 
(Fisher).  The solutions were placed in a 1 L brown glass screw top bottle, capped, and placed in 
the refrigerator at 4 °C until needed.  
Standards consisting of 25, 75, 100, 250, and 500 ng/mL THC-COOH in pH 4.5 and 8.0 
synthetic urine were prepared as described for 6.2 synthetic urine.  Six replicate specimens 
containing 0, 0.5, 1, 2, 5, and 10 mg/mL papain (36 total specimens per set) were prepared as 
described above for each THC-COOH standard at pH 4.5 and 8.0 (10 total sets).  The specimens 
 42 
were assayed for cannabinoids under the same time-temperature treatments as described above 
for pH 6.2 synthetic urine. 
 
FPIA Assays for Other Drugs of Abuse 
 To determine if papain had an effect on the reported concentrations of other drugs of 
abuse, FPIA analyses were performed for amphetamine, barbiturates, benzodiazepines, cocaine, 
opiates, and phencyclidine in pH 6.2 synthetic urine adulterated with 10 mg/mL papain.  Two 
standard solutions, a positive and a negative, were prepared for each analyte in pH 6.2 synthetic 
urine.  The positive solution contained 150% of a respective analytes’ cutoff concentration, and 
the negative solution contained 50% of the a respective analytes’ cutoff concentration.  The 
1500 ng/mL and 500 ng/mL amphetamine solutions were prepared by pipetting 150 and 50 µL 
of 1 mg/mL amphetamine stock methanol standard into two 100 mL volumetric flask with 1 mL 
200 mM DTT and diluting to volume with pH 6.2 synthetic urine. The 300 ng/mL and 100 
ng/mL secobarbital solutions were prepared by pipetting 30 and 10 µL of 1 mg/mL secobarbital 
stock methanol standard into two 100 mL volumetric flask with 1 mL 200 mM DTT and 
diluting to volume with pH 6.2 synthetic urine. The 300 ng/mL and 100 ng/mL nordiazepam 
solutions were prepared by pipetting 30 and 10 µL of 1 mg/mL nordiazepam stock methanol 
standard into two 100 mL volumetric flask with 1 mL 200 mM DTT and diluting to volume with 
pH 6.2 synthetic urine. The 450 ng/mL and 150 ng/mL benzoylecgonine solutions were prepared 
by pipetting 45 and 15 µL of 1 mg/mL benzoylecgonine stock methanol standard into two 100 
mL volumetric flask with 1 mL 200 mM DTT and diluting to volume with pH 6.2 synthetic 
urine. The 450 ng/mL and the 150 ng/mL morphine solutions were prepared by pipetting 45 and 
15 µL of 1 mg/mL morphine stock methanol standard into two 100 mL volumetric flask with 1 
mL 200 mM DTT and diluting to volume with pH 6.2 synthetic urine. The 37.5 ng/mL and the 
12.5 ng/mL phencyclidine solutions were prepared by pipetting 37.5 and 12.5 µL of 0.1 mg/mL 
phency-clidine stock methanol standard into two 100 mL volumetric flask with 1 mL 200 mM 
DTT and diluting to volume with pH 6.2 synthetic urine. 
Six unadulterated specimens and 6 specimens adulterated with 10 mg/mL papain were 
prepared for both the negative and the positive solutions for each analyte (144 total specimens).  
The adulterated specimens were prepared by placing 50 mg of papain into 13 x 100 screw top 
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test tubes and delivering 5 mL of the respective solution to every tube with an Eppendorf 
Repeater®.  This process was repeated for each analyte’s negative and positive solution.  The 
unadulterated specimens were prepared by delivering 5 mL of the respective solution to an 
empty 13 x 100 screw top test tube with an Eppendorf Repeater®.  This process was repeated 
for each analyte’s negative and positive solution.  The reagent lot for the amphetamine, 
barbiturates, benzodiazepines, cocaine, opiate, and phencyclidine assays were calibrated by their 
respective assay calibrators (Abbott) as described for the cannabinoid assay.  A 200 µL aliquot 
of the prepared specimens and 2 assay controls (Abbott) for each assay were pipetted into the 
Axsym™ sample cups with a 100-1000 mL Eppendorf™ pipette. The sample cups were placed 
in a sample cup rack and placed on the sample cup rack carousel.  Sample identifiers were 
entered on the Axsym™ touch screen and assayed for their respective analyte.  The prepared 
specimens were capped with a teflon screw cap and allowed to remain at room temperature (~ 23 
°C) for 6 hours after the initial preparation before being re-assayed on the Axsym™ for their 
respective analyte.  The specimens were then capped with a teflon screw cap and refrigerated (4 
°C) and re-assayed on the Axsym™ for their respective analyte at 72 hours after preparation. 
 
Recrystallized Papain and Inhibition by E-64 
Based on results obtained by FPIA analysis for cannabinoids and other drugs of abuse in 
specimens adulterated with papain, the following FPIA analyses were performed with twice 
recrystallized papain (RP) with a standardized activity of 21 U/mg.  Inhibition of RP enzymatic 
activity with trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane (E-64) was necessary to 
determine if the observed effects of papain on specimens containing THC-COOH and 
nordiazepam were due to its enzymatic activity.   E-64 covalently binds to the cysteine-25 active 
site on papain preventing enzymatic activity. 
 
BANI Assay of Inhibited RP Enzymatic Activity.  To determine the quantity of E-64 
required to inhibit a 1 mg/mL solution of RP, a BANI enzyme activity assay was performed. The 
microplate reader was allowed to stabilize during the preparation of the specimens.  The 
software program “KC Jr.” was opened and the wavelength was set to 405 nm.  The kinetics 
program instructed the microplate reader to read the specimen wells every 20 seconds for 4 
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minutes.  A working solution of 1 mg/mL RP was prepared by pipetting 76 µL of 26.4 mg/mL 
RP stock suspension into a 2 mL volumetric flask with 20 µL of 200 mM DTT and diluting to 
volume with 18 MOhm deionized water.  A working solution of deactivated recrystallized 
papain (DRP) was prepared by placing 1 mg of E-64 into a 1 mL volumetric flask and diluting 
to volume with the 1 mg/mL RP working solution, yielding a 58.7 molar excess of E-64 to 
papain.  The DRP solution incubated for 2 hours at room temperature to allow the E-64 to 
covalently bind to papain.  A solution of 2 mM DTT was prepared by pipetting 10 µL of 200 
mM DTT stock standard solution into a 1 mL volumetric flask and diluting to volume with 18 
MOhm deionized water.  A stock solution of 20 mM BANI was prepared by placing 43.5 mg 
into a 5 mL volumetric flask with 1 mL DMSO (Sigma) and diluting to volume with 18 MOhm 
deionized water.  A working solution of 4 mM BANI was prepared by pipetting 1 mL of the 20 
mM BANI stock solution into a 5 mL volumetric flask with 50 mL of 200 mM DTT and diluting 
to volume with 18 MOhm deionized water.  A blank specimen was prepared by pipetting 150 µL 
of 4 mM BANI into a well of a 96 well acrylic microplate (Neogen) and adding 150 µL of 2 mM 
DTT.  Control specimens of RP were prepared in triplicate by pipetting 150 µL of 4 mM BANI 
into 3 wells of the 96 well microplate with 150 mL of 1 mg/mL RP solution.  Triplicate 
specimens of DRP were prepared by pipetting 150 µL of 4 mM BANI into 3 wells of the 96 well 
microplate with 150 mL of 1 mg/mL DRP solution.  The absorbance in every specimen well was 
sequentially measured at 405 nm every 5 seconds for 4 minutes. 
 
 FPIA Assays with RP and DRP.  A 2 mg/mL RP working solution was prepared by 
pipetting 152 µL of 26.4 mg/mL RP stock suspension into a 2 mL volumetric flask with 20 µL 
of 200 mM DTT and diluting to volume with 18 MOhm deionized water.  A 2 mg/mL DRP 
working solution was prepared by placing 2 mg of E-64 in a 1 mL volumetric flask and diluting 
to volume with the 2 mg/mL RP working solution and allowing the DRP solution to incubate for 
2 hours at room temperature.  A 2 mM DTT solution was prepared by pipetting 100 µL of 200 
mM DTT into a 10 mL volumetric flask and diluting to volume with 18 MOhm deionized water.  
A 120 ng/mL THC-COOH working solution was prepared by pipetting 120 µL of 100 mg/mL 
THC-COOH stock methanol standard into a 10 mL volumetric flask with 100 µL of 200 mM 
DTT and diluting to volume with 18 MOhm deionized water.  Six replicate blank specimens 
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were prepared by pipetting 100 µL of the 120 ng/mL THC-COOH working solution into 6 
Axsym™ sample cups with 100 µL of 2mM DTT solution.  Six replicate RP adulterated 
specimens were prepared by pipetting 100 µL of the 120 ng/mL THC-COOH working solution 
into 6 Axsym™ sample cup with 100 µL of the 2 mg/mL RP working solution. Six replicate 
DRP adulterated specimens were prepared by pipetting 100 µL of the 120 ng/mL THC-COOH 
working solution into 6 Axsym™ sample cups with 100 µL of the 2 mg/mL DRP working 
solution.  The specimens were allowed to incubate at room temperature for 2 hours before being 
assayed for cannabinoids on the calibrated Axsym™ analyzer as described in the previous 
section.   
A 500 ng/mL working solution of nordiazepam was prepared by pipetting 5 µL of the  
1 mg/mL nordiazepam stock methanol standard into a 10 mL volumetric flask with 100 µL of  
2 mM DTT.  The 2 mg/mL RP and DRP working solutions were prepared as described as above 
for the THC-COOH assay. Six replicate blank specimens were prepared by pipetting 100 µL of 
the 500 ng/mL nordiazepam working solution into 6 Axsym™ sample cups with 100 µL of 
2mM DTT solution.  Six replicate RP adulterated specimens were prepared by pipetting 100 µL 
of the 500 ng/mL nordiazepam working solution into 6 Axsym™ sample cups with 100 µL of 
the 2 mg/mL RP working solution. Six replicate DRP adulterated specimens were prepared by 
pipetting 100 µL of the 500 ng/mL nordiazepam working solution into 6 Axsym™ sample cups 
with 100 µL of the 2 mg/mL DRP working solution. The specimens were allowed to incubate at 
room temperature for 2 hours before being assayed for benzodiazepines on the calibrated 
Axsym™ analyzer as described in the previous section. 
 
Gas Chromatography/ Mass Spectroscopy of THC-COOH 
 
Preparation of Buffers/Reagents 
 A solution of 100 mM hydrochloric acid (HCl) was prepared by placing 4.2 mL 
concentrated HCl (Optima®, Fisher) into a 500 mL volumetric flask and diluting to volume with 
18  MOhm deionized water.  A solution of 100 mM HCl/acetonitrile (70/30) was prepared by 
placing 70 mL of 100 mM HCl in a 100 mL volumetric flask and diluting to volume with 
acetonitrile (Optima®, Fisher).  A solution of hexane/ethyl acetate (50/50) was prepared by 
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placing 25 mL of hexane (Optima®, Fisher) into a 50 mL volumetric flask with a volumetric 
pipette and diluting to volume with ethyl acetate (Optima®, Fisher).  The derivatizing reagent 
N,O-bis[Trimethylsilyl]trifluoroacetamide (BSTFA, Sigma) was purchased in 1 mL aliquots 
sealed in a 1.5 mL glass vial. 
 
Preparation of Standards and Specimens 
 A 500 ng/mL THC-COOH working standard was prepared by pipetting 250 µL of the 
100 mcg/mL THC-COOH stock methanol standard into a 50 mL volumetric flask with 500 µL 
of 200 mM DTT.  The flask was diluted to volume with pH 6.2 synthetic urine.  A solution of  
2 mM DTT was prepared in blank synthetic urine by pipetting 25 µL of the 200 mM DTT stock 
solution into a 25 mL volumetric flask and diluting to volume with pH 6.2 synthetic urine.  A 
standard curve was prepared by pipetting 0.0, 1.0, 2.0, 3.0, 4.0, and 5.0 mL of the 500 ng/mL 
THC-COOH working standard into six 13 x 100 mm glass screw top test tubes that contained 
5.0, 4.0, 3.0, 2.0, 1.0, and 0.0 mL of 2 mM DTT in blank pH 6.2 synthetic urine to yield 
concentrations of 0, 100, 200, 300, 400, and 500 ng/mL THC-COOH.  Six replicate adulterated 
specimens that contained 500 ng/mL THC-COOH and 10 mg/mL papain were prepared by 
pipetting 5.0 mL of the 500 ng/mL THC-COOH working standard into six 13 x 100 mm glass 
screw top test tubes  that each contained 50 mg of papain.  A blank adulterated specimen was 
also prepared by pipetting 5.0 mL of blank pH 6.2 synthetic urine in a 13 x 100 mm glass screw 
top test tube that contained 50 mg of papain.  All standards and specimens were capped with a 
teflon screw cap and allowed to remain at room temperature for 24 hours before analysis. 
 
Solid Phase Extraction and Derivatization 
 All standards and specimens were extracted by solid phase extraction (SPE) according to 
a method adapted from the United Chemical Technologies (United Chemical Technologies, 
Bristol, PA) Applications Manual.  Just prior to beginning the extraction procedure, 10 µL of the 
10 mcg/mL d3-THC-COOH stock methanol standard was pipetted to every specimen tube with 
an Eppendorf Repeater® as an internal standard and vortexed.  The pH of the standards and 
specimens was assessed by pHydron™ papers, 4.5-7.5 range (Micro Essential Laboratories, 
Brooklyn, N.Y.) and were adjusted to pH 6.0 +/- 0.5 with 100 mM (mono-, di-) basic sodium 
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phosphate as needed.  Thirteen SPE cartridges, model ZSDAU020 (United Chemical 
Technologies) were labeled and placed on a 29 cm x 7.5 cm x 10 cm vacuum apparatus 
connected to a model DOL-101-AA vacuum pump (Gast, Benton Harbor, MI.).   The vacuum 
pump was adjusted to apply a 25 mmHg negative pressure to the vacuum apparatus.  The SPE 
cartridges were conditioned with 3 mL of methanol (Optima®, Fisher), followed by 3 mL of 
deionized water, then 1 mL of 100 mM HCl.  Standards and specimens were applied to the 
column at 1 to 2 mL/min.  The column was washed with 2 mL of deionized water, followed by 2 
mL of 100 mM HCl/acetonitrile (70/30) before being allowed to dry.  A 200 mL aliquot of 
hexane was pipetted into the cartridges before shutting off the vacuum pump and eluting the 
THC-COOH.  The specimens were eluted by gravity into 5 mL conical glass screw top 
derivatization vials (Sigma) with 3 mL of hexane/ethyl acetate (50/50).  The eluate was 
evaporated to dryness overnight in a laboratory hood.   
 A 50 µL aliquot of BSTFA was added to every derivatization vial with an Eppendorf 
Repeater® before being capped with a teflon top and plastic screw cap.  The derivatization vials 
were incubated at room temperature (~ 23 °C) overnight.  The derivatized standards and 
specimens were then transferred with a disposable glass pasteur pipette (Fisher) to 12 x 32 mm 
glass autosampler vials (National Scientific, Duluth, GA.) containing a glass microsample 
inserts (National Scientific) supported by an insert compression spring (National Scientific).  
The derivatized specimens and standards were then capped with a teflon lined screw cap 
(National Scientific) and placed on the gas chromatograph autosampler for subsequent assay. 
 
 GC/MS Parameters 
 The GC/MS software method “northcsm” (Table 5) was initialized with the following 
instrument parameters: injection volume, 3 µL; injector temperature, 250 °C; helium flow, 1 
mL/min; column temperature program, 200 °C for 0.5 min, then raised at 30 °C/min to 300 °C 
for 6.5 minutes; GC/MS interface temperature, 250 °C; mass selective ion detector temperature, 
250 °C; monitored ions (m/z), THC-COOH: 371, 473, 488, d3-THC-COOH: 374, 476, 491.   
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Table 5  Gas chromatography/mass spectroscopy parameters for “northcsm” 
Instrument Hewlett-Packard 5890 gas chromatograph coupled to a 5972 
mass selective ion detector 
Injection volume 3 µL 
Injector temperature 250 °C 
Column 30 m x 0.25 mm DB-5 capillary column 
Column conditions 200 °C for 0.5 min, then raised at 30 °C/min to 300 °C for 6.5 
minutes 
Mass selective ion detector Electronic ionization with 70 eV at 250 °C, and an electron 
multiplier voltage of 1753mV. 
Monitored ions 
(quantitation) 
THC-COOH: (371), 473, 488; d3-THC-COOH: (374), 476, 491 
 
Figure 7 illustrates the high degree of linearity (r2 = 0.998) of the PAR (371:374) versus THC-
COOH (ng/mL) standard curve.   
THC-COOH Concentration (ng/mL)
0 100 200 300 400 500
Sheet: Untitled1
Pe
ak
 A
re
a 
Ra
tio
 o
f m
/z
 3
71
:3
74
-0.5
4.5
9.5
14.5
19.5 Curve Description:
PAR=(0.028*[THC-COOH])-0.298
r = 0.998
 
Figure 7  The standard curve of peak area ratio (PAR) versus THC-COOH concentration 
 (ng/mL) 
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High Pressure Liquid Chromatography/Ultraviolet Detection of Nordiazepam 
 
Preparation of Buffers/Reagents 
An ammonium chloride/ammonium hydroxide (NH4Cl/NH4OH) buffer, pH 9.2, was 
prepared by saturating a 50 mL aliquot of 18 MOhm deionized water with ammonium chloride 
(Fisher), followed by titration to pH 9.2 with concentrated ammonium hydroxide (reagent grade, 
Fisher) with a digital pH meter.  A 100 mM monobasic potassium phosphate (KH2PO4) solution 
was prepared by dissolving 13.61 g of KH2PO4 in a one liter volumetric flask that contained 500 
mL 18 MOhm deionized water and 5.0 mL of methanol.  The flask was then diluted to volume 
with 18 MOhm deionized water.  A 100 mM phosphoric acid solution (H3PO4) was prepared by 
pipetting 6.7 mL of 85% H3PO4 (reagent grade, Fisher) into a 1 L volumetric flask and diluting 
to volume with 18 MOhm deionized water.  A 15 mM phosphate buffer, pH 3.3, was prepared 
by pouring 300 mL of the 100 mM KH2PO4 buffer, pH 9.2, into a 500 mL graduated cylinder 
and adding the contents to a 2 L volumetric flask, then diluting to volume with 18 MOhm 
deionized water.  The 15 mM phosphate buffer was poured into a 5.5 L polypropylene bucket 
(Nalgene, Fisher) and titrated to pH 3.3 with 16 mL of 100mM H3PO4 solution with a digital pH 
meter.  A 107 mL aliquot of 18 MOhm deionized water was added with a 500 mL graduated 
cylinder to the titrated phosphate buffer obtain a 15 mM phosphate concentration.  The 
HPLC/UV mobile phase was prepared by adding 1.4 L of acetonitrile (Optima®, Fisher) with a 
2 L graduated cylinder.  The mobile phase was then filtered and de-gassed under vacuum with a 
0.45 micron glass microfiber filter (Whatman, Middlesex, U.K.) and placed in a 4-liter brown 
glass screw top container.  A methanol/water (50/50) solution was prepared by placing 500 mL 
of methanol (Optima®, Fisher) in a 1 L volumetric flask with a graduated cylinder and diluting 
to volume with 18 MOhm deionized water.  The methanol/water (50/50) solution was degassed 
and filtered under vacuum with a 0.45 micron glass microfiber filter (Whatman) and placed in a 
1 L brown glass screw top container.  Methanol (Optima®, Fisher) was degassed and filtered 
under vacuum with a 0.45 micron glass microfiber filter (Whatman) and placed in a 1 L brown 
glass screw top container. 
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Preparation of Standards and Specimens 
A 500 ng/mL nordiazepam working standard was prepared by pipetting 25 µL of the 1 
mg/mL nordiazepam stock methanol standard into a 50 mL volumetric flask that contained 500 
µL of 200 mM DTT. The flask was to volume with pH 6.2 synthetic urine. A solution of 2 mM 
DTT was prepared in blank synthetic urine by pipetting 25 µL of the 200 mM DTT stock 
solution into a 25 mL volumetric flask and diluting to volume with pH 6.2 synthetic urine.  A 
standard curve was prepared by pipetting 0.0, 2.0, 2.5, 3.0, and 4.0 mL of the 500 ng/mL 
nordiazepam working standard into five 13 x 100 mm glass screw top test tubes that contained 
5.0, 3.0, 2.5, 2.0, and 1.0 mL of 2 mM DTT in pH 6.2 synthetic urine to yield standards of 0, 
200, 250, 300, and 400 ng/mL nordiazepam. Six replicate adulterated specimens that contained 
300 ng/mL nordiazepam and 10 mg/mL papain were prepared by pipetting 3.0 mL of the 500 
ng/mL nordiazepam working standard into six 13 x 100 mm glass screw top test tubes that each 
contained 50 mg of papain and 2.0 mL of 2mM DTT in pH 6.2 synthetic urine. An adulterated 
blank specimen that contained 10 mg/mL papain was prepared by placing 50 mg of papain into 
a 13 x 100 mm glass screw top test tube that contained 5.0 mL of 2 mM DTT in pH 6.2 
synthetic urine.  All standards and specimens were capped with a teflon screw cap and allowed 
to incubate at room temperature for 24 hours. 
 
Liquid/Liquid Extraction 
 A 2 mL aliquot of each specimen and standard was pipetted into new 13 x 100 mm glass 
screw top test tubes and 10 µL of the 1 mg/mL prazepam internal standard was added to every 
tube with and Eppendorf Repeater® and vortexed.  A 1 mL aliquot of pH 9.2 NH4Cl/NH4OH 
buffer was pipetted into every specimen and vortexed.  A 4mL aliquot of butyl chloride (HPLC 
grade, Fisher) was added to every specimen with an adjustable volume solvent dispenser 
(Wheaton, Fisher), capped with a teflon screw cap, and placed on a test tube rocker for 15 
minutes.  The organic phase was transferred with a disposable glass pasteur pipettes (Fisher) to  
25 mL conical glass concentration vials (Supelco).  The contents of the concentration vials were 
allowed to evaporate overnight at room temperature under a laboratory hood.  The specimens 
and standards were reconstituted with 50 µL of mobile phase and vortexed for 30 seconds.  The 
reconstituted specimens and standards were then transferred with a disposable glass pasteur 
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pipette (Fisher) to 2 cm x 12 cm glass autosampler vials (Waters) containing a 0.25 
microcentrifuge tube (Fisher) supported by an insert compression spring (Waters).  The 
specimens and standards were then capped with a PTFE lined H-style screw cap (Waters) and 
placed on the HPLC autosampler for subsequent assay. 
  
HPLC/UV Operation and Assay Parameters 
The radial compression column was conditioned with methanol (Optima®, Fisher) at 2 
mL/min for 10 minutes, followed by a solution of methanol/water (50/50) at 2 mL/min for 10 
minutes, followed by the prepared mobile phase at 2 mL/min for 10 minutes.  The autosampler 
was programmed to inject 20 µL of sample with a run time of 25 minutes and a 1 minute purge 
between samples.  The flow rate of the mobile phase was adjusted to 2.5 mL/minute.  The 
ultraviolet detector was adjusted to 254 nm.  The data module was programmed as follows: 
attenuation, 32; chart speed, 0.5; TFN=PM=1; PT EVAL, <250; Dialog: enable, baseline 
drawing-N; storage menu-N; function number-O; file name, benzos; TT, 25; TF, ER; TV, 1; 
<return><return> (Table 6). 
 
Table 6  High performance liquid chromatography/ultraviolet detection parameters  
Instrument Waters M45 solvent delivery system coupled to a Lambda-Max 
UV detector and a 717 autosampler 
Injection volume 20 µL every 26 minutes 
Flow rate 2.5 mL/min 
Column 8 mm x 100 mm NOVA-PAK C18-4 micron radial compression 
Ultraviolet detector 254 nm 
Data module Attenuation = 32 
 chart speed = 0.5 
 TFN = PM = 1 
 PT EVAL < 250 
 dialog:  
  enable baseline drawing = N 
  storage menu = N 
  function number = O  
  file name = benzos 
  TT = 25  
  TF = ER 
  TV = 1 
  <return><return> 
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Figure 8 illustrates the high degree of linearity (r2 = 0.997) of the PAR 
(nordiazepam:prazepam) versus nordiazepam (ng/mL) standard curve.   
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Figure 8  The standard curve of peak area ratio (PAR) versus nordiazepam concentration  
 (ng/mL)  
 
 
Specimen Validity Testing 
 
 An Institutional Review Board (IRB) from East Tennessee State University and the 
Veterans’ Affair Medical Center approved the following research protocol for the investigation 
of papain’s effects on parameters of specimen validity testing. To examine the effect of papain 
on a population of urine specimens with respect to creatinine, pH, osmolality, and specific 
gravity, 30 urine specimens were randomly selected from our specimen refrigerator.  The 
specimens were residual quantities that remained after other unrelated clinical assays were 
performed.  All patient identifiers were removed and the specimens were arbitrarily numbered 
from 1 to 30.  For osmolality, pH, creatinine, and specific gravity assays, specimens 1-30 were 
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pipetted into thirty 1.5 mL flat top microcentrifuge tubes.  Paired adulterated specimens that 
contained 10 mg/mL papain were prepared by pipetting 1 mL of the unadulterated specimens 
into thirty 1.5 mL flat top microcentrifuge tubes that contained 10 mg of papain.  All 60 
specimens were assayed immediately for creatinine, specific gravity, pH and osmolality as 
described below.  Six urine specimens that encompassed the range of creatinine, specific 
gravity, pH and osmolality values observed out of the 30 random urine specimens measured, 
were selected to undergo time course experiments.  The six specimens, unadulterated and 
adulterated with 10 mg/mL papain, were prepared by pipetting 1 mL of each specimen into a 1.5 
mL flat top microcentrifuge tube and a 1.5 mL flat top microcentrifuge tube that contained 10 
mg of papain.  The twelve specimens were assayed for creatinine, osmolality, pH, and specific 
gravity, then capped and allowed to remain at room temperature (~23 °C) for 6 hours before 
being re-assayed for each parameter.  The specimens were then refrigerated (4 °C) and re-
assayed for creatinine, osmolality, pH, and specific gravity 72 hours after their initial 
preparation.  The effect of 10 mg/mL papain on urine specimens with respect to nitrite 
concentration and the presence of glutaraldehyde and oxidants was measured in a subset of 6 
urine specimens that encompassed the range of  observed specific gravity values out of the 
original 30 random urine specimen measured. 
 
Creatinine 
 The following method was adapted from a previously published method to quantitate 
urine creatinine (Kroll and others, 1986).  The software program “Kinetics” was opened and the 
wavelength adjusted to 520nm.  A 151 mM sodium hydroxide (NaOH) stock solution was 
prepared by placing 302 mg of sodium hydroxide (Fisher) in a 50 mL volumetric flask and 
diluting to volume with 18 MOhm deionized water.  A 50 mL alkaline picric acid working 
solution was prepared by pipetting 9.2 mL of saturated (1.3% w/v) picric acid solution (Sigma) 
into a 50 mL volumetric flask that contained 20 mL of the 151 mM NaOH stock solution and 
diluting to volume with 18 MOhm deionized water. The Cary UV/Vis spectrophotometer was 
turned on and allowed to stabilize for 1 hour.  The reference cuvette consisted of 360 µL of the 
alkaline picric acid  working solution and 9 µL of 18 MOhm deionized water pipetted into a 1-
cm matched quartz cuvette (Fisher).  
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 A standard curve was constructed with 0, 3, 7, and 23 mg/dL creatinine standards 
(Sciteck Diagnostics, Raleigh, NC.) and two quality control specimens were prepared with 5 and 
12 mg/dL creatinine standards (Scitek). The sample cell contained of 360 µL of the alkaline 
picric acid working solution.  Just prior to recording absorbance data, 9 µL of standard, quality 
control, or urine specimen was pipetted into the sample cuvette and mixed by repeated pumping 
of the pipette plunger. The absorbance of the picric acid chromaphor being evolved was 
measured for 30 seconds and the rate of absorbance change (delta-mabs/min) was obtained.  
Specimens that produced an absorbance change greater than the rate of absorbance change of 
the 23 mg/dL creatinine standard were diluted accordingly with 18 MOhm deionized water and 
re-assayed.  Figure 9 depicts a typical standard curve of creatinine analysis by UV/Vis 
spectroscopy and  illustrates the high degree of linearity of the creatinine standard curve with a 
correlation coefficient(r2) of 0.999.  The 5.0 and 12.0 mg/dL creatinine quality control 
specimens yielded values of 4.45 and 11.4 mg/dL creatinine.   
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Figure 9  A typical standard curve of urine creatinine analysis by UV/Vis spectroscopy
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Specific Gravity 
 The Sper scientific model 300026 digital refractometer was turned on and calibrated with 
distilled water (Sper).  A quality control specimens consisted of  1.002, 1.005, and 1.030 
specific gravity standards (Scitek).  Specific gravity of the standards and the prepared urine 
specimens was measured directly by placing 3 drops of standards or specimens on the optical 
sample plate with a polypropylene disposable pipette and pressing the “mes” button.  
 
pH 
 The Beckmann model 4500 digital pH meter was calibrated with pH 7.0 and 4.0 
calibrators (Fisher) and the temperature knob was adjusted to the current room temperature.  
Specimen pH was measured directly by placing the pH electrode into the 1.5 mL flat top 
microcentrifuge tube that contained the aliquoted unadulterated and adulterated specimens.  
 
Osmolality 
 The Advanced Digmatic® osmometer was calibrated with 100 and 900 mOsm/L 
calibration standards (Advanced Instruments) and the calibration was confirmed with a 200 
mOsm/L quality control standard (Advanced Instruments).  The osmolality of the calibrators, 
quality control and prepared urine specimens were measured directly by pipetting 200 µL of the 
calibrator, quality control or prepared urine specimens into the disposable plastic osmometer 
sample cup that was placed in the osmometer and pressing the “read” button. 
 
Nitrates, Glutaraldehyde, and Oxidants 
 MASK tri-level controls (Kacey Incorporated, Asheville, NC.) were placed on 3 
individual MASK test strips and their absorbent pads were compared to the reference chart 
printed on the test strip container.  Six urine specimens that encompassed the range of specific 
gravity values observed out of the 30 random urine specimens measured, were selected.  The 6 
specimens, unadulterated and adulterated with 10 mg/mL papain, were prepared by pipetting 1 
mL of each specimen into a 1.5 mL flat top microcentrifuge tube and a 1.5 mL flat top 
microcentrifuge tube that contained 10 mg of papain.  The 12 specimens and control solutions 
were placed on individual MASK test strips with a disposable polypropylene pipettes 
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immediately after preparation.  The MASK test strips were then compared to the reference chart 
for the presence of nitrite, oxidants, and glutaraldehyde.  
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CHAPTER 3 
CALCULATIONS AND STATISTICS 
 
Papain Standardization 
 The rate of absorbance change (delta-mabs/min) of each RP standard was plotted against 
its respective RP standard concentration (U/mL), and a linear regression was performed to yield 
a standard curve with a calculated slope (m), intercept (b), and correlation coefficient (r).  The 
CLP concentrations ((C), U/mL) were obtained from interpolation (C=((rate of absorbance 
change)-b)/m) of the standard curve.  The CLP activity (U/mg) was obtained by dividing the 
interpolated CLP concentration (U/mL) by the concentration of the prepared CLP solutions 
(mg/mL).  An average (arithmetic mean) and standard deviation (SD) were calculated from the 4 
prepared CLP solutions. 
 
Enzyme Multiplied Immunoassay Technique 
 The ETS™ analyzer was calibrated daily in accordance with the standard operating 
procedure published by Syva Dade-Behring.  A chi squared analysis was performed to compare 
the data obtained between the unadulterated control group and the group adulterated with 10 
mg/mL papain. Groups were denoted as being significantly different if the comparison yielded a 
p-value <0.01. 
 
Fluorescence Polarized Immunoassay Technique 
 
THC-COOH Assays 
 For each concentration of THC-COOH in pH 4.5, 6.2, and 8.0 synthetic urine, an 
analysis of variance (ANOVA) was performed to compare the mean values obtained between the 
unadulterated control group and the groups containing 0.5, 1, 2, 5, and 10 mg/mL papain within 
each time point.  These were designated as the “intra-temporal” ANOVAs.  Paired sample 
ANOVAs were also performed to compare the mean values obtained between the groups 
containing 0, 0.5, 1, 2, 5, and 10 mg/mL papain at baseline (T=0 hours) and their respective 
group containing 0, 0.5, 1, 2, 5, and 10 mg/mL papain at the latter time points (T= 4, 6, 24, and 
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72 hours). These were designated as the “inter-temporal” ANOVAs.  A significant effect was 
attributed to papain only if both the inter-temporal and intra-temporal ANOVAs yielded a p-
value <0.01.  The minimum percent decrease, less the decrease in the unadulterated control, was 
calculated by subtracting the adulterated group that exhibited the least effect from its own 
baseline value, then subtracting the value obtained from the difference of the unadulterated 
control at the same time point and its baseline value.  The overall difference was divided by the 
initial THC-COOH concentration and multiplied by 100 to obtain a percentage difference.  In 
addition, the adulterated groups that yielded THC-COOH concentration values < 50 ng/mL were 
noted to summarize the results of each set of FPIA assays for the purposes of discussion.  The 
effects of papain concentration, time, THC-COOH concentration, and pH were compared were 
calculated as described below only with the experimental groups that had a significant effect 
attributed to papain. 
 
 The Effect of Papain Concentration, Time, Initial THC-COOH Concentration, and pH 
on the Percent Decrease of THC-COOH.  The percent decrease in THC-COOH concentration 
after 72 hours, less the THC-COOH concentration decrease in the unadulterated control, in 
specimens adulterated with 0.5 to 10 mg/mL papain in pH 6.2 synthetic urine were plotted 
versus their respective initial THC-COOH concentration.  ANOVAs were performed to compare 
the mean values between the papain concentration groups within each initial THC-COOH 
concentration group. The percent decrease in THC-COOH concentration after 4, 24, and 72 
hours, less the THC-COOH concentration decrease in the unadulterated control, in specimens 
adulterated with 10 mg/mL papain in pH 6.2 synthetic urine were plotted versus their respective 
initial THC-COOH concentrations.  Paired sample ANOVAs were performed to compare the 
mean values between incubation times within a particular THC-COOH concentration group.  
The percent decrease in THC-COOH concentration after 72 hours, less the THC-COOH 
concentration decrease in the unadulterated control, in specimens adulterated with 10 mg/mL 
papain in pH 6.2 synthetic urine were plotted versus their respective initial THC-COOH 
concentrations.  ANOVAs were performed compare the mean values between the initial THC-
COOH concentration groups.  The percent decrease in THC-COOH concentration after 72 
hours, less the THC-COOH concentration decrease in the unadulterated control, in specimens 
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adulterated with 10 mg/mL papain in pH 4.5, 6.2, and 8.0 synthetic urine were plotted versus 
their respective initial THC-COOH concentration.  ANOVAs were performed compare the mean 
values between the papain concentration groups within each initial THC-COOH concentration 
group. In every comparison chart, significant differences between mean values were established 
with p<0.01. 
 
FPIA Assays for Other Drugs of Abuse 
 For each set of amphetamine, barbiturate, benzodiazepine, cocaine, opiate, and 
phencyclidine assays an “intra-temporal” ANOVA was performed to compare the values 
obtained between the unadulterated control group and the group adulterated with 10 mg/mL for 
each time point.  A paired sample “inter-temporal” ANOVA was also performed between the 
groups containing 0 and 10 mg/mL papain and their respective group containing 0 and 10 
mg/mL papain at the latter time points (T= 6 and 72 hours).  A significant effect was attributed 
to papain only if both the inter-temporal and intra-temporal ANOVAs yielded a p-value <0.01. 
 
BANI Assay of Inhibited RP Enzymatic Activity 
 The absorbance change (delta-mabs) in 4 minutes of each RP and DRP specimen was 
averaged and compared with the absorbance change of the blank specimen.  The absorbance 
change (delta-mabs) in 4 minutes of each RP specimens was compared with the limit of 
detection (1 delta-mabs/min) for enzyme activity. 
 
FPIA Assays with RP and DRP 
 For each set of cannabinoid and benzodiazepine assays an ANOVA was performed to 
compare the values between the unadulterated control group and each group adulterated with 1 
mg/mL RP and with 1 mg/mL DRP.  An ANOVA was also performed to compare the values 
between the group adulterated with 1 mg/mL RP and the group adulterated with 1 mg/mL DRP.  
Groups were denoted as being significantly different, if the ANOVA yielded a p-value <0.01. 
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Gas Chromatography/Mass Spectroscopy of THC-COOH 
Quantitation ions for THC-COOH (m/z 371) and d3-THC-COOH (m/z 374) co-eluted at 
6.44 minutes and were integrated by the RTE integrator to yield peak areas of each ion.  The 
quotients of the peak areas were calculated into peak area ratios (PAR) of ions 371 : 374.    The 
PAR of each standard was plotted against its respective concentration (ng/mL THC-COOH) and 
a linear regression was performed to yield a standard curve with a given slope (m), intercept (b), 
and correlation coefficient (r).  Concentrations (C) of the adulterated specimens were obtained 
from interpolation (C=(PAR-b)/m) of the standard curve.  
 
High Pressure Liquid Chromatography/Ultraviolet Detection of Nordiazepam 
Nordiazepam eluted at 5.01 minutes, 0.2343 relative retention time to the internal 
standard prazepam that eluted at 21.4 minutes.  Peak areas of each peak were obtained by the 
integration on the 746 data module.  The peak areas were then quotiented into a PAR of 
nordiazepam : prazepam.  The PAR of each standard was plotted against its respective 
concentration (ng/mL nordiazepam) and a linear regression was performed to yield a standard 
curve with a given slope (m), intercept (b), and correlation coefficient (r).  Concentrations (C) of 
the adulterated specimens were obtained from interpolation (C=(PAR-b)/m) of the standard 
curve.  
 
THC-COOH Binding Plots 
 The quantities of bound THC-COOH (ng/mg of papain), B, were plotted versus the 
concentration of free THC-COOH, THC-COOHfree in an attempt to elucidate a potential 
mechanism of the interference of papain on the concentration of THC-COOH as measured by 
FPIA.  Bound THC-COOH was defined as the difference between the mean concentration of 
THC-COOH in the control group less the mean concentration of THC-COOH in the adulterated 
group after 24 hours.  The free concentration of THC-COOH was defined as the reported 
concentration of THC-COOH at 24 hours.  A linear regression was performed to yield a line 
with a calculated slope of kobs. 
 
 
 61 
Creatinine 
 The rate of absorbance change (delta-mabs/min) of each creatinine standard was 
plotted against its respective creatinine standard concentration (mg/dL), and a linear regression 
was performed to yield a standard curve with a given slope (m), intercept (b), and correlation 
coefficient (r). The creatinine concentrations (mg/dL) of the prepared urine and quality control 
specimens were obtained from interpolation of the standard curve.  A paired t-test was 
performed to compare the creatinine values obtained from unadulterated group and the group 
adulterated with 10 mg/mL papain in the population of 30 urine specimens.  Groups were 
denoted as being significantly different, if the t-test yielded a p-value <0.05.  A paired  t-test was 
performed to compare the creatinine values obtained from the unadulterated group and the group 
adulterated with 10 mg/mL papain in the subpopulation of 6 urine specimens at each time point 
(T=0, 6, and 72 hours).  Groups were denoted as being significantly different if the t-test yielded 
a p-value <0.05.  
 
Specific Gravity 
 A paired t-test was performed to compare the specific gravity values obtained from 
unadulterated group and the group adulterated with 10 mg/mL papain in the population of 30 
urine specimens. Groups were denoted as being significantly different if the t-test yielded a p-
value <0.05.  A paired t-test was performed to compare the specific gravity values obtained from 
the unadulterated group and the group adulterated with 10 mg/mL papain in the subpopulation 
of 6 urine specimens at each time point (T=0, 6, and 72 hours).  Groups were denoted as being 
significantly different if the t-test yielded a p-value <0.05. 
 
pH 
 A paired t-test was performed to compare the pH values obtained from unadulterated 
group and the group adulterated with 10 mg/mL papain in the population of 30 urine specimens. 
Groups were denoted as being significantly different, if the t-test yielded a p-value <0.05.  A 
paired t-test was performed to compare the pH values obtained from the unadulterated group and 
the group adulterated with 10 mg/mL papain in the sub-population of 6 urine specimens at each 
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time point (T=0, 6, and 72 hours).  Groups were denoted as being significantly different if the t-
test yielded a p-value <0.05. 
 
Osmolality 
 A paired t-test was performed to compare the osmolality values obtained from 
unadulterated group and the group adulterated with 10 mg/mL papain in the population of 30 
urine specimens. Groups were denoted as being significantly different if the t-test yielded a p-
value <0.05.  A paired t-test was performed to compare the osmolality values obtained from the 
unadulterated group and the group adulterated with 10 mg/mL papain in the sub-population of 6 
urine specimens at each time point (T=0, 6, and 72 hours).  Groups were denoted as being 
significantly different if the t-test yielded a p-value <0.05. 
 
Nitrates, Glutaraldehyde, and Oxidants 
 Chi square analyses were performed to compare the data obtained between the 
unadulterated group and the group adulterated with 10 mg/mL papain in the population of 6 
urine specimens.  Groups were denoted as being significantly different if the chi square analyses 
yielded a p-value <0.05.   
 
  63 
CHAPTER 4 
RESULTS 
 
Papain Standardization 
 Figure 10 illustrates a recrystallized papain (RP) enzyme activity standard curve with a 
correlation coefficient of 0.998.  The rate of absorbance change was a maximum of 5 mabs/min 
in an absorbance range of approximately 0.100 abs.  The linearity of the BANI assay for RP 
activity suggests the limitations of the assay were not exceeded in terms of a maximum UV 
absorbance of 2000 mabs or depletion of the BANI substrate.   
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Figure 10  Standard curve of the rate of absorbance change (delta-mabs/min) versus the    
    concentration (U/mL) of twice recrystallized papain 
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The third column in Table 7 lists the average activity of CLP interpolated from the 
standard curve in Figure 10 was 0.912 (+/- 0.050) U/mg.  The coefficient of variation of the 
results from the CLP standardization assays was 5.4%.   
 
Table 7  The activity of crude latex papain 
Concentration of 
 prepared CLP (mg/mL) 
Activity interpolated from 
 the standard curve (U/mL) 
Activity interpolated from the 
 standard curve (U/mg) 
1.25 1.08 0.869 
2.5 2.17 0.869 
5.0 4.72 0.945 
10.0 9.66 0.966 
   Average       0.912 
   SD               0.050 
 
Synthetic Urine 
 The osmolality of the synthetic urine was 627 (+/- 1) mOsm/kg and within the range 
of normal urine osmolality of 500-800 mOsm (Tietz 2001).  The particular preparation for 
synthetic urine adapted for our research is currently used by Pacific Northwest Laboratories for 
method validation and is cited by the United States Department of Commerce as a valid matrix 
to conduct laboratory research (PNL-6490 1988).   
 
Enzyme Multiplied Immunoassay Technique 
 The results given in Table 8 of the EMIT cannabinoid assays indicate a significant 
difference, p<0.01, between the control group of unadulterated specimens and specimens 
adulterated with 10 mg/mL papain.   
 
Table 8  Results of EMIT analysis of specimens adulterated with papain  
Group   Results  
  Negative  Positive 
Unadulterated, n=6    6 
Adulterated, n=6, 10 mg/mL 
 papain* 
 6   
* Significant difference, p<0.01 
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Fluorescence Polarized Immunoassay Technique 
 
THC-COOH Assays 
 Figures 11-15 and Tables 9-13 depict the effect of papain (0-10 mg/mL) on various 
concentrations of THC-COOH (25-500 ng/mL) over time (0-72 hours) in pH 6.2 synthetic urine 
as measured by FPIA analyses.  
 The overall data in Figure 11 and Table 9 illustrate a minimum 24% decrease, less the 
decrease in the unadulterated control, in THC-COOH concentration in almost every group of 
adulterated specimens with various papain concentrations at 4, 6, 24, and 72 hours.  The 
cannabinoid assays at 72 hours revealed an apparent 31% increase in THC-COOH concentration 
for specimens adulterated with 0.5 and 1.0 mg/mL papain.  There were no adulterated groups 
that yielded a THC-COOH concentration > 50 ng/mL, indicating a false positive result over 72 
hours.  
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Figure 11  Effects of papain on measured THC-COOH (25 ng/mL) over time in pH 6.2  
 synthetic urine, n=6 
A Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 9  The average concentration of THC-COOH in pH 6.2 synthetic urine containing 25 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration  
(ng/mL), n=6 
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 24.15 1.41   
 0.5 22.84 1.85   
 1.0 23.36 1.65   
 2.0 24.81 0.54   
 5.0 24.61 1.42   
 10.0 24.00 3.10   
4 0.0 22.71 2.30   
 0.5 18.34 1.66 X X 
 1.0 18.96 1.11 X X 
 2.0 18.23 0.85 X X 
 5.0 17.37 0.53 X X 
 10.0 14.73 1.63 X X 
6 0.0 21.10 2.39   
 0.5 17.59 0.98 X X 
 1.0 18.16 0.78 X X 
 2.0 17.18 1.14 X X 
 5.0 13.92 0.78 X X 
 10.0 11.47 1.26 X X 
24 0.0 22.06 2.14   
 0.5 15.45 2.64 X X 
 1.0 17.56 2.48 X X 
 2.0 17.00 2.22 X X 
 5.0 14.96 1.07 X X 
 10.0 12.58 0.75 X X 
72 0.0 24.69 2.92   
 0.5 31.16 1.11 X X 
 1.0 31.80 2.43 X X 
 2.0 28.87 1.14 X X 
 5.0 19.25 2.24 X X 
 10.0 12.35 1.59 X X 
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 The overall data in Figure 12 and Table 10 illustrated a minimum 16% decrease, less 
the decrease in the unadulterated control, in THC-COOH concentration in every group of 
adulterated specimens with various papain concentrations at 4, 24 and 72 hours.  Groups 
adulterated with 1.0, 5.0,  and 10 mg/mL papain after 4 hours; and all adulterated groups after 
24 and 72 hours yielded an average THC-COOH concentration < 50 ng/mL, indicating  false 
negative results.   
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Figure 12  Effects of papain on measured THC-COOH (75 ng/mL) over time in pH 6.2 synthetic  
  urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------ 
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Table 10  The average concentration of THC-COOH in pH 6.2 synthetic urine containing 75 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 80.99 4.86   
 0.5 71.10 2.23   
 1.0 77.76 5.27   
 2.0 80.87 5.54   
 5.0 79.31 4.38   
 10.0 80.87 4.21   
4 0.0 94.58 5.10  X 
 0.5 55.61 6.92 X X 
 1.0 49.73 2.24 X X 
 2.0 56.68 4.79 X X 
 5.0 41.48 3.00 X X 
 10.0 28.35 4.52 X X 
24 0.0 69.80 6.01  X 
 0.5 46.41 2.82 X X 
 1.0 47.87 5.39 X X 
 2.0 44.28 3.57 X X 
 5.0 33.31 2.13 X X 
 10.0 28.69 1.57 X X 
72 0.0 61.92 3.52  X 
 0.5 40.61 2.20 X X 
 1.0 34.32 2.48 X X 
 2.0 28.89 0.86 X X 
 5.0 21.70 2.03 X X 
 10.0 19.72 2.81 X X 
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 The overall data in Figure 13 and Table 11 indicate that papain contributed to a 
significant effect on 100 ng/mL THC-COOH in pH 6.2 synthetic urine over time.  There was a 
minimum 7% decrease, less the decrease in the unadulterated control, in THC-COOH 
concentration in every group of adulterated specimens with various papain concentrations at 4, 
24 and 72 hours.  Groups adulterated with 5.0  and 10 mg/mL papain after 4 hours; 2.0, 5.0, and 
10 mg/mL papain after 24 hours; and all adulterated groups after 72 hours yielded an average 
THC-COOH concentration < 50 ng/mL, indicating false negative results.   
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Figure 13  Effects of papain on measured THC-COOH (100 ng/mL) over time in pH 6.2  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 11  The average concentration of THC-COOH in pH 6.2 synthetic urine containing 100 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 94.41 8.39   
 0.5 85.27 8.15   
 1.0 100.43 12.14   
 2.0 105.57 3.89   
 5.0 107.73 11.23   
 10.0 89.12 5.03   
4 0.0 94.58 5.10   
 0.5 65.05 3.99 X X 
 1.0 62.57 6.44 X X 
 2.0 56.68 4.79 X X 
 5.0 45.35 5.21 X X 
 10.0 32.74 2.72 X X 
24 0.0 73.13 4.69  X 
 0.5 56.83 3.28 X X 
 1.0 52.40 3.22 X X 
 2.0 46.72 2.86 X X 
 5.0 40.24 2.36 X X 
 10.0 28.78 3.04 X X 
72 0.0 75.62 5.42  X 
 0.5 43.58 5.51 X X 
 1.0 42.00 2.40 X X 
 2.0 35.97 1.33 X X 
 5.0 30.78 4.24 X X 
 10.0 25.48 1.52 X X 
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 The overall data in Figure 14 and Table 12 indicate that papain contributed to a 
significant effect on 250 ng/mL THC-COOH in pH 6.2 synthetic urine over time.  There was a 
minimum 23% decrease, less the decrease in the unadulterated control, in THC-COOH 
concentration in almost every group of adulterated specimens with various papain 
concentrations at 4, 6, 24 and 72 hours.  Only the group adulterated with 10 mg/mL papain after 
72 hours yielded an average THC-COOH concentration < 50 ng/mL, indicating a false negative 
result. 
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Figure 14  Effects of papain on measured THC-COOH (250 ng/mL) over time in pH 6.2  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 12  The average concentration of THC-COOH in pH 6.2 synthetic urine containing 250 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 202.60 13.47   
 0.5 178.23 24.36   
 1.0 203.09 22.91   
 2.0 222.78 23.97   
 5.0 215.19 13.79   
 10.0 198.03 16.99   
4 0.0 228.01 12.57   
 0.5 186.03 7.11 X X 
 1.0 167.18 8.43 X X 
 2.0 125.08 8.79 X X 
 5.0 98.11 14.29 X X 
 10.0 75.12 5.81 X X 
6 0.0 242.43 21.33  X 
 0.5 171.00 7.64 X X 
 1.0 154.65 13.58 X X 
 2.0 134.45 15.22 X X 
 5.0 96.64 10.50 X X 
 10.0 106.93 6.61 X X 
24 0.0 179.92 22.22   
 0.5 156.51 40.34  X 
 1.0 122.26 15.22 X X 
 2.0 102.09 13.43 X X 
 5.0 71.23 4.07 X X 
 10.0 54.38 2.41 X X 
72 0.0 167.89 32.21   
 0.5 100.76 13.05 X X 
 1.0 97.89 12.71 X X 
 2.0 75.78 6.05 X X 
 5.0 67.55 8.44 X X 
 10.0 49.31 2.39 X X 
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The overall data in Figure 15 and Table 13 indicate that papain contributed to a 
significant effect on 500 ng/mL THC-COOH in pH 6.2 synthetic urine over time.  There was a 
minimum 16% decrease, less the decrease in the unadulterated control, in THC-COOH 
concentration in almost every group of adulterated specimens with various papain 
concentrations at 4, 6, 24, and 72 hours.  There were no adulterated groups that yielded an 
average THC-COOH concentration < 50 ng/mL over 72 hours. 
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Figure 15  Effects of papain on measured THC-COOH (500 ng/mL) over time in pH 6.2  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 13  The average concentration of THC-COOH in pH 6.2 synthetic urine containing 500 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 367.49 52.33   
 0.5 362.22 32.38   
 1.0 311.41 23.94   
 2.0 296.83 30.05   
 5.0 269.28 23.25   
 10.0 269.56 46.98   
4 0.0 397.33 39.54   
 0.5 309.16 14.81 X  
 1.0 308.13 40.92 X  
 2.0 268.91 19.30 X  
 5.0 216.05 25.42 X X 
 10.0 166.18 13.62 X X 
6 0.0 457.23 37.05  X 
 0.5 318.86 25.46 X  
 1.0 286.54 55.65 X  
 2.0 269.93 26.78 X  
 5.0 200.34 16.04 X X 
 10.0 130.42 11.49 X X 
24 0.0 410.35 35.91   
 0.5 231.61 12.13  X 
 1.0 200.10 23.95 X X 
 2.0 190.06 28.17 X X 
 5.0 138.17 21.88 X X 
 10.0 92.54 9.32 X X 
72 0.0 467.83 39.70  X 
 0.5 227.11 22.63 X X 
 1.0 204.86 23.23 X X 
 2.0 156.82 9.61 X X 
 5.0 105.53 5.98 X X 
 10.0 87.42 12.80 X X 
  
 
 Figures 16-20 and Tables 14-18 depict the effect of papain (0-10 mg/mL) on various 
concentrations of THC-COOH (25-500 ng/mL) over time in pH 4.5 synthetic urine as measured 
by FPIA analyses.  
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 The overall data in Figure 16 and Table 14 indicate that papain did not contribute to a 
significant effect on 25 ng/mL THC-COOH in pH 4.5 synthetic urine over time.  Almost every 
group of adulterated specimens was not significantly different from its intra-temporal 
unadulterated control.  A minimum 5% decrease, less the decrease in the unadulterated control, 
in THC-COOH concentration was noted for the group adulterated with 2 mg/mL papain at 4 
hours and all adulterated groups at 72 hours. There were no adulterated groups that yielded a 
THC-COOH concentration > 50 ng/mL, indicating a false positive result, over 72 hours.   
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Figure 16  Effects of papain on measured THC-COOH (25 ng/mL) over time in pH 4.5 synthetic  
 urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01
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Table 14  The average concentration of THC-COOH in pH 4.5 synthetic urine containing 25 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 19.34 1.10   
 0.5 21.84 1.11   
 1.0 22.63 2.46   
 2.0 23.63 1.88   
 5.0 26.50 1.26   
 10.0 25.33 0.70   
4 0.0 14.24 0.68  X 
 0.5 15.00 0.83  X 
 1.0 13.77 1.44  X 
 2.0 17.33 1.34 X X 
 5.0 16.06 1.30  X 
 10.0 16.76 1.21  X 
6 0.0 18.31 1.56  X 
 0.5 16.51 2.07  X 
 1.0 17.50 1.44  X 
 2.0 15.33 1.46  X 
 5.0 17.34 2.23  X 
 10.0 18.58 1.11  X 
24 0.0 14.18 2.32  X 
 0.5 13.43 1.50  X 
 1.0 13.96 1.82  X 
 2.0 13.04 1.64  X 
 5.0 15.06 1.27  X 
 10.0 16.09 1.83  X 
72 0.0 17.28 1.48 X X 
 0.5 12.03 2.24 X X 
 1.0 12.20 1.65 X X 
 2.0 12.29 1.21 X X 
 5.0 12.70 0.61 X X 
 10.0 13.11 1.21 X X 
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 The overall data in Figure 17 and Table 15 indicate that papain sporadically affected 
75 ng/mL THC-COOH in pH 4.5 synthetic urine over time.  There was a minimum 15% 
decrease, less the decrease in the unadulterated control,  in THC-COOH concentration for 
adulterated groups in which papain had a significant effect at 4, 6, 24, and 72 hours.  All 
unadulterated and adulterated groups yielded average THC-COOH concentrations < 50 ng/mL, 
indicating false negative results.  Although papain may have augmented the decrease in THC-
COOH in pH 4.5 synthetic urine, a majority of this effect is attributable to the pH of the matrix. 
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Figure 17  Effects of papain on measured THC-COOH (75 ng/mL) over time in pH 4.5 synthetic  
 urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 15  The average concentration of THC-COOH in pH 4.5 synthetic urine containing 75 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 63.69 3.07   
 0.5 69.68 6.55   
 1.0 76.18 11.51   
 2.0 78.65 11.94   
 5.0 72.26 8.13   
 10.0 69.00 5.67   
4 0.0 43.56 3.37  X 
 0.5 37.48 4.07  X 
 1.0 35.96 4.40  X 
 2.0 35.65 6.03  X 
 5.0 33.84 2.97 X X 
 10.0 31.50 3.26 X X 
6 0.0 31.96 1.23  X 
 0.5 28.06 2.13  X 
 1.0 29.42 3.76  X 
 2.0 28.14 1.73  X 
 5.0 27.59 1.00  X 
 10.0 26.05 1.95 X X 
24 0.0 41.09 4.05  X 
 0.5 27.54 1.58 X X 
 1.0 30.65 3.86 X X 
 2.0 28.76 3.56 X X 
 5.0 25.94 2.12 X X 
 10.0 25.22 2.25 X X 
72 0.0 33.01 3.24  X 
 0.5 25.70 2.47 X X 
 1.0 26.06 4.56  X 
 2.0 31.65 3.92  X 
 5.0 32.19 3.30  X 
 10.0 26.84 4.94  X 
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 The overall data in Figure 18 and Table 16 indicate papain sporadically affected 100 
ng/mL THC-COOH in pH 4.5 synthetic urine over time.  There was a minimum 15% decrease, 
less the decrease in the unadulterated control,  in THC-COOH concentration for adulterated 
groups in which papain had a significant effect at 4, 6, 24, and 72 hours.  Almost every 
unadulterated and adulterated groups yielded average THC-COOH concentrations < 50 ng/mL, 
indicating false negative results.  Although papain may have augmented the decrease in THC-
COOH in pH 4.5 synthetic urine, a majority of this effect is attributable to the pH of the matrix. 
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Figure 18  Effects of papain on measured THC-COOH (100 ng/mL) over time in pH 4.5  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 16  The average concentration of THC-COOH in pH 4.5 synthetic urine containing 100 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 95.21 3.58   
 0.5 104.04 12.81   
 1.0 103.32 5.13   
 2.0 93.59 6.31   
 5.0 114.16 14.33   
 10.0 104.97 4.72   
4 0.0 42.80 2.76  X 
 0.5 43.54 1.81  X 
 1.0 40.46 2.82  X 
 2.0 41.61 2.98  X 
 5.0 39.81 3.09  X 
 10.0 42.31 3.30  X 
6 0.0 42.75 2.43  X 
 0.5 40.17 2.24  X 
 1.0 35.02 2.08 X X 
 2.0 33.89 2.39 X X 
 5.0 32.31 1.86 X X 
 10.0 30.92 3.60 X X 
24 0.0 50.85 3.27  X 
 0.5 42.92 1.80 X X 
 1.0 37.58 3.05 X X 
 2.0 34.94 3.94 X X 
 5.0 32.90 2.98 X X 
 10.0 29.64 3.44 X X 
72 0.0 48.08 2.50  X 
 0.5 39.25 1.21 X X 
 1.0 35.31 2.45 X X 
 2.0 35.37 3.49 X X 
 5.0 33.45 4.66 X X 
 10.0 31.71 3.84 X X 
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 The overall data in Figure 19 and Table 17 indicate that papain contributed to a 
significant effect on 250 ng/mL THC-COOH in pH 4.5 synthetic urine over time.  There was a 
minimum 4% decrease, less the decrease in the unadulterated control,  in THC-COOH 
concentration for adulterated groups in which papain had a significant effect at 4, 6, 24, and 72 
hours.  Groups adulterated with 5.0  and 10 mg/mL papain after 6 hours and the group 
adulterated groups after 72 hours yielded an average THC-COOH concentration < 50 ng/mL, 
indicating false negative results.  Although papain may have augmented the decrease in THC-
COOH in pH 4.5 synthetic urine, a majority of this effect is attributable to the pH of the matrix. 
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Figure 19  Effects of papain on measured THC-COOH (250 ng/mL) over time in pH 4.5  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01
Cutoff concentration, 50 ng/mL, ------.
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Table 17  The average concentration of THC-COOH in pH 4.5 synthetic urine containing 250 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 127.26 5.80   
 0.5 107.40 12.13   
 1.0 102.12 5.92   
 2.0 100.85 9.63   
 5.0 109.25 12.70   
 10.0 118.93 19.43   
4 0.0 172.43 19.50  X 
 0.5 116.43 17.83 X  
 1.0 100.90 10.63 X  
 2.0 75.64 17.11 X X 
 5.0 67.68 14.88 X X 
 10.0 68.65 12.73 X X 
6 0.0 107.18 7.16  X 
 0.5 76.63 8.89 X X 
 1.0 58.03 6.23 X X 
 2.0 51.66 10.94 X X 
 5.0 40.13 4.38 X X 
 10.0 46.40 5.31 X X 
24 0.0 100.93 12.97  X 
 0.5 56.15 6.94 X X 
 1.0 55.51 6.23 X X 
 2.0 48.67 7.86 X X 
 5.0 53.00 7.24 X X 
 10.0 56.00 5.14 X X 
72 0.0 88.08 10.64  X 
 0.5 64.18 10.67  X 
 1.0 65.76 13.88  X 
 2.0 49.12 10.68 X X 
 5.0 63.25 18.56  X 
 10.0 56.59 15.58 X X 
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The overall data in Figure 20 and Table 18 indicate that papain sporadically affected 500 
ng/mL THC-COOH in pH 4.5 synthetic urine over time.  There was a minimum 11% decrease, 
less the decrease in the unadulterated control,  in THC-COOH concentration for adulterated 
groups in which papain had a significant effect at 4, 6, 24, and 72 hours.  No adulterated groups 
yielded at THC-COOH concentration < 50 ng/mL.  Although papain may have augmented the 
decrease in THC-COOH in pH 4.5 synthetic urine, a majority of this effect is attributable to the 
pH of the matrix. 
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Figure 20  Effects of papain on measured THC-COOH (500 ng/mL) over time in pH 4.5  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 18  The average concentration of THC-COOH in pH 4.5 synthetic urine containing 500 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 261.07 27.71   
 0.5 256.16 28.70   
 1.0 252.15 11.11   
 2.0 239.13 20.69   
 5.0 301.02 112.55   
 10.0 279.72 60.53   
4 0.0 239.97 48.23   
 0.5 210.45 23.25   
 1.0 188.65 22.30   
 2.0 162.22 18.16 X X 
 5.0 139.31 13.60 X  
 10.0 138.39 33.19 X X 
6 0.0 417.27 26.04  X 
 0.5 360.84 32.65  X 
 1.0 321.56 64.47 X  
 2.0 258.75 56.96 X  
 5.0 170.46 25.91 X  
 10.0 144.35 15.49 X X 
24 0.0 364.44 22.73  X 
 0.5 291.03 24.51 X  
 1.0 288.07 37.92 X  
 2.0 250.35 25.46 X  
 5.0 233.56 27.09 X  
 10.0 211.50 19.80 X  
72 0.0 300.62 55.17   
 0.5 238.23 64.32   
 1.0 170.38 24.97 X X 
 2.0 125.31 16.69 X X 
 5.0 130.45 102.61 X  
 10.0 82.91 15.39 X X 
 
 
 Figures 21-25 and Tables 19-23 depict the effect of papain (0-10 mg/mL) on various 
concentrations of THC-COOH (25-500 ng/mL) over time in pH 8.0 synthetic urine as measured 
by FPIA analyses.  
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 The overall data in Figure 21 and Table 19 indicate that papain sporadically affected 25 
ng/mL THC-COOH in pH 8.0 synthetic urine over time.  There was a minimum 21% decrease, 
less the decrease in the unadulterated control,  in THC-COOH concentration for adulterated 
groups in which papain had a significant effect at 4, 6, 24, and 72 hours.  There were no 
adulterated groups that yielded at THC-COOH concentration > 50 ng/mL , indicating a false 
positive result, over 72 hours.   
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Figure 21  Effects of papain on measured THC-COOH (25 ng/mL) over time in pH 8.0 synthetic  
 urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01
Cutoff concentration, 50 ng/mL, ------.
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Table 19  The average concentration of THC-COOH in pH 8.0 synthetic urine containing 25 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 26.32 2.40   
 0.5 26.58 1.75   
 1.0 30.34 1.24   
 2.0 31.07 1.56   
 5.0 28.84 1.23   
 10.0 22.69 2.23   
4 0.0 25.62 2.91   
 0.5 26.07 1.69   
 1.0 28.47 1.20   
 2.0 27.65 1.43  X 
 5.0 21.94 2.27  X 
 10.0 16.72 1.52 X X 
6 0.0 24.68 1.27   
 0.5 26.37 0.50   
 1.0 28.11 2.10 X  
 2.0 26.85 1.61  X 
 5.0 19.56 1.10 X X 
 10.0 15.14 1.22 X X 
24 0.0 23.65 2.05   
 0.5 28.40 1.34 X  
 1.0 28.76 1.08 X  
 2.0 28.26 2.19 X  
 5.0 21.05 1.95  X 
 10.0 16.38 1.23 X X 
72 0.0 24.52 3.28   
 0.5 29.87 1.48 X  
 1.0 33.04 2.14 X  
 2.0 27.95 2.41   
 5.0 19.36 1.76 X X 
 10.0 14.62 1.86 X X 
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 The overall data in Figure 22 and Table 20 indicate that papain contributed to a 
significant effect on 75 ng/mL THC-COOH in pH 8.0 synthetic urine over time.  There was a 
minimum 17% decrease, less the decrease in the unadulterated control,  in THC-COOH 
concentration in almost every group of adulterated specimens with various papain 
concentrations at 4, 6, 24, and 72 hours.  Groups adulterated with 10 mg/mL papain after 4 and 
6hours; 5.0 and 10 mg/mL papain after 24 and 72 hours yielded an average THC-COOH 
concentration < 50 ng/mL, indicating false negative results.   
 
 
0 4 6 24 72
B B
B
B
B
B
B B BB B
B B
BB
BB
A A
A
A
A
A
A
A A
A
A A
A
A
A
A
A
Time (h)
TH
C-
CO
O
H
 (n
g/m
L)
 +/
- S
D
0
25
50
75
100
125
Effects of Papain on THCCOOH (75 ng/mL)
Over Time in pH 8.0 Synthetic Urine
Papain Concentration (mg/mL)
Control
0.5
1
2
5
10
 
Figure 22  Effects of papain on measured THC-COOH (75 ng/mL) over time in pH 8.0 synthetic  
 urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 20  The average concentration of THC-COOH in pH 8.0 synthetic urine containing 75 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 65.63 4.13   
 0.5 69.48 8.50   
 1.0 64.93 5.93   
 2.0 76.22 15.88   
 5.0 81.77 4.34   
 10.0 70.67 2.02   
4 0.0 79.18 5.04  X 
 0.5 65.26 1.39 X  
 1.0 56.10 5.18 X X 
 2.0 59.60 13.47 X X 
 5.0 60.95 2.60 X X 
 10.0 38.75 3.04 X X 
6 0.0 79.13 3.51  X 
 0.5 64.18 2.81 X  
 1.0 52.22 4.10 X X 
 2.0 54.63 10.77 X X 
 5.0 57.65 5.69 X X 
 10.0 36.22 4.39 X X 
24 0.0 70.75 5.82   
 0.5 62.79 3.86   
 1.0 57.04 4.78 X X 
 2.0 51.45 12.01 X X 
 5.0 38.68 1.30 X X 
 10.0 23.97 2.03 X X 
72 0.0 70.47 4.02   
 0.5 65.23 9.34   
 1.0 62.43 4.75   
 2.0 55.22 10.38 X X 
 5.0 38.76 3.95 X X 
 10.0 20.05 2.53 X X 
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 The overall data in Figure 23 and Table 21 indicate that papain contributed to a 
significant bi-modal effect on 100 ng/mL THC-COOH in pH 8.0 synthetic urine over time.  
There was a minimum 24% decrease, the decrease in the unadulterated control, in the specimens 
adulterated with 5.0 and 10 mg/mL papain over 4, 6, 24, and 72 hours.  There was an apparent 
maximum 35% increase, less the decrease in the unadulterated control, in the specimens 
adulterated with 0.5 and 1.0 mg/mL papain over  6, 24, and 72 hours.  Groups adulterated with 
10 mg/mL papain after 6 and 24 hours; 5.0 and 10 mg/mL papain after 72 hours yielded an 
average THC-COOH concentration < 50 ng/mL, indicating false negative results.   
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Figure 23  Effects of papain on measured THC-COOH (100 ng/mL) over time in pH 8.0  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01
Cutoff concentration, 50 ng/mL, ------.
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Table 21  The average concentration of THC-COOH in pH 8.0 synthetic urine containing 100
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 88.56 4.18   
 0.5 102.73 10.78   
 1.0 104.70 4.35   
 2.0 107.53 4.64   
 5.0 86.02 6.51   
 10.0 75.79 7.93   
4 0.0 97.72 5.05  X 
 0.5 102.69 9.98   
 1.0 108.98 4.92   
 2.0 106.04 5.13   
 5.0 75.14 8.05 X X 
 10.0 54.17 7.87 X X 
6 0.0 92.41 4.94   
 0.5 114.90 3.51 X  
 1.0 117.93 5.39 X X 
 2.0 100.27 7.53   
 5.0 62.22 3.60 X X 
 10.0 41.15 4.91 X X 
24 0.0 89.33 5.97   
 0.5 121.47 6.30 X X 
 1.0 118.71 2.52 X X 
 2.0 100.92 9.05   
 5.0 55.58 4.44 X X 
 10.0 34.98 2.45 X X 
72 0.0 73.90 7.46  X 
 0.5 122.40 3.66 X X 
 1.0 125.82 3.78 X X 
 2.0 104.33 7.27 X  
 5.0 49.41 3.84 X X 
 10.0 32.63 4.32 X X 
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The overall data in Figure 24 and Table 22 indicate that papain sporadically affected 250 
ng/mL THC-COOH in pH 8.0 synthetic urine over time.  There was a minimum 18% decrease, 
less the decrease in the unadulterated control,  in THC-COOH concentration for groups in which 
papain had a significant effect at 4, 6, 24, and 72 hours.  There were no adulterated groups that 
yielded a concentration < 50 ng/mL over 72 hours.  
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Figure 24  Effects of papain on measured THC-COOH (250 ng/mL) over time in pH 8.0  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 22  The average concentration of THC-COOH in pH 8.0 synthetic urine containing 250 
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 281.00 4.27   
 0.5 249.55 10.52   
 1.0 245.47 12.95   
 2.0 245.24 6.17   
 5.0 234.53 8.33   
 10.0 214.59 15.62   
4 0.0 276.86 48.53   
 0.5 235.91 4.96   
 1.0 228.60 12.40   
 2.0 223.33 17.70 X  
 5.0 184.44 7.81 X X 
 10.0 137.01 8.91 X X 
6 0.0 224.98 16.48  X 
 0.5 220.34 10.94  X 
 1.0 206.77 10.60  X 
 2.0 182.29 10.47 X X 
 5.0 151.42 8.27 X X 
 10.0 99.88 7.60 X X 
24 0.0 208.07 14.59  X 
 0.5 205.92 4.70  X 
 1.0 194.40 18.28  X 
 2.0 174.96 4.97  X 
 5.0 146.72 38.04 X X 
 10.0 78.51 4.83 X X 
72 0.0 200.98 15.15  X 
 0.5 217.52 14.60  X 
 1.0 207.07 17.55  X 
 2.0 188.34 13.02  X 
 5.0 122.65 5.16 X X 
 10.0 76.40 3.80 X X 
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 The overall data in Figure 25 and Table 23 indicate that papain sporadically affected 500 
ng/mL THC-COOH in pH 8.0 synthetic urine over time.  There was a minimum 13% decrease, 
less the decrease in the unadulterated control,  in THC-COOH concentration for groups in which 
papain had a significant effect at 4, 6, 24, and 72 hours.  There were no adulterated groups that 
yielded a concentration < 50 ng/mL over 72 hours.   
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Figure 25  Effects of papain on measured THC-COOH (500 ng/mL) over time in pH 8.0  
 synthetic urine, n=6 
A
 Significant “intra-temporal” difference, p<0.01 
B
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 50 ng/mL, ------.
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Table 23  The average concentration of THC-COOH in pH 8.0 synthetic urine containing 500
 ng/mL THC-COOH with various concentrations of papain over time 
Time(h) Papain concentration 
(mg/mL) 
Average THC-COOH 
concentration (ng/mL) 
n=6  
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
0 0.0 428.09 44.53   
 0.5 416.70 27.30   
 1.0 417.80 21.28   
 2.0 445.54 17.22   
 5.0 419.44 17.59   
 10.0 381.73 7.37   
4 0.0 424.89 28.68   
 0.5 388.06 16.16   
 1.0 396.29 32.33   
 2.0 376.37 23.67 X X 
 5.0 300.63 11.77 X X 
 10.0 215.35 18.27 X X 
6 0.0 484.10 15.41   
 0.5 428.99 42.47   
 1.0 398.04 22.96 X  
 2.0 393.11 21.66 X X 
 5.0 330.46 67.30 X X 
 10.0 215.44 46.97 X X 
24 0.0 381.62 27.18   
 0.5 410.84 43.56   
 1.0 400.24 24.50   
 2.0 364.79 11.70  X 
 5.0 266.39 21.03 X X 
 10.0 178.18 19.11 X X 
72 0.0 392.16 38.23   
 0.5 372.80 76.97   
 1.0 384.67 28.08   
 2.0 348.78 42.75  X 
 5.0 249.02 21.58 X X 
 10.0 135.72 15.85 X X 
 
 The Effect of Papain Concentration, Time, THC-COOH Concentration, and pH on the 
Percent Decrease of THC-COOH.  Figure 26 illustrates and Table 24 lists the percent decrease 
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in THC-COOH concentration after 72 hours, less the THC-COOH concentration decrease in the 
unadulterated control, in specimens adulterated with 0.5 to 10 mg/mL papain in pH 6.2 
synthetic urine plotted versus their respective initial THC-COOH concentration.  Data indicate 
the percent decrease in THC-COOH in pH 6.2 synthetic urine with 0.5 to 10 mg/mL papain after 
72 hours was statistically less than or equal to 2.0 mg/mL papain over all concentrations of 
THC-COOH.  There was an average (SD) 22% (15%) decrease in THC-COOH for specimens 
adulterated with 1 mg/mL papain over 25 to 500 ng/mL initial THC-COOH concentrations in 
pH 6.2 synthetic urine.  There was an average (SD) 50% (15%) decrease in THC-COOH for 
specimens adulterated with 10 mg/mL papain over 25 to 500 ng/mL initial THC-COOH 
concentrations in pH 6.2 synthetic urine.  Although the most demonstrative effects were 
observed in specimens adulterated with 10 mg/mL papain, they were not statistically different 
from specimens adulterated with 2.0 or 5.0 mg/mL papain.  The lack of statistical difference 
between 2.0, 5.0, and 10.0 mg/mL papain concentrations was due, in part, to the large standard 
deviations that resulted from the propagation of the 4 standard deviations required for the 
comparison.  The overall data suggest a direct correlate between the percent decrease in THC-
COOH and the concentration of papain 
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Figure 26  The percent decrease of THC-COOH after 72 hours versus specimens adulterated  
 with 0.5-10 mg/mL papain containing various initial THC-COOH concentrations in  
 pH 6.2 synthetic urine  
A,B,C
 Groups denoted with the same letter are not significantly different, p<0.01 
*
 Papain concentrations of 0.5 and 1.0 mg/mL yielded a 31% increase 
#
 A significant effect was not attributed to the 2 mg/mL papain at this concentration of THC- 
 COOH 
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Table 24  The percent decrease of THC-COOH over 72 hours in specimens adulterated with  
 0.5-10 mg/mL papain in specimens containing various concentrations of THC- 
 COOH 
Initial THC-COOH 
concentration (ng/mL) 
Papain concentration 
(mg/mL) 
Percent decrease in 
THC-COOH  
S.D. Statistical 
differences* 
25 0.5 -31.13 15.57 A 
 1 -31.59 17.51 A 
 2#    
 5 23.61 16.76 B 
 10 48.74 19.02 B 
75 0.5 15.23 9.03 A 
 1 32.50 11.16 AB 
 2 43.89 10.95 B 
 5 51.40 10.27 B 
 10 56.11 10.47 B 
100 0.5 22.90 14.02 A 
 1 39.65 15.90 AB 
 2 50.82 10.80 B 
 5 58.16 15.62 B 
 10 44.85 11.29 AB 
250 0.5 17.10 17.81 A 
 1 28.19 17.46 AB 
 2 44.92 17.11 B 
 5 45.17 15.39 B 
 10 45.60 15.56 B 
500 0.5 47.09 15.33 A 
 1 41.38 14.73 A 
 2 48.07 14.57 A 
 5 52.82 13.99 A 
 10 56.50 16.35 A 
*
 Groups denoted with the same letter are not statistically different within a THC-COOH  
   concentration group, p<0.01 
#
 A significant effect was not attributed to the 2 mg/mL papain at this concentration of  
  THC-COOH 
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 Figure 27 illustrates and Table 25 lists the percent decrease in THC-COOH 
concentration after 4, 24, and 72 hours, less the THC-COOH concentration decrease in the 
unadulterated control, in specimens adulterated with 10 mg/mL papain in pH 6.2 synthetic urine 
plotted versus their respective initial THC-COOH concentrations.  Data indicate the percent 
decreases in THC-COOH in pH 6.2 synthetic urine with 10 mg/mL papain at  24 and 72 hours, 
were statistically less than or equal to the percent decrease at 4 hours for initial THC-COOH 
concentrations of 25 to 250 ng/mL.  Within the first 4 hours, there was an average (SD) 52% 
(14%) decrease in THC-COOH for specimens adulterated with 10 mg/mL papain over 25 to 500 
ng/mL initial THC-COOH concentrations.  After 72 hours, there was an average (SD) 50% 
(15%) decrease in THC-COOH for specimens adulterated with 10 mg/mL papain over 25 to 500 
ng/mL initial THC-COOH concentrations.  The data suggest the reduction of THC-COOH in 
synthetic urine is not enzymatic, as the percent reduction in THC-COOH was not greater after 
24 or 72 hours than after 4 hours except for THC-COOH concentrations of 500 ng/mL. 
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Figure 27  The percent decrease of THC-COOH over 4, 24, and 72 hours versus specimens  
 containing various initial THC-COOH concentrations in pH 6.2 synthetic urine  
 adulterated with 10 mg/mL papain 
A,B
 Groups denoted with the same letter are not significantly different within a THC-COOH  
 concentration group, p<0.01 
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Table 25  The percent decrease of THC-COOH concentration over 4, 24, and 72  
 hours in specimens containing various initial THC-COOH concentrations in pH  
 6.2 synthetic urine adulterated with 10 mg/mL papain 
Initial THC-COOH 
concentration (ng/mL) 
Time (h) from 
baseline 
Percent decrease in THC-
COOH, n=6 
S.D. Statistical 
differences* 
25 4 31.30 17.68 A 
 24 37.29 16.36 A 
 72 48.74 19.02 A 
75 4 88.16 12.49 A 
 24 54.66 11.92 B 
 72 56.11 10.47 B 
100 4 56.55 11.36 A 
 24 39.05 11.27 A 
 72 44.85 11.29 A 
250 4 59.33 10.29 A 
 24 48.39 12.46 A 
 72 45.60 15.56 A 
500 4 26.65 16.36 A 
 24 43.98 15.90 AB 
 72 56.50 16.35 B 
* Groups with the same letter are not statistically different within a THC-COOH concentration 
 group. 
 
 
  Figure 28 illustrates and Table 26 lists the percent decrease in THC-COOH 
concentration after 72 hours, less the THC-COOH concentration decrease in the unadulterated 
control, in specimens adulterated with 10 mg/mL papain in pH 6.2 synthetic urine plotted versus 
their respective initial THC-COOH concentrations.  Data indicate the percent decreases in THC-
COOH in pH 6.2 synthetic urine containing 25 to 500 ng/mL THC-COOH were not statistically 
different across the concentration range of THC-COOH.  There was an average (SD) 50% (15%) 
decrease in THC-COOH for specimens adulterated with 10 mg/mL papain over 25 to 500 ng/mL 
initial THC-COOH concentrations.  An equal percent decrease in THC-COOH in specimens 
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containing higher concentrations of THC-COOH translates into a greater absolute decrease in 
THC-COOH that directly correlates with the initial THC-COOH concentration.   
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Figure 28  The percent decrease of THC-COOH over 72 hours versus specimens containing  
 various initial THC-COOH concentrations in pH 6.2 synthetic urine adulterated with  
 10 mg/mL papain. 
 
 
Table 26  The percent decrease in THC-COOH concentration over 72 hours in specimens 
 containing various initial THC-COOH concentrations in pH 6.2  
 synthetic urine adulterated with 10 mg/mL papain 
Initial THC-COOH 
concentration (ng/mL) 
Percent decrease in THC-
COOH, n=6 
S.D. Statistical 
difference, p<0.01 
25 48.74 19.02  
75 56.11 10.47  
100 44.85 11.29  
250 45.60 15.56  
500 56.50 16.35  
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 Figure 29 illustrates and Table 27 lists the percent decrease in THC-COOH 
concentration after 72 hours, less the THC-COOH concentration decrease in the unadulterated 
control, in specimens adulterated with 10 mg/mL papain in pH 4.5, 6.2, and 8.0 synthetic urine 
plotted versus their respective initial THC-COOH concentration.  Data indicate the percent 
decreases in THC-COOH in pH 4.5, 6.2, and 8.0 synthetic urine were most demonstrative at pH 
6.2.  For pH 4.5, 6.2, and 8.0 synthetic urine, there was an average (+/-SD) decrease of 31% 
(11%), 50% (15%), and 39% (13%) in THC-COOH concentrations for specimens adulterated 
with 10 mg/mL papain over 25 to 500 ng/mL initial THC-COOH concentrations.  The percent 
decrease in THC-COOH in pH 6.2 synthetic urine was not statistically different from the percent 
decrease in THC-COOH in pH 8.0 synthetic urine, and in some instances pH 4.5 synthetic urine.  
However, the lack of significant difference is attributed, in part, to the large standard deviations 
that resulted from the propagation of the 4 standard deviations required for the comparison.  The 
data in Figure 29 and Table 27 also indicate that a matrix with an acidic pH attenuated papain’s 
effect on the reduction of THC-COOH concentration.  The distribution of pH values in normal 
urine is greatest circa 6.2, while the distribution at the extrema (pH 4.5 and 8.0) are minimal as 
defined by the Gaussian distribution.  Therefore, the results observed in pH 6.2 synthetic urine 
would correlate to the effects observed in the greatest percentage of the population. 
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Figure 29  The percent decrease of THC-COOH over 72 hours versus specimens adulterated  
 with 10 mg/mL papain containing various initial THC-COOH concentrations in pH 
 4.5, 6.2, and 8.0 synthetic urine 
A,B
 Groups denoted with the same letter are not significantly different, p<0.01 
*
 A significant effect was not attributed to papain at 75 ng/mL THC-COOH in pH 4.5 synthetic 
 urine
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Table 27  The percent decrease of THC-COOH concentration over 72 hours in specimens 
 containing various initial THC-COOH concentrations in pH 4.5, 6.2, and 8.0 
synthetic  urine adulterated with 10 mg/mL papain 
Initial THC-COOH 
concentration (ng/mL) 
pH Percent decrease in THC-
COOH  
S.D. Statistical 
differences* 
25 4.5 40.65 9.23 A 
 6.2 48.74 19.02 A 
 8.0 25.09 20.00 A 
75 4.5#    
 6.2 56.11 10.47 A 
 8.0 73.96 8.81 A 
100 4.5 26.12 7.49 B 
 6.2 44.85 11.29 A 
 8.0 28.51 12.44 AB 
250 4.5 9.26 11.08 B 
 6.2 45.60 15.56 A 
 8.0 23.27 9.00 AB 
500 4.5 47.27 17.56 A 
 6.2 56.50 16.35 A 
 8.0 42.02 12.25 A 
*
 Groups denoted with the same letter are not statistically different within a THC-COOH 
concentration group 
#
 A significant effect was not attributed to papain at 75 ng/mL THC-COOH in pH 4.5 synthetic 
urine 
 
 
 
FPIA Assays for Other Drugs of Abuse 
 The Figures 30-35 and Tables 28-33 illustrate the effects of 10 mg/mL papain in pH 
6.2 synthetic urine specimens that contained amphetamine, secobarbital, nordiazepam, 
phencyclidine, morphine, and benzoylecgonine at +/- 50% of their respective cutoff 
concentrations.  Figures 30-34 and Tables 28-32 indicate that 10 mg/mL papain did not have a 
significant effect on the FPIA analyses of either concentration of the amphetamine, secobarbital, 
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phencyclidine, morphine, or benzoylecgonine solutions assayed over time.  Figure 35 and Table 
33 indicate that papain had a significant effect in both concentrations of the nordiazepam 
solutions assayed over time by FPIA.  There was a maximum 12% decrease, less the decrease in 
the unadulterated control, among all of the nordiazepam assays.  
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Figure 30  Effects of papain (10 mg/mL) on amphetamine concentrations over time in pH 6.2  
 synthetic urine, n=6 
Panel A- 500 ng/mL amphetamine solution 
Panel B- 1500 ng/mL amphetamine solution 
Cutoff concentration, 1000 ng/mL, ------.
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Table 28  The average amphetamine concentration over time in pH 6.2 synthetic urine 
containing  0 and 10 mg/mL papain 
Initial 
amphetamine 
concentration 
(ng/mL) 
Time 
(h) 
Papain 
concentratio
n 
Average 
amphetamine 
concentratio
n (ng/mL) 
S.D. Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
500 0 0 584.41 33.31   
 0 10 650.44 43.78   
 6 0 618.16 58.44   
 6 10 689.90 27.61   
 72 0 604.46 26.79   
 72 10 645.65 42.77   
1500 0 0 1576.8 129.3   
 0 10 1589.7 56.27   
 6 0 1604.8 151.2   
 6 10 1520.0 110.6   
 72 0 1662.6 83.30   
 72 10 1612.4 109.5   
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Figure 31  Effects of papain (10 mg/mL) on secobarbital concentrations over  
 time in pH 6.2 synthetic urine, n=6 
Panel A- 100 ng/mL secobarbital solution 
 Panel B- 300 ng/mL secobarbital solution 
  a
 Significant “inter-temporal” difference, p<0.01 
Cutoff concentration, 200 ng/mL, ------.
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Table 29  The average secobarbital concentration over time in pH 6.2 synthetic urine containing   
 0 and 10 mg/mL papain 
Initial 
amphetamine 
concentration 
(ng/mL) 
Time 
(h) 
Papain 
concentratio
n 
Average 
secobarbital 
concentratio
n (ng/mL) 
SD Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
100 0 0 83.99 21.91   
 0 10 97.37 19.09   
 6 0 81.94 11.49   
 6 10 100.45 11.76   
 72 0 74.24 16.77   
 72 10 74.09 6.99   
300 0 0 271.29 13.36   
 0 10 251.93 9.79   
 6 0 277.76 15.22   
 6 10 279.46 20.29  X 
 72 0 250.50 12.97   
 72 10 285.27 28.06   
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Figure 32  Effects of papain (10 mg/mL) on benzoylecgonine concentrations  
 over time in pH 6.2 synthetic urine, n=6 
Panel A- 450 ng/mL benzoylecgonine solution 
Panel B- 150 ng/mL benzoylecgonine solution 
Cutoff concentration, 300 ng/mL, ------. 
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Table 30  The average benzoylecgonine concentration over time in pH 6.2 synthetic urine 
 containing 0 and 10 mg/mL papain 
Initial 
amphetamine 
concentration 
(ng/mL) 
Time 
(h) 
Papain 
concentratio
n 
Average 
benzoylecgo-
nine 
concentratio
n (ng/mL) 
SD Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
150 0 0 102.30 5.89   
 0 10 107.75 7.65   
 6 0 101.13 6.86   
 6 10 110.95 12.45   
 72 0 101.89 11.08   
 72 10 108.54 5.64   
450 0 0 436.54 20.76   
 0 10 450.97 22.78   
 6 0 440.69 31.21   
 6 10 442.53 22.16   
 72 0 443.35 11.64   
 72 10 444.33 22.44   
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Figure 33  Effects of papain (10 mg/mL) on morphine concentrations  
 over time in pH 6.2 synthetic urine, n=6 
Panel A- 450 ng/mL morphine solution 
 Panel B- 150 ng/mL morphine solution 
a
 Significant “intra-temporal” difference, p<0.01 
Cutoff concentration, 300 ng/mL, ------. 
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Table 31  The average morphine concentration over time in pH 6.2 synthetic urine containing 
 0 and 10 mg/mL papain 
Initial 
amphetamine 
concentration 
(ng/mL) 
Time 
(h) 
Papain 
concentratio
n 
Average 
morphine 
concentratio
n (ng/mL) 
SD Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
150 0 0 153.20 8.21   
 0 10 170.13 7.56   
 6 0 163.81 8.72   
 6 10 159.95 3.94   
 72 0 159.20 9.53   
 72 10 157.86 7.72   
450 0 0 484.25 30.88   
 0 10 463.19 56.35   
 6 0 445.15 35.71   
 6 10 519.50 33.99 X  
 72 0 449.99 40.41   
 72 10 457.21 25.07   
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Figure 34  Effects of papain (10 mg/mL) on phencyclidine concentrations over  
 time in pH 6.2 synthetic urine, n=6 
Panel A- 37.5 ng/mL phencyclidine solution 
Panel B- 12.5 ng/mL phencyclidine solution 
a
  Significant “intra-temporal” difference, p<0.01 
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Table 32  The average phencyclidine concentration over time in pH 6.2 synthetic urine 
 containing 0 and 10 mg/mL papain 
Initial 
amphetamine 
concentration 
(ng/mL) 
Time 
(h) 
Papain 
concentratio
n 
Average 
phencyclidine 
concentration 
(ng/mL) 
SD Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
12.5 0 0 9.22 1.88   
 0 10 10.85 1.41   
 6 0 11.27 1.50   
 6 10 11.75 0.41   
 72 0 9.15 1.15   
 72 10 13.02 1.91 X  
37.5 0 0 33.89 1.65   
 0 10 34.18 1.80   
 6 0 34.56 1.96   
 6 10 36.17 1.11   
 72 0 37.99 3.03   
 72 10 38.84 2.17   
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Figure 35  Effects of papain (10 mg/mL) on nordiazepam concentrations  
 over time in pH 6.2 synthetic urine, n=6 
Panel A- 300 ng/mL nordiazepam solution 
Panel B- 100 ng/mL nordiazepam solution 
a
 Significant “intra-temporal” difference, p<0.01 
b
 Significant “inter-temporal” difference, p<0.01 
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Table 33  The average nordiazepam concentration over time in pH 6.2 synthetic urine containing 
 0 and 10 mg/mL papain 
Initial 
amphetamine 
concentration 
(ng/mL) 
Time 
(h) 
Papain 
concentratio
n 
Average 
nordiazepam 
concentratio
n (ng/mL) 
SD Intra-
temporal, 
p<0.01 
Inter-
temporal, 
p<0.01 
100 0 0 108.60 4.04   
 0 10 99.40 2.52   
 6 0 113.03 3.64   
 6 10 91.84 5.22 X X 
 72 0 102.47 3.87   
 72 10 87.64 4.67 X X 
300 0 0 299.44 9.63   
 0 10 257.64 7.46   
 6 0 300.86 2.79   
 6 10 242.95 6.98 X  
 72 0 284.15 11.9   
 72 10 218.06 7.43 X X 
 
 
 
BANI Assay of Inhibited RP Enzymatic Activity 
 The average absorbance changes (delta-mabs) in 4 minutes of the blank, RP, and DRP 
specimens are given in Table 34.  Absorbance changes less than that of the blank specimen 
indicate abolishment of enzymatic activity.  Table 34 indicates the rate of absorbance change of 
the DRP preparations was less than the rate of absorbance change for the blank.  A milligram 
ratio of 1:1 of E-64 to papain is therefore a sufficient quantity to render the papain 
enzymatically inactive.  The RP preparation yielded an absorbance change of 36 mabs/min, thus 
verifying the enzymatic activity of the recrystallized papain. 
 
Table 34  The average absorbance rate change for  
 blank, RP, and  DRP specimens, n=3 
Specimen Average delta-mabs  
in 4 minutes 
S.D. 
Blank 1  0 
RP 36 1 
DRP 0 0 
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FPIA Assays with RP and DRP 
 The effect of 1 mg/mL RP and 1 mg/mL deactivated DRP on THC-COOH and 
nordiazepam concentrations are illustrated in Figures 36 and 37 and Tables 35 and 36.  Figure 
36 and Table 35 indicate that both the 1 mg/mL RP and DRP solutions had a significant effect 
on 60 ng/mL THC-COOH after 2 hours.  The groups adulterated with RP and DRP were not 
statistically different.  There was an average (SD) 37% (6%) difference between the control 
group and the groups adulterated with 1 mg/mL RP and DRP.  Data suggest the reductions in 
THC-COOH concentrations observed with the crude latex powder were, at the very least, partly 
attributable to papain itself versus an effect from the latex matrix.  They also suggest that the 
reduction in THC-COOH is not enzymatic, and may be due to nonspecific binding. 
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Figure 36  The effect of recrystallized papain (RP) and deactivated recrystallized papain (DRP)  
 on THC-COOH concentrations, n=6 
A,B
 Groups denoted with the same letter are not significantly different, p<0.01 
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Table 35  The average concentration of THC-COOH in pH 6.2  synthetic urine containing 60 
 ng/mL THC-COOH with 1 mg/mL recrystallized and deactivated recrystallized 
 papain 
Group Average THC-COOH 
concentration (ng/mL) 
SD Significant 
difference, P<0.01 
Control 66.52 3.56 A 
Recrystallized papain (1 mg/mL) 43.08 2.32 B 
Deactivated recrystallized papain (1 mg/mL) 41.29 1.73 B 
A,B
 Groups denoted with the same letter are not significantly different, p<0.01 
 
Figure 37 and Table 36 indicate that both the 1 mg/mL RP and DRP solutions did not 
have a significant effect on 250 ng/mL nordiazepam after 2 hours.  The groups adulterated with 
RP and DRP were not statistically different from the unadulterated control group.  Data indicate 
reductions the in nordiazepam concentrations observed with the crude latex powder were 
entirely attributable to the latex matrix.   
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Figure 37  The effect of recrystallized papain (RP) and deactivated recrystallized papain  
 (DRP) on nordiazepam concentrations, n=6 
 113 
Table 36  The average concentration of nordiazepam in pH 6.2  synthetic urine containing 250 
 ng/mL nordiazepam with 1 mg/mL recrystallized and deactivated recrystallized 
 papain 
Group Average nordiazepam 
concentration (ng/mL) 
SD Significant 
difference, P<0.01 
Control 209.97 7.79  
Recrystallized papain (1 mg/mL) 212.31 8.28  
Deactivated recrystallized papain (1 mg/mL) 218.09 6.19  
  
 
Gas Chromatography/Mass Spectroscopy of THC-COOH 
 The THC-COOH concentrations of adulterated specimens initially containing 500 
ng/mL THC-COOH in pH 6.2 synthetic urine with 10 mg/mL papain are listed in Table 37. Data 
indicate the average (SD) concentration of the specimens adulterated with 10 mg/mL papain was 
168.36 (+/- 30.34) ng/mL THC-COOH, a 66% decrease from the initial THC-COOH 
concentration of 500 ng/mL.  Data suggest the reported decrease in THC-COOH concentrations 
observed in the FPIA assays involves an interaction between papain and THC-COOH versus an 
interference with the FPIA assay.  Furthermore, the chromatogram and mass spectra of the 
adulterated specimens did not reveal mass fragments that could be attributed to the degradation 
of THC-COOH by papain (data not shown).   
 
Table 37  THC-COOH concentrations of adulterated speci- 
 mens that contained 500 ng/mL THC-COOH  
 and 10 mg/mL papain. 
Replicate number THC-COOH concentration (ng/mL) 
1 208 
2 145 
3 141 
4 141 
5 173 
6 199 
 Average    168 
 SD      30.3 
 
 
High Pressure Liquid Chromatography/Ultraviolet Detection of Nordiazepam 
 The nordiazepam concentrations of adulterated specimens initially containing 300 
ng/mL nordiazepam in pH 6.2 synthetic urine with 10 mg/mL papain are listed in Table 38. Data 
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indicate the average (SD) concentration of the specimens adulterated with 10 mg/mL papain was 
228.18 (+/- 12.14) ng/mL nordiazepam, a 24% decrease from the initial nordiazepam 
concentration of 300 ng/mL.  Data suggest the reported decrease in nordiazepam concentrations 
observed in the FPIA assays involves an interaction between papain and nordiazepam versus an 
interference with the FPIA assay. 
 
 
Table 38  Nordiazepam concentrations of adulterated speci- 
 mens that contained 300 ng/mL nordiazepam  
 and 10 mg/mL papain 
Replicate number Nordiazepam concentration (ng/mL) 
1 249 
2 226 
3 232 
4 220 
5 224 
6 214 
 Average    228 
 SD    12.1 
 
 
THC-COOH Binding Plots 
 Figures 38-40 illustrate the binding (B) of THC-COOH (ng/mg papain) versus free THC-
COOH (THC-COOHfree) as measured by FPIA analyses in synthetic urine at pH 4.5, 6.2, and 
8.0.  Data that yielded “negative” binding of THC-COOH, representing the few instances in 
which the concentration of THC-COOH increased, were not included in the model.  The linear 
regression performed on the data from pH 6.2 and 8.0 analyses yielded a lined defined by the 
equation: B= kobs * [THC-COOHfree], kobs= Σ kn, where kn represents the binding constant of a 
particular constituent of the CLP preparation. The kobs for the binding of THC-COOH in pH 6.2 
synthetic urine was 0.7685.  The kobs for the binding of THC-COOH in pH 8.0 synthetic urine 
was 0.0784.  The linearity of the binding plots from pH 6.2 and 8.0 are indicative of nonspecific 
binding of THC-COOH to papain and further corroborates with the data obtained from the 
experiments performed with RP and DRP preparations of papain, and the data obtained from the 
GC/MS experiments.  The data from pH 4.5 analyses were unable to be fit by a mathematical 
model that describes either specific (hyperbolic) or nonspecific binding (linear), Figure 40.  A 
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mechanism of interference is therefore more difficult to postulate as other factors, i.e. a matrix 
effect, have yielded data that is not able to be interpreted at this time. 
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Figure 38  The binding of THC-COOH (ng/mg papain) versus free THC-COOH, pH 6.2 
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Figure 39  The binding of THC-COOH (ng/mg papain) versus free THC-COOH, pH 8.0 
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Figure 40  The binding of THC-COOH (ng/mg papain) versus free THC-COOH, pH 4.5 
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Creatinine 
   Figure 41 and Table 39 describe the immediate effect of 10 mg/mL papain on 
creatinine in 30 random urine specimens. The median creatinine concentration, skewness, and 
kurtosis values of the control population were 87.8, 1.025, and 0.682. The median creatinine 
concentration, skewness, and kurtosis values of the population adulterated with 10 mg/mL 
papain were 88.9, 1.29, and 1.74.  Figure 42 and Table 40 describe the effect of 10 mg/mL 
papain on creatinine over time in 6 random urine specimens. Figures 41 and 42 and Tables 39 
and 40 indicate that 10 mg/mL papain did not have a significant effect on the distribution of 
urine creatinine values in 30 random urine specimens, nor did 10 mg/mL papain have a 
significant effect on the urine creatinine values over time in 6 random urine specimens.  
Individuals adulterating their urine with up to 10 mg/mL papain would therefore not alter their 
urine creatinine concentration. 
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Figure 41  The effect of 10 mg/mL papain on the distribution of urine creatinine concentrations  
 in a population (n=30) of random urine specimens 
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Table 39  The distribution of urine creatinine concentrations in a population (n=30) of 
 unadulterated random urine specimens and specimens adulterated with 10 mg/mL 
 papain  
Creatinine concentration 
range (mg/dL) 
Frequency of unadulterated 
specimens (n=30) 
Frequency of specimens (n=30) 
adulterated with 10 mg/mL papain 
0-20 3 3 
21-40 3 2 
41-60 7 6 
61-80 1 3 
81-100 4 3 
101-120 2 3 
121-140 2 3 
141-160 2 1 
161-180 2 1 
181-200 1 1 
201-220 1  
221-240 0 2 
241-260 0 1 
261-280 1  
281-300 1  
341-360 
 1 
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Figure 42  The effect of 10 mg/mL papain on the average urine creatinine  
 concentration over time in a population (n=6) of random urine  
 specimens 
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Table 40 The average urine creatinine concentration in a population (n=6) of unadulterated 
 random urine specimens and specimens adulterated with 10 mg/mL papain  
Time 
(h) 
Average creatinine concentration 
(mg/dL) in the unadulterated 
specimens (n=6) 
Average creatinine concentration (mg/dL) 
in the specimens (n=6) adulterated with 10 
mg/mL papain  
0 126.1 120.3 
6 151.2 144.0 
72 135.2 134.7 
  
 
Specific Gravity 
 Table 41 lists the typical reported values of the 1.002, 1.005, and 1.030 specific 
gravity quality control standards.  Table 41 illustrates that the refractometer reported specific 
gravity values with a maximum 0.3% error.  Data indicate the method employed for obtaining 
the specific gravity in urine is valid up to the limit (1.05) of the refractometer.   
 
Table 41  Specific gravity values of the quality control specimens 
Quality control specimen Reported value 
1.002 1.002 
1.005 1.005 
1.030 1.033 
 
 
 Figure 43 and Table 42 describe the immediate effect of 10 mg/mL papain on urine 
specific gravity in 30 random urine specimens. The median specific gravity, skewness, and 
kurtosis values of the control population were 1.014, 0.415, and -0.337. The median specific 
gravity, skewness, and kurtosis values of the population adulterated with 10 mg/mL papain were 
1.019, 0.545, and -0.070.  Figure 44 and Table 43 describe the effect of 10 mg/mL papain on 
urine specific gravity over time in 6 random urine specimens. Figures 43 and 44 and Tables 42 
and 43 illustrate that 10 mg/mL had a significant effect on the distribution of urine specific 
gravity values in 30 random urine specimens, and 10 mg/mL papain had a significant effect on 
the urine specific gravity values over time in 6 random urine specimens.  The maximum increase 
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in urine specific gravity was < 0.008 (0.7%) and there were no specimens in which the specific 
gravity was less than 1.001.  Overall, 10 mg/mL papain in 30 random urine specimens gave the 
appearance of a greater urine concentration.  Individuals adulterating their urine with up to 10 
mg/mL papain would not increase the urine specific gravity above 0.7%. 
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Figure 43  The effect of 10 mg/mL papain on the distribution of urine specific  
 gravity in a population (n=30) of random urine specimens 
* Significant difference, p<0.05 
 
Table 42  The distribution of urine specific gravity in a population (n=30) of unadulterated 
 random urine specimens and specimens adulterated with 10 mg/mL papain   
Specific gravity 
range 
Frequency of unadulterated 
specimens (n=30) 
Frequency of specimens (n=30) 
adulterated with 10 mg/mL papain 
1.001-1.005 3 0 
1.006-1.010 9 3 
1.011-1.015 5 7 
1.016-1.020 6 6 
1.021-1.025 3 6 
1.026-1.030 3 5 
1.031-1.035 1 2 
1.041-1.045 
 1 
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Figure 44  The effect of 10 mg/mL papain on the average urine specific gravity over time in a 
 population (n=6) of  random urine specimens 
* Significant difference, p<0.05 
 
Table 43 The average urine specific gravity in a population (n=6) of unadulterated random 
 urine specimens and specimens adulterated with 10 mg/mL papain  
Time 
(h) 
Average specific gravity in the 
unadulterated specimens (n=6) 
Average specific gravity in the specimens 
(n=6)  adulterated with 10 mg/mL papain  
0 1.016 1.018 
6 1.016 1.019 
72 1.016 1.020 
  
 
pH 
 Figure 45 and Table 44 describe the immediate effect of 10 mg/mL papain on urine pH 
in 30 random urine specimens. The median pH, skewness, and kurtosis values of the control 
population were 6.06, 0.485, and -0.616. The median pH, skewness, and kurtosis values of the 
population adulterated with 10 mg/mL papain were 5.85, 1.06, and 1.67.  Figure 46 and Table 
45 describe the effect of 10 mg/mL papain on urine pH over time in 6 random urine specimens.  
Figure 45 and Table 44 indicate that 10 mg/mL papain had a significant effect on the decrease 
in pH of thirty random urine specimens.  The median pH range of the 30 unadulterated 
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specimens was 6.0 to 6.2 while the median pH range of the 30 specimens adulterated with 10 
mg/mL papain was 5.7 to 5.9.  Figure 46 and Table 45 indicate that 10 mg/mL papain did not 
have a significant effect on the pH of the 30 random urine specimens.  Although there was a 
minor decrease in the pH in the adulterated specimens over time, it was not statistically different 
than the unadulterated control. There were no unadulterated or adulterated specimens with a pH 
>11 or <3.  Individuals adulterating their urine specimens with up to 10 mg/mL papain would 
not increase the pH of their urine to a pH >11 or decrease their urine to a pH <3, thus rendering 
the urine specimen invalid. 
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Figure 45  The effect of 10 mg/mL papain on the distribution of urine pH in a population  
 (n=30) of random urine specimens 
* Significant difference, p<0.05
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Table 44  The distribution of urine pH in a population (n=30) of unadulterated  random urine  
 specimens and specimens adulterated with 10 mg/mL papain   
pH range Frequency of unadulterated 
specimens (n=30) 
Frequency of specimens (n=30) 
adulterated with 10 mg/mL papain 
5.1-5.3 5 4 
5.4-5.6 4 8 
5.7-5.9 4 5 
6.0-6.2 4 2 
6.3-6.5 4 4 
6.6-6.8 2 5 
6.9-7.1 4 1 
7.2-7.3 1  
7.4-7.6 1  
7.7-7.9 1  
8.0-8.2 
 1 
 
 
Time (h)
pH
 +
/- 
SD
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
Effect of Papain (10mg/mL) on Urine pH
0 6 72
Treatment Group
Control
Adulterated (10 mg/mL papain)
 
Figure 46  The effect of 10 mg/mL papain on the average urine pH over time in a population 
 (n=6) of random urine specimens 
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Table 45 The average urine pH in a population (n=6) of unadulterated random urine specimens 
 and specimens adulterated with 10 mg/mL papain 
Time 
(h) 
Average pH values in the unadulterated 
specimens (n=6) 
Average pH values in the specimens 
(n=6) adulterated with 10 mg/mL 
papain  
0 6.4 6.4 
6 6.4 6.4 
72 6.4 6.3 
  
Osmolality 
 Figure 47 and Table 46 describe the immediate effect of 10 mg/mL papain on urine 
osmolality in 30 random urine specimens. The median osmolality, skewness, and kurtosis values 
of the control population were 509, 0.304, and -0.039. The median osmolality, skewness, and 
kurtosis values of the population adulterated with 10 mg/mL papain were 535, 0.261, and -
0.095.  Figure 48 and Table 47 describe the effect of 10 mg/mL papain on urine osmolality over 
time in 6 random urine specimens. Figures 47 and 48 and Tables 46 and 47 indicate that 10 
mg/mL had a significant effect on the distribution of urine osmolality in 30 random urine 
specimens, and 10 mg/mL papain had a significant effect on the urine osmolality over time in 6 
random urine specimens.  The maximum increase in the average urine osmolality was less than 
5.3% over time and there were no specimens in which the urine osmolality < 59 mOsm/kg.  
Individuals adulterating their urine with up to 10 mg/mL papain would not increase their urine 
osmolality by more than 5.3%.  In comparison to the maximum percent increase in specific 
gravity (0.7%), the maximum percent increase in osmolality (5.3%) represents a method of 
quantifying urine concentration that is more sensitive to the addition of adulterating substances.   
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Figure 47  The effect of 10 mg/mL papain on the distribution of urine osmolality in a population 
 (n=30) of random urine specimens 
* Significant difference, p<0.05 
 
Table 46  The distribution of urine osmolality in a population (n=30) of unadulterated   
 random urine specimens and specimens adulterated with 10 mg/mL papain   
Osmolality range 
(mOsm/kg) 
Frequency of unadulterated 
specimens (n=30) 
Frequency of specimens (n=30) 
adulterated with 10 mg/mL papain 
0-100 3 1 
101-200  2 
201-300 2 1 
301-400 7 8 
401-500 2  
501-600 5 6 
601-700 3 4 
701-800 5 5 
801-900 1 1 
901-1000 1 1 
1101-1200 1 1 
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Figure 48  The effect of 10 mg/mL papain on the average urine osmolality over time in a 
 population (n=6) of random urine specimens 
* Significant difference, p<0.05 
 
Table 47 The average urine osmolality in a population (n=6) of unadulterated random urine 
 specimens and specimens adulterated with 10 mg/mL papain  
Time 
(h) 
Average osmolality in the 
unadulterated specimens (n=6) 
Average osmolality in the specimens 
(n=6) adulterated with papain (10 mg/mL) 
0 501 524 
6 502 525 
72 504 531 
  
 
Nitrates, Glutaraldehyde, and Oxidants 
 Table 48 illustrates the effect of 10 mg/mL papain on POC chromaphore assays for 
nitrites, glutaraldehyde, and oxidants on a population of random urine specimens (n=6). Table 
48 illustrates that 10 mg/mL papain did not have a significant effect on the presence of nitrates, 
glutaraldehyde or oxidants in 30 random urine specimens.  The nitrite concentration revealed in 
the unadulterated specimen and paired specimen adulterated with 10 mg/mL papain was < 500 
µg/mL, and therefore below the cutoff level that denotes an adulterated specimen.  The 
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adulterated urine of individuals who add up to 10 mg/mL papain to their urine would not test 
positive for the presence of glutaraldehyde or oxidants, nor would the concentration of nitrites 
increase due to the presence of papain. 
 
Table 48  The presence of nitrite, glutaraldehyde, and oxidants in a population (n=6) with 10 
 mg/mL papain 
Group Nit rite Glutaral dehyde Oxid ants 
 Positive Negative Positive Negative Positive Negative 
Unadulterated,   
 n=6 
1a 
 
5 0 6 0 6 
Adulterated, 10 mg/mL 
 papain, n=6 
1a 
 
5 0 6 0 6 
a
 The nitrite concentration was <500 µg/mL
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CHAPTER 5 
DISCUSSION 
 
Papain Standardization 
The choice of the crude latex preparation of papain (CLP) as the subject of our research 
involved several economic and practical issues.  The commercial manufacture of the crude latex 
preparation of papain as a urine adulterant would be a more economical than a purified 
preparation and is therefore a more marketable adulteration product.  The effects of CLP on the 
measured concentrations of THC-COOH would also represent the minimal effects observed if a 
commercial urine adulterant contained a more refined preparation of papain as the active 
ingredient.  An individual intending to adulterate a urine specimen would be able to transport 
sufficient quantities of a crude powder preparation at room temperature in a clandestine 0.5 
cubic centimeter plastic pouch.   
In contrast to the recrystallized papain, the CLP preparation had an enzyme activity of 
4.32% per milligram the enzyme activity of recrystallized papain.  As research project revealed 
the enzymatic activity was not an essential component of the mechanism of adulteration, the 
significance of the enzymatic activity of CLP preparation is therefore somewhat diminished.   
 
Enzyme Multiplied Immunoassay Technique 
 The preliminary data suggested that further research was required by an alternative 
method to delineate the dose dependent effects of papain with respect to pH, THC-COOH 
concentration, and time.  One hundred percent of the adulterated positive specimens assayed 
yielded a false-negative result.  The further investigation into papain’s effect on the measured 
concentration of THC-COOH by another “class” of immunoassay not only delineated the dose 
dependent effects of papain but revealed more information about the possible mechanism of 
interference and the range of immunoassays that papain’s effects might be observed.  As 
previously stated, the target of the adulterant is of concern, be it the analytes or the 
immunoassay reagents.  A reduction in the measured concentration of THC-COOH by two 
different classes of immunoassays would indicate the mechanism of interference may involve 
the analyte versus the immunoassay’s reagents. 
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Fluorescence Polarized Immunoassay Technique 
 
THC-COOH Assays  
 A majority (94%) of all adulterated specimens, over time and a physiological urine pH 
range, reported a decreased concentration of THC-COOH relative to the unadulterated control 
and the individual baseline value (T=0).  Employing the conservative p-value of 0.01 in the 
“intra-temporal” and “inter-temporal” ANOVAs ensured that the differences between the control 
and the adulterated urine specimens were indeed genuine.  In Figures 12,14,19, and 20 an 
apparent increase of THC-COOH was reported in the control group at selected time points.  
Every analytical toxicology method has an associated degree of variability in which the control 
specimens for a particular assay must lye.  The established FPIA method for the quantitation of 
drugs of abuse allows for a 10 to 32% variation in the reported value of the daily calibrators.  
These variations are established by the U.S. Food and Drug Administration based on the 
research validating the FPIA methodology.  In most instances, the apparent increase in the THC-
COOH concentration of the control group were within the allowed variations of the assay.  In the 
few instances in which the THC-COOH concentration of the control group increased from the 
baseline value, the adulterated specimens were consistent in reporting THC-COOH 
concentrations less than the control group.  Figures 11 and 23 exhibited an apparent increase in 
the reported concentration of THC-COOH in the specimens adulterated with less than 5.0 
mg/mL papain.  A possible explanation of the apparent increase in THC-COOH concentration is 
an interference with the FPIA assay.  Interference with immunoassays such as the FPIA have 
previously been observed with other adulterants, as the quantitation of the analyte is inversely 
proportional to the amount of polarized light emitted from the specimen (Cody and 
Schwartzhoff 1989).  It should be noted however, that the apparent increase in THC-COOH 
concentration occurred in less than 6% of all cannabinoid assays performed and were not 
consistent across THC-COOH concentrations or within a specific pH of synthetic urine.  
Furthermore, the apparent increase was not observed in the FPIA assays for other drugs of abuse, 
Figures 30-35.  These observations are also not consistent with the degradation of papain, as a 
trend for increased analyte concentration over time was not observed among all papain 
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concentration, or FPIA assays.  The lack of consistency across THC-COOH concentrations, pH, 
or among FPIA assays for other drugs of abuse and the infrequency of the apparent increase in 
THC-COOH concentration occurrence is evidence that the apparent increase was artifactual.   
 
 The Effect of Papain Concentration, Time, THC-COOH Concentration, and pH on the 
Percent Decrease of THC-COOH.  Although the statistical significance of papain’s effects on 
THC-COOH concentrations between papain concentrations of 2.0, 5.0 and 10 mg/mL were 
occluded by the large variations generated by the analysis, a direct correlation between the 
percent decrease of THC-COOH concentration and the papain concentration was observed.  
Data does not indicate the decrease in THC-COOH concentration involves an enzymatic 
mechanism as gross significant reductions in THC-COOH concentrations were not observed 
after 4 to 6 hours.  A proportional decrease in the absolute THC-COOH concentration should be 
expected relative to the initial THC-COOH concentration as illustrated by Figure 28. 
 Generally, 10 mg/mL papain had the most demonstrative effects in pH 6.2 synthetic 
urine in terms of percent difference of THC-COOH from the unadulterated control.  The largest 
absolute decrease in THC-COOH was observed in pH 4.5 synthetic urine; however, the decrease 
in THC-COOH concentration was partially attributed to the pH of the matrix.  If an individual 
urine specimen contains < 50 ng/mL THC-COOH, a false positive FPIA result would not be 
expected if an individual adulterated his urine with 10 mg/mL papain.   
 
FPIA Assays for Other Drugs of Abuse 
 The average percent decrease in THC-COOH (~50%) over 72 hours is in stark contrast 
to the maximum percent decrease in nordiazepam (~12%) in specimens adulterated with 10 
mg/mL papain in pH 6.2 synthetic urine.  The difference in percent decreases between the two 
analytes is suggestive of an alternative mechanism of adulteration.  Nevertheless, the potential 
for papain to yield a false negative result by FPIA analyses for the 7 analytes involved in our 
research was limited to cannabinoids and benzodiazepines. To reiterate, the lack of papain’s 
effect on the reported concentrations of other drugs of abuse by the FPIA immunoassay suggests 
that the mechanism of interference involves an interaction with specific analytes versus the FPIA 
reagents.  Figure 4 illustrates that each analyte is structurally foreign to one another and each 
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analyate would therefore have a unique affinity for potentially binding macromolecules such as 
papain. 
 
FPIA Assays with RP and DRP 
The ability for the RP to elicit a 37% reduction in the reported THC-COOH 
concentration after only 2 hours not only implicates papain (versus the latex matrix) as an entity 
participating in the adulteration of a urine specimen by a CLP preparation but illustrates the 
potential for an RP preparation of papain to be profoundly efficacious as a urine adulterant.  
Data also indicate a reformulation of immunoassay reagents to include protease inhibitors would 
not prevent adulteration of urine specimens.  The inability for the RP preparation to reduce the 
nordiazepam concentration implicates the latex matrix in the CLP preparation as the sole entity 
adulterating these urine specimens.  The differences in the percent reduction between THC-
COOH (~50%) and nordiazepam (~12%) by the CLP preparations can be explained by the 
different entities involved in adulterating the urine specimen. 
 
Gas Chromatography/Mass Spectroscopy of THC-COOH 
 The reduction in the THC-COOH concentration as reported by GC/MS verifies, by an 
alternative and more sensitive assay, that the mechanism of interference involves an interaction 
with the analyte.  The quantitation of THC-COOH by GC/MS also verifies the adulterant has the 
potential to interfere with the results obtained from a confirmatory assay.  Therefore screening of 
all specimens, both negative and positive, for THC-COOH by GC/MS would be both 
economically and practically ineffective in revealing specimens that have been adulterated with 
papain. 
 
High Pressure Liquid Chromatography/Ultraviolet Detection of Nordiazepam 
 The reduction in the nordiazepam concentration as reported by HPLC/UV verifies, by an 
alternative and more sensitive assay, that the mechanism of interference involves an interaction 
with the analyte and the adulterant has the potential to interfere with the results obtained from a 
confirmatory assay.  Therefore screening of all specimens, both negative and positive, for 
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nordiazepam by HPLC/UV would be both economically and practically ineffective in revealing 
specimens that have been adulterated with papain. 
 
Nonspecific Binding, A Putative Mechanism of Interference 
 It is imperative to note that the binding of THC-COOH (ng/mg of papain) was performed 
with data from the crude latex preparation of papain.  The data are therefore not interpreted as 
the binding to one specific entity, as the CLP preparation contains multiple constituents.  The 
binding constant is therefore denoted as an observed binding constant, kobs.  The experiments 
with RP and DRP revealed that the papain enzyme itself was at least partially responsible for the 
decrease in THC-COOH with the CLP preparations; however, it did not eliminate the 
contribution of the other constituents.   
 The summation of the data obtained from the effects of CLP, RP, and DRP on THC-
COOH as measured by immunoassay and GC/MS indicate that mechanism of interference is 
nonspecific binding of THC-COOH to papain.  A linear plot of the binding of THC-COOH 
(ng/mg papain) versus free THC-COOH as observed from data obtained from pH 6.2 and 8.0 is 
further indication of this mechanism.  As the pH of the synthetic urine approached the pI of 
papain (9.6), it would be expected that a greater quantity of THC-COOH would participate in 
nonspecific binding.  However, the kobs of the binding in pH 8.0 synthetic urine was 
approximately one-tenth that of the binding in pH 6.2 synthetic urine.  This observation may be 
due to either the other constituents in the CLP preparation of papain exerting a more significant 
effect at pH 6.2 than at 8.0, or a matrix effect on the FPIA assay could also be implicated. 
  
Specimen Validity Testing 
 Specimen validity testing relies on dual parameters (i.e., creatinine and specific gravity) 
to differentiate an adulterated, substituted, or diluted specimen from a specimen obtained from 
an individual with renal pathologies.  Although papain had a significant effect on urine 
osmolality, pH, and specific gravity, the urine creatinine and nitrite concentrations were not 
affected by papain.  An individual with a “normal” urine specimen before adulteration with 
10mg/mL papain would not have his urine specimen rendered invalid after adulteration with 
papain based on the dual qualifying parameters of specimen validity testing or the presence of 
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oxidants or glutaraldehyde.  Conversely, if an unadulterated urine specimen were to be 
considered diluted or substituted based on a specific gravity < 1.001 before adulteration with 
papain, the urine has the potential to be considered “normal” after adulteration with 10 mg/mL 
papain due to the increase in specific gravity. 
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CHAPTER 6 
SUMMARY AND CONCLUSIONS 
 
 
 As the proprietary active ingredient(s) in commercially available urine adulterants 
become public knowledge, the manufacturers of the urine adulterants are required to modify the 
constituents of the urine adulterant to avoid detection by drug testing laboratories.  The detection 
of substances currently employed to adulterate urine specimens and modification of guidelines 
for specimen valid testing have forced manufacturers of urine adulterants to reformulate their 
products with novel ingredients that adulterate urine specimens in a manner that does not render 
the specimen invalid.  The investigation of the effects of papain in a crude latex matrix on the 
FPIA analysis for primary drug screens provides information on the potential for papain to 
become a novel commercially available urine adulterant.   
 The synthetic urine matrix used in our research delineates the conditions in which papain 
exerted its effects with respect to the discrete concentrations of the constituents and pH.  The 
data revealed by EMIT analyses of specimens containing THC-COOH not only provided 
justification for further investigation into the effects of papain but demonstrated that papain is 
an effective urine adulterant by an alternative immunoassay.  The overall FPIA analyses of 
specimens containing THC-COOH revealed that papain exerted a dose dependent significant 
effect on the concentration THC-COOH with respect to pH, THC-COOH concentration, and 
time.  False negative urine results attributed solely to papain were observed most frequently in 
pH 6.2 synthetic urine after 72 hours in specimens containing < 100 ng/mL THC-COOH. 
 The effects observed from specimens adulterated with papain suggest an interaction with 
the analytes versus an interference with the assay as demonstrated by a lack of observed effects 
in FPIA analyses of other drugs of abuse, and was also demonstrated by the confirmation 
(GC/MS, HPLC/UV) analyses of THC-COOH and nordiazepam that revealed a decrease in 
analyte concentration by a direct measurement of the analytes.  The interactions of papain with 
THC-COOH and nordiazepam suggest that the interaction was not enzymatic as demonstrated 
by the “plateau” of the THC-COOH concentrations after 4 to 6 hours, and was also 
demonstrated by FPIA assays of THC-COOH and nordiazepam that involved papain deactivated 
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by E-64.  The latex matrix in which CLP resides can, in itself, act as an adulterant by reducing 
the concentrations of analytes in the specimen as demonstrated by an effect observed in the 
FPIA analyses of nordiazepam with CLP versus a lack of observed effects in the FPIA analyses 
of nordiazepam with RP. 
 An attempt by an individual (with an average urine pH ~6.2) using CLP to obtain a false 
negative FPIA urine drug screen result for cannabinoids within 4 hours would be most 
successful if the individual first minimized the concentration of THC-COOH in the urine by the 
consumption of a large quantity of water followed by the in vitro addition of 10 mg/mL papain.  
If the diuresis induced by the consumption of a large quantity of water yields an initial urine 
THC-COOH concentration <100 ng/mL, then the average 50% decrease of THC-COOH 
concentration by 10 mg/mL papain would render the urine THC-COOH concentration < 50 
ng/mL.  An attempt by an individual using CLP to obtain a false negative FPIA urine drug 
screen result for benzodiazepines may or may not be as successful.  The effects of the CLP on 
the reduction of nordiazepam concentration are entirely due to the latex matrix and would 
therefore be difficult to assay for a standard effect. 
 An individual who attempts to adulterate his urine with 10 mg/mL papain would not 
have their urine specimen rendered invalid based on the parameters of specimen validity testing 
or the presence of glutaraldehyde or oxidants.  If the papain was enzymatically active, a 
microplate BANI enzyme activity assay would readily detect a general class of proteases in the 
urine specimen.  As proteases are not a constituent of normal urine, the specimen could be 
identified as adulterated.  However, enzyme activity is not necessary for a reduction in THC-
COOH concentration, and the sinister placement of inactive papain in a commercially available 
urine adulterant would be likely to avoid detection by an enzyme activity assay.  Papain could 
specifically be identified in a urine specimen by a Western blot.  However, performing a 
Western blot on every specimen in the laboratory is impractical due to the cost and time 
involved in performing the Western blot.  Furthermore, depending on the specificity of the 
probe, the Western blot would only detect papain and not other classes of proteins that could 
potentially interact with THC-COOH.  Although urine typically does not contain proteins > 60 
µg/mL or proteins > 20kDa, a concentration of proteins > 60 µg/mL as determined by a 
nonspecific assay such as coomassie staining, does not differentiate an adulterated specimen 
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from a specimen attained from an individual with renal pathologies.  Only the dual qualifying 
parameters of specimen validity testing will differentiate an adulterated, diluted, or substituted 
urine from an individual with renal pathologies.  Issues of patient privacy (HIPAA) arise in 
regards to federal guidelines that have not implemented a protocol for an observed urine 
collection for drug testing.  A closely observed urine collection, although not guaranteed to 
prevent urine adulteration, is the best measure to prevent adulteration of urine specimens by 
foreign substances.    
The overall goal of our research, as defined by the specific aims of this study, was 
attained by delineating the effects of papain as they apply to the practical application of a urine 
adulterant with respect to the target of papain’s interaction, the concentration of THC-COOH, 
pH of the matrix, time of interaction, and the parameters of specimen validity testing.  Based on 
our results, papain has the potential to be employed as the active ingredient in a commercially 
available urine adulterant and represents the minimal effects that could be observed in a novel 
class of urine adulterants.  The mechanism of interaction of papain with THC-COOH, as 
suggested by our data, is putatively the nonspecific binding of THC-COOH to papain.  The 
observed binding constant was greatest at pH 6.2, a reasonable median value for typical urine 
pH.  The nonspecific binding of THC-COOH would render the THC-COOH unidentifiable to 
the antibody complex in the immunoassays and would not allow solid phase extraction of THC-
COOH in preparation for gas chromatography/mass spectroscopy. 
  The information contained in this research has the potential to be exploited by the 
manufacturers of urine adulterant to include papain as the active ingredient in their products. 
This research can also pioneer investigations into novel classes of urine adulterants in which the 
mechanism of adulteration is the binding and steric hindrance of chemical moieties on the 
analyte.  A scenario involving the adulteration of a urine specimen by microgram quantities of 
polyclonal antibodies, not unlike those used in the immunoassays themselves, has the potential 
to be marketed by commercial manufacturers of urine adulterants.  The polyclonal antibodies 
would be more costly to produce and market than papain but would certainly be more 
efficacious in adulterating a urine specimen. 
The information contained in this research also has the potential to persuade federal 
agencies in drafting a standard protocol for an observed urine collection for drug screening.  The 
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most effective practice in thwarting an attempted in vitro urine adulteration attempt is to 
perform a closely observed urine collection.  To circumvent the issue of infringed patient 
privacy, federal agencies are expending tremendous capital to enact guidelines that will allow 
the interpretation of the results from alternative matrix drug screens.  A standard protocol for 
urine collection that is compliant with current HIPAA guidelines would be a more practical 
approach than alternative matrice drug testing.     
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APPENDIX A 
 
List of Abbreviations 
Abbreviation Description 
CLP Crude Latex Papain 
DRP Deactivated Recrystallized Papain 
EMIT Enzyme Multiplied ImmunoAssay Technique 
FPIA Fluorescence Polarized ImmunoAssay 
GC/MS Gas Chromatography/Mass Spectrometry 
HIPAA Health Insurance Portability and Accountability Act 
HPLC/UV High Performance Liquid Chromatography/Ultraviolet Detection 
RP Recrystallized Papain 
SAMHSA Substance Abuse & Mental Health Administration 
THC Delta-9-tetrahydrocannabinol 
THC-COOH 11-nor-delta-9-tetrahydrocannabinol 
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APPENDIX B 
 
Papain Standardizaiton 
 
Preparation Concentration (mg/mL) delta-mabs 
Twice recrystallized 0.0 -0.1 
 0.0325 1 
 0.065 2.2 
 0.13 4.9 
Crude latex 1.25 1.8 
 2.5 3.8 
 5 8.5 
 10 17.9 
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APPENDIX C 
 
EMIT 
 
Specimen (125 ng/mL THC-COOH) Replicate # Result 
Control (0 mg/mL papain) 1 positive 
 2 positive 
 3 positive 
 4 positive 
 5 positive 
 6 positive 
Adulterated (10 mg/mL papain) 1 negative 
 2 negative 
 3 negative 
 4 negative 
 5 negative 
 6 negative 
 147 
APPENDIX D 
 
FPIA Assays 
 
THC-COOH Assays-25 ng/mL in pH 4.5 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 17.2 22.67 20.77 25.46 28.12 26.14 
 2 20.36 23.21 23.66 26.45 25.7 26.24 
 3 19.67 20.12 26.81 22.55 27.04 25.08 
 4 19.64 21.25 20.32 21.81 24.85 25.09 
 5 19.77 21.56 23.17 23.21 27.56 24.88 
 6 19.37 22.25 21.02 22.31 25.75 24.55 
4 1 14.76 14.63 13.37 15.99 16.22 17.9 
 2 13.77 13.94 12.2 19.64 13.87 16.91 
 3 13.55 14.54 15.89 17.89 15.28 15.3 
 4 15.33 16.46 13.3 16.87 17.49 18.3 
 5 13.89 14.89 12.71 17.68 16.73 15.53 
 6 14.15 15.53 15.15 15.91 16.81 16.65 
6 1 16.57 15.49 15.19 15.62 13.88 19.62 
 2 18.63 14.06 17.09 16.69 17.18 20.05 
 3 17.1 18.08 17.58 14.74 16.35 17.49 
 4 20.13 19.02 19.7 13.1 18.3 18.95 
 5 17.34 17.85 17.66 17.08 17.68 17.73 
 6 20.14 14.55 17.74 14.72 20.62 17.65 
24 1 10.73 15.06 13.38 14.91 14.05 18.84 
 2 13.73 11.06 11.92 10.77 14.35 17.4 
 3 13.03 12.89 14.2 12.26 14.28 15.56 
 4 17.61 13.96 12.15 14.91 14.53 16.18 
 5 15.47 12.75 16.02 13.17 15.85 14.87 
 6 14.53 14.85 16.07 12.24 17.31 13.7 
72 1 15.51 14.21 11.24 12.13 12.52 14.57 
 2 17.78 12.89 10.46 11.41 11.59 14.22 
 3 15.38 13 14.3 10.62 13.3 12.73 
 4 18.35 9.84 14.23 13.79 12.91 12.07 
 5 17.79 13.59 11.75 13.5 13.16 11.52 
 6 18.86 8.64 11.2 12.31 12.71 13.56 
 148 
75 ng/mL in pH 4.5 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 61.98 69.28 73.91 71.09 77 63.93 
 2 63.45 82.4 65.89 100.03 71.98 72.57 
 3 64.65 64.88 78.3 65.6 75.51 64.54 
 4 59.95 64.61 88.83 76.88 83.28 76.3 
 5 63.04 69.07 88.93 75.62 62.83 73.24 
 6 69.07 67.82 61.19 82.67 62.95 63.4 
4 1 41.79 39.65 31.28 43.33 36.86 25.68 
 2 47.42 43.04 32.61 43.41 37.24 33.06 
 3 42.74 37.16 35.19 32.84 31.4 33.34 
 4 39.07 37.48 34.01 31.3 29.93 29.58 
 5 42.67 30.64 40.48 32.39 34.85 34.11 
 6 47.68 36.9 42.21 30.63 32.78 33.22 
6 1 33.17 26.15 29.58 31.26 25.99 26.38 
 2 29.98 29.31 24.86 28.94 27.59 25.93 
 3 32.9 28.91 26.09 26.96 28.03 24.86 
 4 32.57 30.15 34.03 26.59 26.98 27.52 
 5 31.02 24.7 33.51 27.51 28.09 28.54 
 6 32.13 29.13 28.43 27.56 28.86 23.04 
24 1 38.34 24.71 30.33 30.03 24.74 24.35 
 2 43.9 28.89 27.64 34.93 25.72 23.03 
 3 37.63 27.75 29.26 28.8 28.71 28.88 
 4 47.27 27.39 29.99 25.27 27.67 22.97 
 5 37.22 27.36 38.26 25.47 26.06 26.17 
 6 42.2 29.15 28.41 28.03 22.74 25.89 
72 1 27.95 29.47 24.58 31.48 32.21 29.74 
 2 37.59 25.46 19.44 32.39 28.83 29.25 
 3 31.7 23.85 24.58 28.66 29.85 27.05 
 4 35.05 23.57 32.96 26.32 38.23 23.91 
 5 32.7 27.95 28.94 37.66 31.22 32.45 
 6 33.04 23.92 25.83 33.37 32.79 18.62 
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100 ng/mL in pH 4.5 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 88.5 109.8 102.0 93.3 85.8 108.3 
 2 98.1 93.5 102.6 100.0 117.9 108.4 
 3 97.2 123.5 98.4 97.5 115.0 109.3 
 4 97.7 104.5 103.7 94.6 119.7 97.0 
 5 95.0 106.0 100.1 81.7 125.1 102.3 
 6 94.9 86.9 113.1 94.4 121.6 104.6 
4 1 40.7 43.1 35.4 40.3 40.8 39.9 
 2 39.4 43.1 41.1 46.9 38.6 39.8 
 3 41.8 46.4 44.1 43.1 38.0 42.1 
 4 45.6 44.4 40.8 38.5 38.1 39.4 
 5 43.1 43.4 41.1 41.2 45.7 46.7 
 6 46.3 40.9 40.2 39.7 37.7 46.1 
6 1 43.0 38.3 34.1 32.1 32.4 34.9 
 2 42.6 39.7 37.1 35.0 32.2 30.7 
 3 42.9 43.3 34.5 38.1 29.9 25.7 
 4 44.7 41.7 37.5 32.3 30.6 33.6 
 5 45.1 40.8 31.8 33.9 34.4 33.0 
 6 38.3 37.3 35.2 31.9 34.3 27.7 
24 1 55.2 44.0 38.1 40.2 28.4 35.4 
 2 47.8 42.5 41.2 36.3 30.4 30.7 
 3 48.4 43.0 39.3 38.4 32.8 26.2 
 4 48.7 43.0 37.5 32.2 35.8 26.3 
 5 50.5 45.3 37.5 32.5 35.0 30.7 
 6 54.6 39.9 32.0 30.1 35.1 28.6 
72 1 45.1 39.8 34.2 37.1 33.8 29.6 
 2 46.7 36.8 37.4 33.8 29.2 29.9 
 3 51.0 39.7 35.0 40.2 32.9 27.9 
 4 46.0 39.3 38.9 31.5 41.1 38.9 
 5 50.3 39.7 34.1 32.0 35.5 32.3 
 6 49.6 40.1 32.2 37.7 28.2 31.8 
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250 ng/mL in pH 4.5 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 125.1 104.2 101.3 103.3 114.2 148.1 
 2 131.0 112.4 104.2 95.4 123.1 138.6 
 3 120.0 117.6 102.1 90.0 121.7 109.2 
 4 132.9 111.4 105.0 118.2 90.5 106.0 
 5 132.9 114.4 108.8 97.9 101.7 110.4 
 6 121.6 84.4 91.3 100.3 104.3 101.3 
4 1 168.8 112.6 112.5 90.8 95.0 92.8 
 2 176.1 114.9 87.6 101.6 68.4 59.6 
 3 139.7 96.5 96.4 66.2 61.9 65.3 
 4 188.0 112.4 108.7 73.1 67.6 72.4 
 5 195.4 112.0 109.4 65.4 62.9 61.6 
 6 166.7 150.2 90.8 56.7 50.2 60.3 
6 1 120.6 74.7 54.9 71.0 48.4 53.0 
 2 102.2 73.3 58.0 49.7 40.1 47.4 
 3 100.3 93.0 54.6 51.3 35.6 44.3 
 4 105.1 78.6 51.7 54.4 40.0 45.4 
 5 106.8 66.8 69.4 44.9 37.8 50.5 
 6 108.1 73.3 59.6 38.7 38.9 37.8 
24 1 101.1 65.8 67.5 59.5 65.8 56.8 
 2 102.2 53.7 56.1 48.0 48.2 51.9 
 3 96.6 55.0 49.5 51.2 53.5 55.2 
 4 122.3 60.2 53.3 52.8 54.9 49.0 
 5 101.6 57.2 53.5 36.7 50.7 62.7 
 6 81.8 45.0 53.1 43.8 44.9 60.4 
72 1 91.5 81.9 86.5 60.5 80.7 74.3 
 2 101.7 65.2 60.9 55.1 53.3 73.0 
 3 77.0 64.7 72.1 34.2 48.0 48.1 
 4 97.2 66.6 65.4 55.8 63.4 51.3 
 5 85.6 56.1 65.4 51.6 90.1 33.7 
 6 75.6 50.7 44.1 37.7 44.1 59.1 
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500 ng/mL in pH 4.5 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 297.3 252.8 231.4 201.9 257.5 215.0 
 2 243.5 263.3 258.9 243.7 263.1 276.7 
 3 242.0 217.1 250.6 256.6 258.1 380.9 
 4 284.0 244.0 263.5 255.7 272.3 313.7 
 5 272.9 254.7 254.8 247.2 528.6 230.9 
 6 226.6 305.0 253.7 229.7 226.6 261.1 
4 1 219.7 202.0 167.9 133.0 118.4 203.5 
 2 170.9 197.6 171.4 178.0 144.8 117.6 
 3 234.2 217.2 208.8 154.2 128.7 136.8 
 4 319.2 189.1 169.7 157.3 139.2 113.8 
 5 250.5 254.1 194.4 182.6 152.4 123.6 
 6 245.5 202.8 219.6 168.3 152.5 135.1 
6 1 376.1 318.2 289.9 195.6 218.9 173.4 
 2 411.0 351.4 300.1 211.6 160.9 136.1 
 3 406.0 345.3 302.0 229.7 172.0 143.3 
 4 452.0 383.1 274.1 297.7 141.2 127.8 
 5 425.2 354.8 312.9 272.8 165.6 141.3 
 6 433.4 412.3 450.4 345.1 164.3 144.2 
24 1 350.1 326.3 306.2 259.6 259.2 214.2 
 2 368.9 288.2 292.1 226.2 217.4 213.0 
 3 335.3 274.3 351.4 223.1 250.1 198.9 
 4 364.3 300.6 254.6 236.0 197.8 184.4 
 5 364.8 255.4 248.8 282.0 262.4 243.8 
 6 403.3 301.4 275.3 275.3 214.4 214.8 
72 1 274.5 344.3 174.6 155.9 339.8 108.5 
 2 328.9 178.7 177.3 127.8 91.3 80.0 
 3 302.3 205.7 176.8 111.0 85.4 80.0 
 4 215.6 209.8 154.9 127.3 85.8 69.0 
 5 301.1 289.7 132.1 118.6 93.2 92.2 
 6 381.3 201.2 206.6 111.2 87.2 67.7 
 152 
25 ng/mL in pH 6.2 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 24.61 22.35 25.42 25.25 24.35 22.28 
 2 25.11 22.54 23.37 24.31 25.78 23.16 
 3 23.17 19.75 23.84 25.11 24.53 28.57 
 4 22.37 22.94 21.88 24.4 26.65 26.56 
 5 23.44 24.53 21.04 25.49 22.75 23.48 
 6 26.2 24.92 24.63 24.28 23.58 19.93 
4 1 21.34 16.94 17.74 18.67 17.05 13.79 
 2 22.58 18.39 18.17 16.63 17.2 14.22 
 3 20.09 16.46 19.06 18.53 18.36 16.39 
 4 21.54 18.71 18.2 18.31 17.3 13.54 
 5 24.27 21.18 20.18 18.1 16.84 13.28 
 6 26.43 18.37 20.38 19.11 17.46 17.16 
6 1 16.82 17.76 18.09 18.27 14.66 13.62 
 2 20.58 17.09 18.25 15.06 13.06 9.93 
 3 23.3 16.89 16.84 17.05 14.89 10.95 
 4 22.38 19.17 18.31 17.53 13.28 12.08 
 5 22.9 18.14 19.29 17.19 13.38 10.99 
 6 20.61 16.46 18.17 17.99 14.23 11.24 
24 1 24.07 11.59 17.87 14.82 13.02 11.44 
 2 18.31 13.24 17.12 15.4 15.15 13.1 
 3 22.75 14.96 19.2 14.95 16.1 13.46 
 4 22.55 18.17 18.14 19.72 15.77 12.3 
 5 23.75 17.6 20.07 17.96 14.86 13.04 
 6 20.93 17.16 12.96 19.17 14.88 12.16 
72 1 22.15 32.59 33.38 30.71 23.63 11.46 
 2 23.22 29.5 27.86 28.71 18.63 11.32 
 3 23.76 31.26 31.42 27.63 17.16 11.8 
 4 29.51 31.94 30.92 27.72 18.9 11.21 
 5 22.53 31.34 35.03 29.28 18.77 15.29 
 6 26.98 30.35 32.2 29.15 18.38 13.04 
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75 ng/mL in pH 6.2 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 72.32 72.6 77.4 77.24 79.16 86.75 
 2 80.23 69.24 74.1 79.73 71.86 76.12 
 3 80.29 68.99 74.38 81.91 82.55 82.19 
 4 83.67 74.7 77.97 75.48 77.75 76.68 
 5 86.59 69.77 74.72 91.22 80.04 84.04 
 6 82.81 71.28 88 79.64 84.52 79.45 
4 1 89.19 58.53 49.63 49.44 41.21 30.9 
 2 92.19 53.83 48.87 62.57 45.93 27.19 
 3 89.34 49.97 46.04 59.24 38.31 25.4 
 4 98.2 68.33 52.54 59.96 39.78 27.08 
 5 101.55 52.09 49.93 53.98 44.29 36.1 
 6 97.02 50.93 51.39 54.9 39.38 23.44 
24 1 60.52 43.64 45.67 48.05 33.94 29.47 
 2 74.06 43.77 44.83 42.82 30.54 28.77 
 3 72.04 50.49 46.05 39.09 32.43 28.06 
 4 73.25 47.99 57.88 43.88 31.64 27.42 
 5 74.91 47.98 49.81 43.17 35.36 31.36 
 6 64.02 44.57 42.99 48.66 35.94 27.07 
72 1 55.87 39.2 34 29.8 22.64 19 
 2 61.76 38.02 30.73 28.55 23.69 19.46 
 3 60.7 43.53 32.96 29.18 19.38 24.93 
 4 62.95 38.88 38.2 28 19.85 19.03 
 5 66.24 41.91 34.98 27.92 20.56 19.55 
 6 63.98 42.1 35.02 29.87 24.07 16.36 
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100 ng/mL in pH 6.2 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 81.0 99.0 94.9 98.7 101.2 93.3 
 2 100.3 82.3 87.8 108.4 105.5 96.6 
 3 93.8 76.4 87.4 108.7 99.9 88.6 
 4 90.9 78.7 113.5 105.3 130.1 86.0 
 5 105.5 88.1 105.0 103.9 106.0 87.4 
 6 95.0 87.3 114.0 108.4 103.6 82.8 
4 1 89.2 71.4 62.2 49.4 42.8 29.0 
 2 92.2 67.3 60.4 62.6 49.5 30.7 
 3 89.3 59.8 55.1 59.2 38.8 36.7 
 4 98.2 62.6 74.5 60.0 51.7 33.3 
 5 101.6 64.7 60.7 54.0 41.0 34.4 
 6 97.0 64.4 62.6 54.9 48.3 32.3 
24 1 72.9 56.2 58.6 43.6 41.9 26.9 
 2 66.6 56.2 51.9 43.4 39.7 31.0 
 3 72.2 53.8 52.7 45.7 43.9 28.3 
 4 75.8 58.3 51.1 49.9 37.6 31.3 
 5 80.5 62.6 50.5 48.4 40.1 31.4 
 6 70.8 53.9 49.6 49.2 38.2 23.9 
72 1 80.7 38.7 44.5 36.5 31.5 23.4 
 2 68.8 42.9 45.5 35.6 27.9 25.7 
 3 76.4 39.5 40.1 34.4 33.7 27.6 
 4 69.0 39.7 41.3 35.2 37.4 26.7 
 5 78.4 49.2 39.8 35.8 26.8 24.7 
 6 80.4 51.6 40.8 38.3 27.4 24.8 
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250 ng/mL in pH 6.2 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 180.3 162.8 201.5 183.2 214.7 168.7 
 2 201.4 156.0 181.5 205.5 212.4 199.2 
 3 221.0 159.9 246.9 236.7 230.9 209.2 
 4 210.7 173.1 199.9 226.5 215.8 205.4 
 5 201.2 206.2 200.5 246.7 226.1 216.3 
 6 200.9 211.3 188.3 238.1 191.2 189.4 
4 1 208.8 180.8 157.8 125.3 95.1 68.6 
 2 220.7 184.9 166.9 117.7 75.6 67.6 
 3 226.1 182.0 158.5 139.3 92.0 80.5 
 4 239.6 186.7 172.8 123.5 117.9 77.9 
 5 243.0 199.8 179.8 129.8 105.3 75.2 
 6 229.8 181.9 167.2 114.9 102.8 80.8 
6 1 199.5 164.2 161.0 124.4 84.6 105.6 
 2 245.6 164.0 173.2 137.1 97.7 117.5 
 3 251.7 164.9 156.4 147.0 105.0 103.4 
 4 254.6 175.6 147.3 111.8 107.0 99.8 
 5 254.9 175.6 157.2 153.9 102.7 112.2 
 6 248.2 181.8 132.9 132.5 82.9 103.0 
24 1 143.9 238.2 123.0 87.8 67.3 49.9 
 2 175.1 132.6 115.1 97.5 66.9 53.7 
 3 168.7 140.8 111.1 108.7 69.2 55.8 
 4 188.8 139.4 105.6 86.5 73.2 56.6 
 5 200.3 139.6 147.0 117.6 77.1 54.6 
 6 202.9 148.5 131.8 114.3 73.7 55.6 
72 1 144.1 104.7 83.8 82.4 58.5 45.8 
 2 112.7 84.5 95.4 82.3 61.1 51.3 
 3 186.0 85.2 83.6 71.5 64.3 48.6 
 4 184.7 104.2 113.2 78.7 69.7 52.4 
 5 190.7 109.7 110.1 69.4 69.7 48.0 
 6 189.1 116.3 101.4 70.5 82.1 49.9 
 156 
500 ng/mL in pH 6.2 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 302.6 328.4 304.0 262.6 262.4 185.7 
 2 347.5 323.7 344.5 269.7 244.6 268.3 
 3 331.0 389.7 327.6 338.3 303.2 262.5 
 4 365.0 353.3 320.2 289.4 277.7 281.1 
 5 422.4 376.1 293.3 325.7 244.3 326.8 
 6 436.3 402.1 279.0 295.3 283.4 293.0 
4 1 336.1   249.6 183.8 141.8 
 2 416.7 309.8 246.7 291.3 223.9 164.8 
 3 369.4 331.8 312.8 243.1 231.6 176.7 
 4 423.2 309.6 304.0 268.2 183.8 179.9 
 5 444.6 290.9 315.8 275.6 236.8 163.0 
 6 394.2 303.8 361.3 285.6 236.4 170.8 
6 1 399.3   219.3 182.8 127.1 
 2 475.9 293.4 232.8 297.1 208.4 137.7 
 3 486.5 356.9 250.8 271.1 205.4 136.1 
 4 449.0 326.4 330.3 269.6 221.3 108.7 
 5 498.6 298.0 258.1 277.6 179.6 133.5 
 6 434.3 319.7 360.7 284.9 204.4 139.4 
24 1 379.1   169.1 117.8 87.0 
 2 376.1 216.6 167.6 154.8 127.7 79.0 
 3 467.5 248.2 192.6 214.9 113.4 101.9 
 4 397.2 225.0 196.8 229.0 144.8 93.5 
 5 438.9 230.2 210.8 194.0 164.9 90.0 
 6 403.4 238.1 232.6 178.5 160.5 103.7 
72 1 426.1   157.8 98.0 84.9 
 2 489.7 219.1 168.2 163.3 102.3 112.5 
 3 526.1 265.2 199.5 167.0 112.9 78.8 
 4 487.0 228.3 218.6 162.8 108.7 88.3 
 5 450.3 207.0 209.1 144.3 110.5 78.8 
 6 427.9 216.0 228.9 145.8 100.7 81.3 
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25 ng/mL in pH 8.0 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 25.3 26.7 29.3 29.8 27.2 21.3 
 2 24.8 28.0 29.0 29.4 28.9 21.8 
 3 23.0 23.9 31.5 30.9 27.6 20.7 
 4 29.5 27.8 29.7 30.7 29.9 27.0 
 5 28.5 25.1 32.0 32.2 30.3 22.8 
 6 26.8 28.0 30.6 33.6 29.2 22.6 
4 1 22.1 26.6 26.6 28.1 23.2 16.9 
 2 22.7 24.0 29.3 25.1 21.1 14.2 
 3 25.1 27.3 28.6 28.6 20.3 15.7 
 4 26.4 23.8 27.7 28.8 23.4 17.5 
 5 28.0 27.6 29.9 28.4 24.9 18.0 
 6 29.4 27.1 28.8 26.8 18.8 18.0 
6 1 25.2 25.4 28.3 26.4 20.6 15.8 
 2 22.7 26.5 29.5 24.5 19.8 12.8 
 3 23.6 26.3 28.0 28.2 18.5 14.8 
 4 25.4 26.5 28.0 26.6 19.2 15.5 
 5 26.1 26.7 30.5 29.1 21.1 16.1 
 6 25.1 26.9 24.3 26.4 18.4 15.8 
24 1 23.1 27.6 29.1 25.0 23.4 16.2 
 2 20.9 26.6 28.2 28.3 20.0 18.7 
 3 22.2 28.6 28.7 29.9 19.1 15.9 
 4 24.3 30.6 28.8 30.9 19.0 15.1 
 5 26.7 28.2 30.6 29.0 23.0 16.3 
 6 24.7 28.9 27.3 26.6 21.8 16.0 
72 1 20.7 30.5 32.9 25.9 22.7 15.7 
 2 23.3 29.0 29.4 24.2 17.8 17.0 
 3 21.0 29.2 35.2 29.6 18.2 15.7 
 4 26.8 28.5 32.2 29.7 19.2 12.4 
 5 27.3 32.6 33.6 30.2 19.5 12.6 
 6 28.1 29.6 35.0 28.1 18.7 14.5 
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75 ng/mL in pH 8.0 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 62.1 60.0 71.5 61.4 83.6 73.4 
 2 62.8 63.6 71.9 50.9 85.5 70.5 
 3 63.7 63.7 57.3 85.6 80.4 72.0 
 4 69.6 72.6 61.8 86.6 81.2 67.9 
 5 72.0 74.5 61.1 87.2 74.1 68.9 
 6 63.6 82.5 66.1 85.6 85.8 71.3 
4 1 75.4 65.7 60.8 45.3 59.1 38.9 
 2 70.9 67.1 62.7 40.8 60.0 35.9 
 3 80.9 66.1 48.6 60.5 61.4 38.8 
 4 81.0 65.3 55.3 71.0 62.6 39.8 
 5 84.4 63.3 52.8 70.5 57.7 35.4 
 6 82.5 64.0 56.5 69.6 65.0 43.8 
6 1 78.4 62.2 58.6 42.8 52.3 33.6 
 2 75.0 67.8 55.0 41.6 67.7 30.9 
 3 76.9 67.7 47.7 52.6 59.4 36.9 
 4 77.9 62.8 51.1 66.3 58.5 38.6 
 5 82.1 61.5 48.5 59.4 53.1 34.0 
 6 84.5 63.1 52.4 65.1 54.9 43.3 
24 1 63.3 57.9 65.0 38.8 38.4 21.1 
 2 66.7 65.5 60.0 33.7 37.8 23.2 
 3 72.9 63.7 51.5 57.4 39.3 26.4 
 4 68.9 68.2 55.6 60.7 40.0 24.6 
 5 72.9 59.3 54.2 56.7 39.9 22.7 
 6 79.9 62.2 56.0 61.4 36.7 25.9 
72 1 69.5 65.5 68.3 44.5 37.5 19.9 
 2 64.3 57.6 63.9 40.1 35.0 18.5 
 3 69.0 54.7 66.7 61.5 40.3 16.2 
 4 74.0 60.9 55.7 64.1 46.0 22.6 
 5 75.6 75.1 59.3 57.5 36.8 20.4 
 6 70.5 77.5 60.7 63.7 36.9 22.9 
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100 ng/mL in pH 8.0 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 82.1 93.1 98.2 109.5 84.2 70.4 
 2 86.8 90.3 104.6 105.4 75.1 78.0 
 3 86.7 97.4 106.6 99.4 95.0 65.5 
 4 91.7 116.2 105.4 109.5 88.0 71.9 
 5 93.7 113.5 111.2 112.9 85.9 82.2 
 6 90.4 105.8 102.2 108.6 87.9 86.7 
4 1 90.4 96.4 103.0 100.2 80.4 51.5 
 2 94.5 88.8 106.7 107.3 63.6 55.7 
 3 95.3 104.1 107.7 99.2 71.9 41.7 
 4 100.9 110.7 107.5 110.9 71.7 54.3 
 5 102.5 99.7 111.6 110.8 87.0 55.8 
 6 102.7 116.5 117.4 107.7 76.2 66.1 
6 1 87.0 109.0 116.1 106.1 64.4 35.5 
 2 86.8 118.6 114.6 105.9 57.0 41.6 
 3 93.7 115.8 121.5 92.9 63.9 42.5 
 4 98.7 117.7 124.5 89.3 65.6 35.4 
 5 91.6 115.3 109.9 100.6 64.1 44.3 
 6 96.8 112.9 121.0 106.9 58.3 47.7 
24 1 83.5 114.8 121.2 91.7 54.5 35.4 
 2 81.5 121.8 121.4 110.7 49.7 30.7 
 3 88.1 133.4 116.2 100.8 52.8 37.1 
 4 92.7 119.0 120.0 90.3 62.3 33.5 
 5 93.9 119.5 115.7 100.4 58.8 36.2 
 6 96.4 120.3 117.8 111.6 55.4 36.9 
72 1 67.7 119.1  108.5 54.6 30.8 
 2 67.7 120.3 130.9 100.2 44.1 28.2 
 3 66.6 125.6 124.8 105.6 49.3 32.5 
 4 83.9 126.8 121.4 96.0 52.7 29.1 
 5 78.7 118.2 123.7 99.6 49.2 35.4 
 6 78.8 124.5 128.2 116.0 46.6 39.7 
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250 ng/mL in pH 8.0 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 287.1 251.7 260.4 251.9 237.1 193.1 
 2 279.1 261.0 254.0 242.2 243.6 233.4 
 3 277.1 239.9 226.9 250.6 234.6 200.9 
 4 276.5 247.9 253.1 249.6 241.2 214.4 
 5 281.5 261.0 233.7 239.5 230.0 216.4 
 6 284.8 235.8 244.8 237.7 220.7 229.3 
4 1 242.0 235.1 219.8 204.9 181.0 135.6 
 2 249.6 231.3 223.9 238.0 179.6 124.0 
 3 252.7 230.3 236.4 208.4 195.5 134.0 
 4 257.0 243.4 212.2 250.7 173.8 136.4 
 5 370.0 235.8 232.8 218.5 189.4 151.2 
 6 289.9 239.6 246.5 219.5 187.5 140.9 
6 1 195.2 201.8 191.6 173.3 161.6 103.6 
 2 231.2 222.4 197.0 173.8 138.7 88.7 
 3 221.6 225.4 216.9 195.6 158.1 108.2 
 4 237.7 221.0 214.3 194.0 145.9 93.5 
 5 241.1 216.6 215.4 173.4 151.4 106.2 
 6 223.1 234.8 205.6 183.7 152.7 99.1 
24 1 191.0 198.0 211.2 181.7 143.0 75.6 
 2 217.1 205.3 159.9 167.3 122.5 74.8 
 3 202.7 204.3 201.7 174.7 222.9 85.3 
 4 193.6 208.2 198.4 178.9 125.9 79.8 
 5 216.6 207.7 190.1 173.3 130.1 82.5 
 6 227.6 212.0 205.1 173.8 135.9 73.1 
72 1 176.4 232.4 230.9 208.0 129.8 77.8 
 2 202.5 211.5 193.7 170.9 125.3 80.4 
 3 216.1 192.6 185.4 198.4 124.1 80.3 
 4 206.1 220.4 200.4 182.7 115.4 72.9 
 5 190.5 217.4 208.1 183.9 118.3 75.6 
 6 214.3 230.9 223.9 186.2 123.0 71.3 
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500 ng/mL in pH 8.0 synthetic urine 
time (h) replicate #  papain concentra tion (mg/mL)   
  0 0.5 1 2 5 10 
0 1 396.0 453.8 390.8 435.8 412.2 382.3 
 2 380.9 407.5 431.0 463.5 439.1 377.6 
 3 496.3 427.8 398.0 441.1 409.6 372.7 
 4 401.2 436.0 413.4 426.6 431.9 385.2 
 5 463.7 381.7 447.5 436.2 392.6 394.0 
 6 430.4 393.4 426.1 470.0 431.2 378.5 
4 1 383.8 358.4 376.1 356.1 303.4 251.4 
 2 435.4 398.0 359.8 373.1 312.6 211.5 
 3 402.8 398.0 369.2 367.9 308.9 208.0 
 4 422.6 394.4 414.2 352.1 282.2 205.1 
 5 464.9 380.2 417.6 396.2 306.2 201.3 
 6 439.7 399.4 440.8 412.8 290.5 214.9 
6 1 501.2 504.4 360.1 386.0 439.2 261.5 
 2 460.2 378.8 401.0 411.4 302.8 284.6 
 3 471.9 414.0 402.5 421.3 372.5 170.4 
 4 484.4 443.2 406.9 372.8 335.9 183.5 
 5 492.8 410.3 388.3 366.7 264.2 183.3 
 6 494.0 423.2 429.5 400.6 268.2 209.3 
24 1 380.6 427.6 362.7 381.5 257.9 202.6 
 2 374.5 485.9 396.9 366.5 290.2 154.3 
 3 343.6 398.2 387.3 346.3 265.0 191.5 
 4 397.4 357.2 402.3 359.8 230.4 188.0 
 5 424.1 408.1 420.2 364.0 281.4 173.6 
 6 369.5 388.0 432.0 370.7 273.4 159.1 
72 1 367.7 382.5 369.1 350.6 242.2 145.6 
 2 351.8 436.9 434.4 309.7 258.7 121.0 
 3 385.6 422.5 399.1 315.2 246.3 141.8 
 4 387.0 223.9 380.8 336.5 220.3 156.7 
 5 462.7 400.5 362.0 352.6 241.4 135.1 
 6 398.1 370.6 362.6 428.2 285.1 114.2 
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  164 
RP and DRP 
 
BANI Assay of RP Inhibition 
Preparation Replicate # delta-mabs 
Blank 1 1 
1 mg/mL papain 1 38 
 2 37 
 3 35 
1 mg/mL papain+1 mg/mL E-64 1 0 
 2 0 
 3 1 
 
 
FPIA of 60 mg/mL THC-COOH with RP and DRP 
Specimen  Replicate # Result 
Control (0 mg/mL RP) 1 63.44 
 2 62.38 
 3 66.91 
 4 70.08 
 5 65.12 
 6 71.19 
1 mg/mL RP 1 39.28 
 2 43.73 
 3 44.24 
 4 42.06 
 5 42.98 
 6 46.19 
1 mg/mL DRP 1 43.65 
 2 40.78 
 3 40.25 
 4 42.72 
 5 41.49 
 6 38.85 
165 
FPIA of 250 mg/mL nordiazepam with RP and DRP 
Specimen  Replicate # Result 
Control (0 mg/mL RP) 1 196.08 
 2 210.12 
 3 212.35 
 4 217.9 
 5 207.46 
 6 215.93 
1 mg/mL RP 1 209.76 
 2 201.19 
 3 223.64 
 4 205.93 
 5 214.98 
 6 218.36 
1 mg/mL DRP 1 227.79 
 2 212.99 
 3 214.91 
 4 211.28 
 5 220.31 
 6 221.27 
 
 
166 
APPENDIX E 
 
GC/MS of THC-COOH 
 
THC-COOH (ng/mL) THC-COOH area d3-THC-COOH area 
Standard Curve   
0 578 11558 
100 44327 20567 
200 120520 22500 
300 266254 33843 
400 626387 57495 
500 882399 64039 
Specimens w/ 10 mg/mL papain   
500 108912 19663 
500 61606 16315 
500 46820 12798 
500 61923 16864 
500 91118 20028 
500 48939 9268 
167 
APPENDIX F 
 
HPLC/UV of Nordiazepam 
 
Nordiazepam (ng/mL) Nordiazepam area Prazepam area 
Standard Curve   
0 0 4911435 
200 278920 3293260 
250 266769 2265366 
300 624154 4439322 
400 925367 5144384 
   
Specimens w/ 10 mg/mL papain   
500 58123 511652 
500 381144 3694503 
500 462029 4367027 
500 490568 4887712 
500 493657 4839268 
500 506353 5189691 
 
 
168 
APPENDIX G 
 
Specimen Validity Testing  
 
Creatinine Standard Curve 
Specimen Absorb. (mabs/min)  
0 2 
3 9.1 
5 13.5 
7 20.5 
12 36.3 
23 75.2 
169 
Creatinine assay of 30 random urine specimens 
Specimen Dilution 
Factor 
Absorb. (mabs/min) in the 
unadulterated specimens 
Absorb. (mabs/min) in the specimens 
adulterated with 10 mg/mL papain 
1 5 26.9 31.9 
2 5 35.8 39.1 
3 2 19.4 13 
4 20 26.4 27.2 
5 5 20.5 19.5 
6 10 36.1 33.5 
7 5 37.3 40.2 
8 10 59.5 74.9 
9 20 44.8 36.6 
10 10 49.8 49 
11 5 38.7 43.9 
12 5 39.9 43.1 
13 5 33.2 33.8 
14 10 30.5 28.3 
15 5 24.7 37 
16 10 36.1 34.1 
17 5 30.9 35.9 
18 10 57.7 61.5 
19 20 34.1 41.4 
20 10 41.1 40.6 
21 5 56.4 58.6 
22 5 57.3 62.5 
23 10 45.7 44.4 
24 5 64.1 74.9 
25 5 33.3 31.9 
26 10 41.7 40.7 
27 20 46.5 57 
28 5 7.9 7.4 
29 5 15.9 20.3 
30 2 16.9 14.9 
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Creatinine assay of 6 random urine specimens 
Time 
(h) 
Specimen DF Absorb. (mabs/min) in the 
unadulterated specimens 
Absorb. (mabs/min) in the specimens 
adulterated with 10 mg/mL papain 
0 30 2 15.1 12.6 
 17 5 25.7 25.1 
 12 5 38.1 34.2 
 6 10 24.9 21.8 
 18 10 52.5 47 
 27 20 36.9 38.3 
6 30 2 13.4 5.3 
 17 5 18 22.5 
 12 5 39.1 30.7 
 6 10 24.7 24.7 
 18 10 48.6 48.2 
 27 20 44.8 41.8 
72 30 2 12 12.1 
 17 5 26.4 26.6 
 12 5 39.7 37.9 
 6 10 30.7 29 
 18 10 54.8 54.7 
 27 20 43.3 44.2 
 
Specific Gravity Standard Curve 
Specimen Absorb. (mabs/min)  
1.000 1.000 
1.002 1.002 
1.005 1.005 
1.030 1.034 
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Specific gravity of 30 random urine specimens 
Specimen Specific Gravity of  the 
unadulterated specimens 
Specific Gravity of the specimens adulterated 
with 10 mg/mL papain 
1 1.008 1.011 
2 1.030 1.034 
3 1.026 1.030 
4 1.024 1.028 
5 1.019 1.023 
6 1.019 1.023 
7 1.014 1.018 
8 1.013 1.017 
9 1.009 1.013 
10 1.009 1.013 
11 1.007 1.011 
12 1.028 1.033 
13 1.023 1.028 
14 1.021 1.026 
15 1.019 1.024 
16 1.018 1.023 
17 1.014 1.019 
18 1.012 1.017 
19 1.009 1.014 
20 1.009 1.014 
21 1.020 1.026 
22 1.016 1.022 
23 1.010 1.016 
24 1.010 1.016 
25 1.009 1.015 
26 1.003 1.009 
27 1.002 1.008 
28 1.001 1.007 
29 1.034 1.041 
30 1.015 1.022 
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Specific gravity of 6 random urine specimens 
Time 
(h) 
Specimen Specific Gravity of the 
unadulterated specimens 
Specific Gravity of the specimens 
adulterated with 10 mg/mL papain 
0 30 1.002 1.004 
 17 1.009 1.010 
 12 1.009 1.011 
 6 1.021 1.023 
 18 1.021 1.023 
 27 1.035 1.038 
6 30 1.002 1.005 
 17 1.009 1.012 
 12 1.009 1.013 
 6 1.021 1.024 
 18 1.021 1.024 
 27 1.035 1.038 
72 30 1.002 1.005 
 17 1.009 1.012 
 12 1.010 1.013 
 6 1.020 1.024 
 18 1.020 1.026 
 27 1.036 1.038 
 
173 
pH of 30 random urine specimens 
Specimen pH of  the unadulterated 
specimens 
pH of the specimens adulterated with 10 
mg/mL papain 
1 7.0 7.0 
2 7.0 6.6 
3 7.3 6.3 
4 6.7 6.0 
5 7.1 6.7 
6 5.5 5.4 
7 6.5 6.3 
8 5.9 5.8 
9 5.7 5.6 
10 6.5 6.5 
11 6.4 6.2 
12 5.7 5.1 
13 6.5 6.5 
14 6.8 6.8 
15 6.0 5.9 
16 7.9 8.2 
17 6.2 5.9 
18 5.1 5.5 
19 5.3 5.4 
20 5.3 5.2 
21 5.5 5.4 
22 5.8 5.6 
23 5.3 5.2 
24 6.0 5.9 
25 5.6 5.4 
26 5.2 5.2 
27 5.6 5.5 
28 6.9 6.7 
29 6.2 5.9 
30 7.6 6.7 
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Specific gravity of 6 random urine specimens 
Time 
(h) 
Specimen pH of the unadulterated 
specimens 
pH of the specimens adulterated with 10 
mg/mL papain 
0 18 5.5 5.5 
 6 5.5 5.5 
 22 5.7 5.7 
 10 6.6 6.6 
 1 7.0 7.0 
 16 7.9 7.9 
6 18 5.5 5.5 
 6 5.5 5.4 
 22 5.8 5.8 
 10 6.7 6.6 
 1 7.1 7.0 
 16 8.0 8.0 
72 18 5.4 5.4 
 6 5.4 5.4 
 22 5.8 5.8 
 10 6.6 6.5 
 1 7.1 6.8 
 16 8.0 7.7 
 
POC test strips 
Specimen Nitrite Glutaraldehyde Oxidants 
Control     
L1  neg pos neg 
L2 neg neg neg 
L3 pos neg pos 
Unadult    
30 neg neg neg 
17 100 mg/dL neg neg 
12 neg neg neg 
6 neg neg neg 
18 neg neg neg 
27 neg neg neg 
Adult (10mg/mL papain)    
30 neg neg neg 
17 100 mg/dL neg neg 
12 neg neg neg 
6 neg neg neg 
18 neg neg neg 
27 neg neg neg 
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